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SUMMARY 
Platelet activation and aggregation at sites of vascular injury involves massive cytoskeletal re-
organization, which is required for proper platelet function. Moreover, the cytoskeleton plays 
central roles in megakaryo- and thrombopoiesis. Thus, cytoskeletal protein aberrations can be 
the underlying reason for many pathological phenotypes. Although intensive research is 
carried out to identify the key players involved in cytoskeletal reorganization, the signaling 
cascades orchestrating these complex processes are still poorly understood. This thesis 
investigates the role of three actin-binding proteins, Coactosin-like (Cotl) 1, Profilin (Pfn) 1 and 
Thymosin (T) β4, in platelet formation and function using genetically modified mice. 
ADF-H-containing proteins such as Twinfilin or Cofilin are well characterized as regulators of 
thrombopoesis and cytoskeletal reorganization. Although Cotl1 belongs to the ADF-H protein 
family, lack of Cotl1 did not affect platelet count or cytoskeletal dynamics. However, Cotl1-
deficiency resulted in significant protection from arterial thrombus formation and ischemic 
stroke in vivo. Defective GPIb-vWF interactions and altered second wave mediator release 
present potential reasons for the beneficial effect of Cotl1-deficiency. These results reveal an 
unexpected function of Cotl1 as a regulator of thrombosis and hemostasis, establishing it as a 
potential target for a safe therapeutic therapy to prevent arterial thrombosis or ischemic stroke.  
Recent studies showed that the organization of the circumferential actin cytoskeleton 
modulates calpain-mediated αIIbβ3 integrin closure, thereby also controlling αIIbβ3 integrin 
localization. The second part of this thesis identified the actin-sequestering protein Pfn1 as a 
central regulator of platelet integrin function as Pfn1-deficient platelets displayed almost 
abolished αIIbβ3 integrin signaling. This translated into a profound protection from arterial 
thrombus formation and prolonged tail bleeding times in vivo which was caused by enhanced 
calpain-dependent integrin closure. These findings further emphasize the importance of a 
functional actin cytoskeleton for intact platelet function in vitro and in vivo.  
Tβ4 is a moonlighting protein, acting as one of the major actin-sequestering proteins in cells 
of higher eukaryotes and exerting various paracrine functions including anti-inflammatory, 
immunomodulatory and pro-angiogenic effects. Although excessively studied, its role for 
cytoskeletal dynamics, the distinction between endo- and exogenous protein function and its 
uptake and release mechanisms are still poorly understood. Constitutive Tβ4-deficiency 
resulted in thrombocytopenia accompanied by a largely diminished G-actin pool in platelets 
and divergent effects on platelet reactivity. Pre-incubation of platelets with recombinant Tβ4 
will help to understand the function of endo- and exogenous protein, which is under current 
investigation.  
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ZUSAMMENFASSUNG 
Die Aktivierung und Aggregation von Thrombozyten bei Gefäßverletzungen zieht massive 
Umstrukturierungen des Zytoskeletts nach sich, die eine Voraussetzung für die intakte 
Funktion der Zellen darstellen. Des Weiteren nimmt das Zytoskelett eine zentrale Rolle in der 
Megakaryo- und Thrombopoese ein. Daher können Anomalien zytoskeletaler Proteine eine 
Vielzahl von Krankheitsbildern verursachen. Obwohl intensiv an den beteiligten Proteinen 
geforscht wird, sind die Signalkaskaden, die den komplexen Vorgang der Umstrukturierung 
des Zytoskeletts steuern, noch weitgehend unbekannt. In dieser Dissertation wurden drei 
Aktin-bindende Proteine, Coactosin-like (Cotl) 1, Profilin (Pfn) 1 und Thymosin (T) β4, 
hinsichtlich ihrer Rolle für die Bildung und Funktion von Thrombozyten mittels genetisch 
veränderter Mäuse untersucht.  
Proteine wie Twinfilin oder Cofilin, die ADF-H-Domänen enthalten, sind oftmals an der 
Thrombopoese sowie an zytoskeletaler Umstrukturierung beteiligt. Obgleich Cotl1 der ADF-H 
Proteinfamilie zugehörig ist, konnte in Cotl1-defizienten Mäusen weder eine Veränderung der 
Thrombozytenzahlen, noch der zytoskeletalen Dynamik festgestellt werden. Unerwarteter-
weise zog eine Cotl1-Defizienz in vivo einen Schutz vor arterieller Thrombose und Schlaganfall 
nach sich. Defekte GPIb-vWF-Interaktionen sowie eine veränderte Freisetzung von 
sekundären intrazellulären Mediatoren zeigen mögliche Gründe für den schützenden Effekt 
einer Cotl1-Defizienz auf. Diese Ergebnisse verdeutlichen, dass Cotl1 ein zentraler Regulator 
von Thrombose und Hämostase ist und etabliert es damit als potentielle antithrombotische 
Zielstruktur für eine effektive und sichere Behandlung von kardio- und zerebrovaskulären 
Erkrankungen. 
Studien zeigten, dass die Organisation des kortikalen Aktin-Zytoskeletts die Calpain-
vermittelte αIIbβ3-Integrin-Inaktivierung moduliert und dadurch die Lokalisation der Integrine 
kontrolliert. Der zweite Teil dieser Dissertation identifizierte das Aktin-komplexierende Molekül 
Pfn1 als zentralen Regulator der Integrinfunktion in Thrombozyten, da Pfn1-defiziente 
Thrombozyten eine stark verminderte Reaktivität nach αIIbβ3-Integrin Aktivierung zeigten. 
Dies führte zu einem profunden Schutz vor arterieller Thrombusbildung und verlängerten 
Blutungszeiten in vivo, der durch eine verstärkte Calpain-vermittelte Integrin-Inaktivierung 
verursacht wurde. Diese Befunde unterstreichen erneut die zentrale Bedeutung eines 
funktionales Aktin-Zytoskeletts für die Aufrechterhaltung der Thrombozytenfunktion in vitro und 
in vivo.  
Tβ4 ist ein bivalentes Protein, das einerseits eine Funktion als Aktin-komplexierendes Protein 
in Zellen höherer Eukaryoten ausübt und andererseits unterschiedliche parakrine Funktionen 
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hat, zu denen entzündungshemmende, immunmodulierende und pro-angiogene Wirkungen 
zählen. Obwohl intensiv an Tβ4 geforscht wird, ist seine Bedeutung für die Dynamik des 
Zytoskeletts sowie die Unterscheidung zwischen endo- und exogener Proteinfunktion und 
seine Aufnahme- und Freisetzungsmechanismen kaum verstanden. Konstitutive Tβ4-
Defizienz zog eine Thrombozytopenie, begleitet von einem stark verminderten G-Aktin-Gehalt 
in Thrombozyten und gegensätzlichen Effekten auf die Thrombozytenreaktivität, nach sich. 
Der Effekt von rekombinant exprimiertem Tβ4 auf Thrombozyten, der derzeit untersucht wird, 
wird zum besseren Verständnis der endo- und exogenen Proteinfunktion, beitragen. 
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1. INTRODUCTION 
1.1 Platelets 
Platelets are small, anucleated, discoid-shaped cell fragments that are released from bone 
marrow (BM) megakaryocytes (MKs). Protrusions, reaching into the sinusoidal vessels of the 
BM, are shed off by shear forces generated by the blood stream and get further fragmented 
into platelets [1]. This process is permanently active to compensate for the clearing of aged 
platelets by macrophages in liver and spleen, keeping the platelet concentration at constant 
levels of 150,000-450,000 µL-1 in humans and approximately 1,000,000 µL-1 in mice. Whereas 
human platelets have a lifespan of 7-10 days, murine platelets circulate for approximately 5 
days. With a diameter of 3-4 µm (1-2 µm in mice) they are the smallest blood cells. Their main 
function is to safeguard the integrity of the vascular system. In addition to platelets, efficient 
hemostasis requires a functional coagulation system with its central product thrombin, which 
mediates the conversion of fibrinogen into fibrin and further acts as a powerful platelet 
activator. The coagulation cascade is either initiated by tissue factor (TF), which is exposed 
upon vascular injury, or by negatively charged surfaces via the ‘contact-activation’ pathway 
(intrinsic coagulation) initiated by the activation of coagulation factor (F) XII.  
Although most platelets are cleared without undergoing activation, they are able to respond 
rapidly to damage of endothelial layers of the vessel wall by forming a plug that prevents 
excessive blood loss. The exposure of extracellular matrix (ECM) proteins, such as collagens 
and laminins, to the flowing blood leads to initial platelet adhesion and activation. 
Subsequently, soluble mediators are released and secreted by activated platelets leading to 
the activation and recruitment of additional platelets to the site of injury, thus facilitating 
thrombus formation. However, under pathologic conditions, such as the rupture of an 
atherosclerotic plaque, the exposure of ECM proteins can cause uncontrolled platelet 
activation. This can lead to thrombotic events resulting in the obstruction of blood flow, loss of 
oxygen supply and subsequent tissue damage, as seen in myocardial infarction and ischemic 
stroke [2]. Since these pathologies are the leading causes of death and disability in the 
developed world, there is a particular demand for the development of effective and safe 
antithrombotic therapies for the prophylaxis and treatment of ischemic cardio- and 
cerebrovascular diseases [3, 4]. 
Maintaining the balance of sealing a wound on the one hand and uncontrolled thrombotic 
events on the other hand requires a tight regulation of diverse activating and inhibitory platelet 
receptors and thus a complex network of signaling pathways. 
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1.2 Platelet activation and thrombus formation 
As described above, platelets normally never get in touch with components of the 
thrombogenic ECM. However, upon injury or pathological alterations of the endothelial barrier, 
ECM macromolecules are exposed to the flowing blood, activate platelets and allow platelet 
adhesion. In detail, the complex signaling process, which is involved in platelet activation and 
thrombus formation can be divided into three major steps. (1) Initial platelet binding occurs via 
the interaction of platelet receptors with exposed ECM constituents, thereby decelerating the 
cells. Subsequently, platelets are activated upon initiation of receptor-triggered signaling 
cascades resulting in integrin activation and granule secretion (2). Ultimately, firm adhesion 
and platelet aggregation are facilitated through remodeling of the platelet cytoskeleton leading 
to spreading on the reactive surface and a further recruitment of platelets into the growing 
thrombus (3) (Fig. 1).  
     
 
Figure 1. Schematic overview of thrombus formation. Upon endothelial damage, components of the 
ECM become exposed to the flowing blood allowing platelets to tether upon interaction of GPIb-V-IX 
with collagen-bound vWF. The interaction of GPVI with collagen leads to integrin activation and the 
release of second wave mediators such as ADP, TxA2 and Ca2+. In parallel, locally exposed TF induces 
thrombin formation enabling additional platelets to become activated and recruited into the growing 
thrombus. Finally, integrins mediate firm adhesion through binding to ECM components and aggregation 
of platelets via the interaction with fibrinogen [5]. ECM, extracellular matrix; GP, glycoprotein; vWF, von 
Willebrand factor; ADP, adenosine diphosphate; TxA2, thromboxane A2; TF: tissue factor. Modified from 
Varga-Szabo et al., ATVB, 2008 [6]. 
Tethering of platelets occurs under intermediate or high shear forces (1,000-10,000 s-1), which 
are predominantly present in arterioles or stenosed arteries. During this process, platelets are 
decelerated by the transient interaction of platelet glycoprotein (GP) Ib-V-IX (GPIb) and 
collagen-bound von Willebrand factor (vWF) leading to ‘rolling’ of the platelets (Fig. 1). The 
important role of the vWF-GPIb interaction for thrombus formation is reflected by the severe 
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macrothrombocytopenia and bleeding disorder found in patients suffering from the Bernard-
Soulier syndrome, which is caused by absent or dysfunctional GPIb. Activated GPIb can 
additionally transduce signaling events leading to weak αIIbβ3 integrin activation. Although the 
underlying mechanisms are not fully understood, proteins such as the actin-binding protein 14-
3-3ζ, phosphoinositide 3-kinase (PI3K), Src-related tyrosine kinases, GTPase activating 
proteins and phospholipase (PL) D1 have been proposed to be important for GPIb-dependent 
adhesion processes [7, 8]. Of note, the affinity of GPIb towards vWF is too weak to mediate 
firm adhesion, thus rather mediating the localization of platelets at the vessel wall. Firm 
adhesion of platelets to the vessel wall is enabled by the interaction of the platelet GPVI 
receptor with collagens of the ECM ultimately causing platelet activation. Besides GPVI 
activation, this initial phase of platelet activation also comprises the activation of the 
transmembrane-related C-type lectin-like receptor (CLEC)-2, the receptor for the snake venom 
toxin rhodocytin. Signaling induced by these receptors involves tyrosine phosphorylation 
cascades via the Src family kinases Fyn and Lyn that phosphorylate the noncovalently 
associated intracellular immunoreceptor tyrosine-based activation motif (ITAM)-bearing Fc 
receptor (FcR) γ chain [9]. While the ITAM motif of GPVI harbors two YXXL-motifs through 
which receptor activation is initiated, CLEC-2 consists of only one YXXL-motif and is therefore 
called “hemITAM” receptor [10]. Phosphorylation of the YXXL motif leads to subsequent 
recruitment and activation of the spleen tyrosine kinase (Syk), that in turn triggers the 
activation of other downstream signaling molecules, such as the linker of activated T-cells 
(LAT), the SH2 domain-containing leukocyte protein of 76 kDa (SLP-76) or growth factor 
receptor-bound protein 2 (Grb2), ultimately culminating in the activation of effector molecules 
such as PLCγ2 or PI3K [11]. Activated PLCγ2 cleaves the membrane phospholipid 
phosphatidylinositol-4,5-bisphosphate (PIP2) into inositol-1,4,5-triphosphate (IP3) and 
diacylglycerol (DAG). Binding of IP3 to the IP3 receptor present in the membranes of the 
endoplasmatic reticulum induces the release of intracellular Ca2+. The sarcoplasmic 
membrane protein stromal interaction molecule (STIM) 1 senses the decrease of Ca2+ levels 
in the internal store and in turn induces store operated calcium entry (SOCE) through activation 
of Ca2+ release-activated calcium channel protein 1 (Orai1) [12]. The combined work of Ca2+ 
and PLCγ2-generated DAG activate protein kinase (PK)C´s and Ca2+-dependent DAG-
regulated guanine nucleotide exchange factor I (CalDAG-GEFI). While CalDAG-GEFI and 
PI3K play important roles in integrin activation, PKCs are involved in platelet spreading, 
granule release and contribute to the activation of CalDAG-GEFI [13].  
The temporally and spatially controlled release of second wave mediators leads to the 
recruitment of additional platelets into the growing thrombus. Besides a plethora of other 
molecules platelet α-granules contain the adhesive proteins vWF and fibrinogen, whereas 
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dense granules secrete the second wave mediators adenosine diphosphate (ADP), adenosine 
triphosphate (ATP), Ca2+, histamines and serotonin [14]. Thrombin is locally produced on the 
surface of activated platelets, linking platelet activation to coagulation. Thrombin catalyzes the 
conversion of fibrinogen to fibrin and acts as a potent activator of platelets. Its generation can 
be initiated by two distinct pathways (intrinsic and extrinsic coagulation pathway), both of which 
culminate in the cleavage and activation of the proenzyme prothrombin (FII) to thrombin. Upon 
vascular injury, exposed TF interacts with FVII, which circulates in the blood stream, thereby 
promoting the extrinsic pathway of blood coagulation. In parallel, negatively charged 
phosphatidylserine (PS) is exposed on the platelet surface in response to sustained Ca2+ 
signaling. This allows the assembly and activation of the prothrombinase and tenase 
complexes accelerating the clotting process [15]. Regarding the intrinsic pathway, negatively 
charged surfaces, such as polyphosphates or RNA, have been proposed as physiological 
initiators. This pathway includes the activation of FXII, which in turn triggers sequential 
activation of FXI, FIX and FX [16]. Among the released second wave mediators, ADP binds to 
the P2Y1 and P2Y12 receptors that activate G-proteins (G)q and Gi, respectively, whereas 
thromboxane A2 (TxA2) and thrombin stimulate the TxA2 (TP) and protease-activated receptors 
(PAR)1/3 or PAR3/4 receptors, which mainly signal through Gq and G12/13 (Fig. 2).  
 
Figure 2. Signaling pathways induced by G-protein coupled receptor (GPCR) stimulation in 
platelets. Platelet agonists such as ADP, TxA2 and thrombin activate platelets via GPCR. G12/13, Gq and 
Gi, thus linking receptor activation to platelet shape change, integrin activation, aggregation and 
degranulation. PLC, phospholipase C; MLC, myosin light chain; DAG, diacyl glycerol; CalDAG-GEF, 
calcium and diacyl glycerol-regulated guanine nucleotide exchange factor; PIP3, phosphatidylinositol-
3,4,5-trisphosphate; PIP2, phosphatidylinositol-4,5-bisphosphate; PAR, protease-activated receptor; 
TP, TxA2 receptor; RhoGEF, Rho-specific guanine nucleotide exchange factor; PI3K, phosphoinositide-
3-kinase; ROCK, Rho associated coiled-coil containing protein kinase; ATP, adenosine triphosphate, 
cAMP, cyclic adenosine monophosphate. Modified from Offermanns et al., Circ Res, 2006 [17]. 
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Signaling through G-protein-coupled receptors (GPCR) leads to amplification of platelet 
activation by inducing the generation of TxA2 and release of ADP and ATP. Signaling through 
Gq culminates in the activation of PLCβ isoforms, generation of IP3 and DAG via hydrolysis of 
PIP2, which subsequently leads to the increase of the cytoplasmic Ca2+ concentration, 
activation of PKC and consequently to the activation of integrins and granule release (Fig. 3) 
[17, 18].  
        
Figure 3. Signaling mechanisms during platelet activation. Different signaling pathways are induced 
upon platelet receptor stimulation. GPCRs transduce signals through different G-proteins. G12/13 
activation triggers Rho kinase-dependent pathways and Gq activates PLCβ, while Gi/z inhibits AC. 
(hem)ITAM signaling initiates a complex tyrosine phosphorylation cascade resulting in the activation of 
PLCγ2. Active PLCs generate IP3 and DAG, increasing the cytosolic Ca2+ concentration and activating 
PKCs. Altogether these events lead to the activation of integrins resulting in platelet aggregation, 
secretion and shape change. PIP2, phosphatidylinositol-4,5-bisphosphate; PAR protease-activated 
receptor; TxA2, thromboxane A2; TP, TxA2 receptor; Rho-GEF, Rho-specific guanine nucleotide 
exchange factor; PI3K, phosphoinositide-3-kinase; IP3, inositol-1,4,5-triphosphate; DAG, diacyl glycerol; 
PIP3, phosphatidylinositol-3,4,5-trisphosphate. Taken from Stegner et al., J Mol Med, 2011 [19]. 
 
Very recently, Gq signaling was shown to be critical for the proper phosphorylation of protein 
kinase B (Akt) downstream of Gi signaling [20].  In contrast, activation of G12/13 family members 
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leads to the activation of Rho specific guanine nucleotide exchange factor (Rho-GEFs) that 
activate RhoA, which culminates in increased phosphorylation of myosin light chain (MLC) 
through Rho associated coiled-coil containing protein kinase (ROCK)-mediated inhibition of 
the myosin phosphatase. Activated MLC in turn induces the reorganization of the platelet 
cytoskeleton, known as shape change [21]. Moreover, stimulation of the Gi-coupled P2Y12 
receptor inhibits adenylyl cyclase (AC) activity and activates PI3K, which in turn generates 
phosphatidylinositol-3,4,5-triphosphate (PIP3) that activates multiple downstream effectors 
such as Akt and ultimately leads to integrin activation (Fig. 3) [22, 23]. Finally, GPVI and PAR 
signaling act synergistically to fully activate platelets and mediate firm adhesion mainly through 
binding of α2β1 integrins to collagen and αIIbβ3 integrins to fibrinogen and collagen-bound 
vWF. Platelet aggregation is mainly mediated through binding and cross-linking of activated 
αIIbβ3 integrins to fibrinogen. The activation of platelets in general is characterized by a 
marked rearrangement of the actin and tubulin cytoskeleton, resulting in the formation of 
membrane protrusions, so-called filopodia and lamellipodia [24]. 
1.3 The platelet cytoskeleton 
The cytoskeleton consists of a highly interconnected structure of filamentous polymers and 
associated proteins that enables a eukaryotic cell to cope with deforming forces, allows active 
transport of intracellular cargos and facilitates the shape change of the cell, which is required 
for movement. This is achieved by the combined functions of a plethora of cytoplasmic proteins 
and organelles. Although the name cytoskeleton indicates a stable and rigid structure, it is a 
highly adaptive and dynamic network and the components are in a constant equilibrium of 
assembly and disassembly. Three major types of filaments can be distinguished: micro-
tubules, intermediate and actin filaments. 
1.3.1 Tubulin cytoskeleton 
The tubulin cytoskeleton consists of different α- and β-tubulin isoforms which in their GTP- 
bound state, form heterodimers and can be further assembled into long and polarized plus-  
(β-subunit is exposed) and minus-end (α-subunit is exposed) protofilaments. Thirteen of these 
protofilaments can further associate laterally and thereby build microtubules, which are hollow 
cylinders with an average diameter of 24 nm that can have a length of up to 50 µm [25, 26]. 
Microtubules exist in a steady state of assembly and disassembly termed dynamic instability. 
In general, assembly can occur at both, the plus- and minus-end, even though it occurs much 
faster at the plus-end [27]. Hydrolysis of GTP bound to the β-subunit of the polymerized 
heterodimer decreases filament stability and leads to microtubule depolymerization. Once the 
microtubule tip (plus-end) contains GDP-tubulin, a rapid depolymerization occurs, which is 
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termed ‘catastrophe’. This process can be rescued by the addition of new GTP-tubulin 
heterodimers [28]. Microtubule stability strongly depends on posttranslational modifications 
such as acetylation, detyrosination, polyglutamylation or polyglycylation [29]. Thus, an acetyl-
residue added to lysine 40 of the α-tubulin subunit indicates stable microtubules. Acetylation 
is mostly mediated via the α-tubulin N-acetyltransferase 1 (α-TAT1), while deacetylation is 
mainly accomplished by histone-deacetylases (HDAC) 5/6 and the nicotinamide adenine 
dinucleotide (NAD)-dependent deacetylase sirtuin-2 (SIRT2) [30-33]. Similarly, removal of the 
C-terminal tyrosine from the α-tubulin subunit leading to the exposure of the preceding C-
terminal glutamate is another indicator for stable microtubules. The enzyme mediating the 
detyrosination, however, still needs to be identified [29, 34]. Polyglutamylation and 
polyglycylation can occur on both the α- and β-tubulin subunits and are mediated via tubulin-
tyrosine ligase (TTL)-like family member enzymes (TTLLs), that add a γ-linked glutamine or 
glycine to one or more of the five C-terminal glutamates [29]. The temporal and spatial 
coordination of microtubule dynamics is essential as microtubules do not only maintain the 
structure of the cell, but are also of critical importance for cell migration, mitosis, meiosis, 
developmental processes and for the transportation of intracellular cargos. In platelets, 
microtubules are organized into the characteristic marginal band that consists of 8-12 
microtubule coils in the platelet periphery that maintains the discoid shape of resting platelets. 
Consequently, microtubule disassembly induced at temperatures below 16°C or upon 
treatment with microtubule destabilizing toxins, such as colchicine or nocodazole, leads to a 
spherical platelet shape [35]. The critical role of microtubules for maintaining a discoid platelet 
shape was further confirmed by a knockout (KO) mouse model lacking the hematopoietic 
lineage-specific β1-tubulin that displayed a macrothrombocytopenia with spherical platelets 
with a markedly reduced number of discontinuous microtubule coils within the marginal band 
[36]. 
 
   
1.3.2 Actin cytoskeleton 
The intracellular actin cytoskeleton participates in a large variety of cellular processes such as 
cytokinesis, cell motility and polarization, phago- and exocytosis. These processes critically 
depend on its dynamic behavior to depolymerize existing filamentous (F-) actin filaments to 
replenish the globular (G-) actin pool and on the contrary to build new actin filaments. F-actin 
is composed of monomeric G-actin molecules, of which in mammals, three isoforms have been 
identified: the mainly muscle specific α-actin and the ubiquitously expressed β- and γ-actin 
isoforms [37]. The typical helix structure is achieved by a 166° rotation of two parallel F-actin 
strands, which yields an F-actin microfilament with an average diameter of 7 nm. Platelets 
contain over two million actin molecules, which are present in a dynamic monomer-polymer 
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equilibrium [38, 39]. Approximately 40-50% of the total actin monomers are present in the 
filamentous form in a resting platelet and constitute 2,000-5,000 actin filaments [40].  
The remaining 50-60% of monomeric actin is stored in stoichiometric 1:1 complexes with 
thymosin (T) β4, profilin (Pfn) 1, Twinfilin (Twf) 1/2a and other actin sequestering proteins and 
becomes incorporated into filaments upon platelet activation. Within 20 seconds after platelet 
stimulation with thrombin the total amount of F-actin increases up to 70% [41, 42]. The actin 
filaments of resting platelets are highly cross-linked and form a stiff network through numerous 
actin crosslinking molecules such as filamin (Fln) A, spectrins or α-actinin. FlnA recruits and 
positions numerous proteins including Ras homologue gene family member (Rho) A, Ras-
related C3 botulinum toxin substrate (Rac) 1, p21/ Cdc42/ Rac1-activated kinase (PAK1) and 
many others [43, 44]. The dynamics of the well-organized cytoskeletal architecture need to be 
tightly regulated, which is achieved by the combined action of actin-binding proteins.  
1.4 Regulation of actin dynamics 
Actin polymerization is a two-step process that comprises nucleation and elongation. The 
formation of polymerization-competent nuclei is the rate-limiting step, since it is energetically 
unfavorable, whereas the elongation process proceeds rapidly. During association to one end 
of a growing filament, ATP bound to G-actin is hydrolyzed into ADP and phosphate. Since 
ATP-hydrolysis associated with polymerization occurs with a delay after subunit association, 
two different filament ends can be distinguished: The fast growing plus (+) - or barbed end with 
ATP-actin subunits and the slow-growing minus (-) - or pointed end with ADP-actin subunits. 
Both differ in their rates of monomer association and dissociation. Elongation of growing actin 
filaments occurs until the free monomer concentration has fallen to the critical concentration 
(cc) of polymerization that is closer to the dissociation constant (KD) of the barbed end. At cc, 
the number of actin subunits that associate to the barbed end, equals the number of monomers 
dissociating from the pointed, the so-called actin treadmilling [45]. In resting cells, G-actin 
levels are maintained far above cc for polymerization, as found in lamellipodia, where levels of 
G-actin and F-actin are estimated to 150 and 500 µM, respectively. Therefore, the barbed ends 
are blocked by so-called capping proteins (CP) to prevent nonproductive polymerization [46]. 
As shown in Figure 5, the availability of the G-actin pool is tightly regulated by the actin-
sequestering proteins, Tβ4, Pfn1 and Twf1/2a.  
β-thymosins are short peptides that can completely sequester G-actin, whereas Pfn1 can both 
sequester G-actin in isolation as well as actively participate in barbed end elongation in the 
presence of actin nucleation and elongation machineries. Twf was shown to inhibit actin 
filament growth by two modes: (1) inhibition of barbed end growth by capping of barbed ends 
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and (2) inhibition of pointed end growth by sequestration of G-actin monomers, resulting in a 
decreased availability of G-actin [47, 48]. 
 
Figure 5. Proposed model of actin dynamics (not all involved proteins are depicted). Actin filaments 
consist of G-actin monomers, which can be divided into three energetic states: ATP-G-actin (bright 
green), ADP-Pi-G-actin (orange) and ADP-G-actin (light blue). Cofilin (grey) severs and depolymerizes 
ADP-G-actin from actin filaments. Severing results in free barbed ends (+), thus providing a new target 
available for polymerization and for disassembly at the newly provided pointed end (-). Twinfilins (green) 
compete with cofilin in binding to ADP-G-actin monomers. Since twinfilin has a higher affinity for ADP-
G-actin, this interaction is preferred. Moreover, twinfilin was shown to interact with heterodimeric capping 
protein (red). Profilin (dark blue) acts as a nucleotide exchange factor for G-actin monomers replenishing 
the pool of high-energy ATP-G-actin for the assembly of actin filaments. Furthermore, twinfilin, profilin 
and cofilin were shown to interact with PIP2, which results in a down-regulation of the sequestering 
function of twinfilin and profilin on G-actin monomers and the severing activity of cofilin. CAP, cyclase-
associated protein; Tmsb4x, Thymosin β4 [38, 40, 49-51]. Figure was kindly provided by Dr. Simon 
Stritt. 
Actively elongating filaments are created through controlled uncapping, severing or nucleation 
mechanisms. Spontaneous actin nucleation can either occur by activation of formin family 
members such as the mammalian diaphanous 1 protein (mDia1, DIAPH1) by small GTPases 
or binding of adenomatous polyposis coli (APC), which both can overcome the inhibitory effects 
of CPs. On the other hand, nucleation can be induced by the action of the Arp2/3 complex, 
which in turn can be activated by binding of Wiskott-Aldrich syndrome protein (WASp) family 
members via their verprolin, central, acidic (VCA) domain. Actin turnover and the creation of 
new barbed ends is achieved by the action of severing proteins such as cofilamentous 
structures with actin (Cofilin/Cof) or cyclase-associated proteins (CAP). Cof has the unique 
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property to induce a twist in the actin filament of about 5° rotation per subunit, thereby 
weakening the lateral binding. Following this, actin turnover is enhanced by dissociation of 
actin monomers from the pointed end and by filament severing [52-54]. CAPs are highly 
conserved actin monomer binding proteins present in all eukaryotes [55], which were first 
identified in budding yeast (here called Srv2) as a suppressor of the activated ras allele [56] 
and as factor associated with AC [57]. In yeast cells, CAP/Srv2 localizes to cortical actin 
patches through an interaction with the actin filament binding protein (Abp1) [58] [59]. The loss 
of CAP was accompanied by cytoskeletal defects in budding yeast, Dictyostelium and 
Drosophila [55]. Interestingly, depletion of the isoform CAP1 leads to an accumulation of Cof 
into abnormal cytoplasmic aggregates and to similar cytoskeletal defects observed in Cof 
knockdown cells, demonstrating that CAP1 is required for recycling of actin-depolymerizing 
factor/destrin (ADF)/cofilin for new rounds of filament depolymerization and actin monomers to 
replenish the assembly-competent pool of actin [42] [59] [60]. Another study identified an 
interaction between CAP and Twf, which accelerated depolymerization of actin filaments at 
their barbed and pointed ends. This interaction could explain the observed discrepancy 
between very rapid in vivo actin filament turnover and the slow depolymerization of purified 
actin filaments in vitro. [61]. 
Cytoskeletal protein aberrations are the underlying reason for many pathological phenotypes. 
Several studies showed that a deregulated actin cytoskeleton, e.g. defects in proteins 
controlling actin dynamics, have been associated with platelet disorders in humans and mice. 
For instance, patients suffering from the Wiskott-Aldrich-syndrome (WAS), an X-linked 
inherited disorder, display microthrombocytopenia, immunodeficiency, eczema and an 
increased risk of autoimmune disorders and cancer (Online Mendelian Inheritance in Man; 
Accession number #301000) [62]. WAS is caused by mutations within the WAS gene encoding 
the WAS protein (WASp), which was reported to be involved in the signal transduction from 
membrane receptors to the actin cytoskeleton. WASp was shown to regulate the activity of the 
Arp2/3 complex, thereby enabling the nucleation of new actin filaments [63]. Consequently, 
WASp is an important regulator of actin assembly and is constitutively associated with WASp-
interacting protein (WIP) in resting and activated platelets to prevent its degradation [64-66]. 
The severe phenotype found in these patients underscores the important role of the actin 
cytoskeleton for the proper function of platelets. 
Interestingly, cytoskeletal abnormalities were not only shown to be of importance in platelet 
disorders, but further influence the outcome of a variety of other diseases including 
cardiovascular disease syndromes, neuro-degeneration, cancer (invasion), liver cirrhosis, 
pulmonary fibrosis and blistering skin diseases. Attempts to modulate the cytoskeleton by 
  INTRODUCTION 
 
11 
peptides or other specific drugs have already yielded interesting results, thus rendering the 
cytoskeleton a possible new therapeutic target. Two convincing examples: anti-cytoskeletal 
(microtubule targeted) drugs are already used to inhibit cell division in certain cancer types and 
antibodies against the cytoskeleton are widely used for diagnostic purposes [67]. 
1.4.1 The ADF-H protein family 
The ADF homology domain (ADF-H) is one of the best-characterized actin-binding motifs. It is 
present in at least three distinct groups of actin-binding proteins: ADF/cofilins, twinfilins, and 
Abp1/debrins [68]. Each group of ADF-H family members shows unique actin-binding 
properties and biological activities. Whereas ADF/cofilins contain only one ADF-H domain and 
can bind both G- and F-actin [69], Twfs consist of two ADF-H domains separated by a short 
linker region and are only able to bind monomeric actin [38, 66]. Abp1/debrins on the other 
hand are relatively large proteins consisting of an N-terminal ADF-H domain, a variable region 
and a C-terminal SH3 domain. These proteins only bind F-actin [58, 59, 70]. As a fourth class 
of ADF-H-containing proteins, Coactosins have been identified. However, due to low sequence 
homology to other ADF-H proteins it has long been unclear whether coactosin like F-actin 
binding protein 1 (Cotl1) is indeed an ADF-H family member.  
1.4.1.1 Cofilin  
In the early 1980s, the first members of the ADF/cofilin family were identified. ADF and cofilin 
are actin-binding proteins of a molecular mass of about 15-21 kDa, which share a sequence 
identity of about 70%. Both proteins contain a single ADF-H domain; the actin binding site as 
well as a phosphorylation site at serine 3 are the most conserved regions of ADF/cofilin 
between different species [51, 71]. In mammals, three isoforms of the ADF/cofilin family exist 
on different chromosomes, ADF, cofilin-1 (non-muscle (n)-cofilin) and cofilin-2 (muscle (m)-
cofilin). ADF and n-cofilin are expressed in most tissues, whereas m-cofilin is only found in 
muscle cells [72, 73]. ADF was first observed to rapidly reduce the viscosity of F-actin in 
solution, whereas cofilin was primarily found to bind to F-actin. After dephosphorylation, ADF 
and n-cofilin preferentially bind in a cooperative manner to ADP-bound F-actin, which acts as 
a turnover marker for older filaments [71, 74]. Upon binding to actin, ADF and n-cofilin have 
the unique property to induce a twist in the actin filament (5° rotation per subunit) thereby 
weakening the lateral binding. Following this, actin turnover is enhanced by (1) dissociation of 
actin monomers from the pointed end, which are transferred to the barbed end and (2) by 
filament severing, which provides new barbed ends for the addition of actin monomers [52-54, 
69, 75]. Although the activity of ADF/n-cofilin is regulated by several mechanisms, including 
the isoform expression pattern, competitive binding with other proteins like tropomyosin or PIP2 
binding [51], the main and best studied regulatory mechanism is (de)phosphorylation of ADF/n-
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cofilin at the highly conserved amino acid serine 3 [76]. LIM kinase (LIMK) and testicular protein 
kinase (TESK) phosphorylate and inactivate ADF/n-cofilin activity, whereas dephosphorylation 
and thereby activation of ADF/n-cofilin is mediated by phosphatases such as the serine 
phosphatases PP1 and PP2A, slingshot and chronophin [77-81]. Activation of phosphorylated 
ADF/n-cofilin is a rapid process in response to different stimuli in many cell types [77]. In 
platelets, approximately 90% of n-cofilin is phosphorylated at position serine 3 in the resting 
state, suggesting a slow actin turnover. After stimulation with thrombin, maximal n-cofilin 
dephosphorylation of about 75% occurs within 10 minutes [82].  
Studies on different model organisms have revealed an essential role for ADF/cofilin during 
development. Deficiency for either ADF or cofilin in yeast or Drosophila (D.) melanogaster 
resulted in lethality [83, 84]. The same was found in Caenorhabditis (C.) elegans when both 
isoforms UNC-60A and UNC-60B were affected [85, 86]. In mice, n-cofilin deficiency led to 
embryonic lethality due to defects in neural crest cell migration and neural tube closure [87]. 
Furthermore, conditional gene targeting in mice revealed an association of n-cofilin with cell 
cycle control in the cerebral cortex and disorders in neuronal migration. In contrast, mice 
constitutively lacking ADF are viable and display no obvious defects in brain development [88]. 
However, mice with a combined deficiency for ADF and n-cofilin in MKs and platelets displayed 
a severe macrothrombocytopenia combined with an abnormal ultrastructure of the platelets, 
which was the result of almost abolished proplatelet formation. Analysis of BM MKs revealed 
a hypermegakaryoplasia with an abnormal ultrastructure. Moreover, agonist-induced F-actin 
polymerization was almost eliminated in platelets of these mice. This study clearly 
demonstrates that dynamic changes of the actin cytoskeleton play a critical role for platelet 
production from MKs in vivo [82]. 
1.4.1.2 Twinfilin 
Human Twf was first identified in 1994 and initially thought to represent the catalytic domain of 
PKC [89-91]. Twf homologues have been identified in human, mouse, and C. elegans, but not 
in plants [47]. Although the sequence homology of Twfs two ADF-H domains and ADF/cofilin 
is rather low, their crystal structures are almost superimposable [47, 92]. While unicellular 
organisms and lower animals, such as Saccharomyces (S.) cervesiae or D. melanogaster, 
respectively, only have one Twf isoform, the ubiquitously expressed Twf1 and Twf2a, as well 
as the muscle-specific Twf2b have been identified in mammals [93, 94]. Although both Twf 
ADF-H domains can bind G-actin, they interact in a molar ratio of 1:1, with the affinity towards 
ADP-G-actin being approximately 10-fold higher compared to ATP-G-actin [47, 69, 94, 95]. 
Twf was shown to inhibit actin filament growth by two distinct mechanisms: on the one hand, 
Twf prevents barbed end growth by capping of actin filaments (Fig. 5). On the other hand, it 
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inhibits pointed end growth by sequestering G-actin monomers, thus reducing the pool of free 
monomers [47, 48]. Moreover, Twfs interact with heterodimeric CPs and, at least in yeast, this 
interaction was reported to be important for its proper function in actin dynamics [96]. Of note, 
binding of CPs to actin filament barbed ends inhibits both depolymerization as well as the 
addition of new monomers. However, the Twf-CP interaction is thought to localize ADP-G-actin 
monomers close to places of rapid actin turnover, thus providing new monomers for actin 
filament growth [52, 94, 96]. Upon ADF/cofilin-mediated dissociation of G-actin monomers from 
actin filaments, Twf is thought to compete with ADF/cofilin in binding to these monomers [93, 
95, 97]. In addition, Twf also interacts with PIP2, which inhibits its actin monomer sequestering 
function [50].  
In vivo, Twf-deficiency in yeast resulted in mild alterations in the cortical actin patches and a 
defective budding pattern. However, the combination of a Cof or Pfn1 functional mutant with a 
Twf-deficiency in yeast resulted in synthetic lethality [47]. In contrast, D. melanogaster mutants 
lacking Twf displayed a reduced body size, were less active, exhibited a retarded development, 
a rough eye phenotype and an aberrant, often bend and rough bristle morphology, which was 
due to an uncontrolled polymerization of actin [98]. In 2011, Nevalainen et al. generated a 
constitutive Twf2a-deficient mouse line (Twf2a-/-) and studied the morphology and histology of 
different organs. However, they could not detect a striking phenotype, which led to the 
conclusion that Twf2a is dispensable in mouse development [94]. Nevertheless, Nevalainen 
et al. hypothesized that the functionally redundant Twf1 isoform might compensate for the lack 
of Twf2a [94]. In 2017, Stritt et al. performed additional studies on the Twf2a-/- mouse line, and 
found a mild macrothrombocytopenia resulting from a markedly accelerated, macrophage-
independent platelet clearance in the spleen. Twf2a-/- platelets showed enhanced integrin 
activation and α-granule release in response to stimulation of (hem)ITAM receptors and 
GPCRs, increased adhesion and aggregate formation on collagen under flow, accelerated clot 
retraction and enhanced spreading on fibrinogen. In vivo, Twf2a-deficiency resulted in 
shortened tail bleeding times and faster occlusive arterial thrombus formation. The 
hyperreactivity of Twf2a-/- platelets was attributed to enhanced actin dynamics, characterized 
by an increased activity of n-cofilin and Pfn1, leading to a thickened cortical cytoskeleton and 
hence sustained integrin activation due to limited calpain-mediated integrin inactivation. Thus, 
Twf2a-controlled actin rearrangements dampen platelet activation responses in a Cof- and 
Pfn1-dependent manner, thereby indirectly regulating platelet reactivity and lifespan in mice. 
However, an MK- and platelet-specific Twf1-deficient mouse did not reveal any defects in MK 
maturation, thrombopoiesis, platelet function, or actin assembly, thus further suggesting that 
the two Twf isoforms at least in part functionally overlap [99]. 
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1.4.1.3 Cotl1 
Cotl1 was originally identified in Dyctyostelium (D.) discoideum as a 17 kDa protein copurifying 
with actomyosin complexes [100]. To date, coactosin homologues have been identified in D. 
melanogaster, Xenopus (X.) laevis and mammals [101]. Like ADF/cofilins, Cotl1 contains one 
ADF-H domain. As shown in Figure 6, the amino acid sequences of coactosins from different 
species share less than 25% sequence identity to other ADF-H family members. Nevertheless, 
their 3D structures are almost identical [100, 101]. Especially, the regions important for actin 
filament interactions are structurally highly conserved between ADF/cofilin and Cotl1 
suggesting a similar binding mode. Indeed, Coactosins were shown to bind F-actin, although 
with relatively weak affinity and they do not interact with actin monomers [100, 101]. Site-
directed mutagenesis has determined that lysine 75, located in the ADF-H domain, plays a 
critical role in F-actin binding. 
     
Figure 6. Structural comparison of Cotl1, yeast cofilin and N-twinfilin. Structural sequence 
alignment. The secondary structure elements and sequences of cofilin, coactosin and N-twinfilin are 
indicated. Acidic and basic amino acids are color-coded with light blue and grey rectangles, respectively. 
The residues that have been shown to be important for actin monomer and filament interactions in 
ADF/cofilins and N-twinfilin are marked with orange diamonds and violet triangles. Ribbon diagrams of 
coactosin (left), cofilin (middle; residues 6-138 shown, crystal structure) and N-twinfilin (right; residues 
7-139 shown, crystal structure). The side chains of the residues important for F-actin and G-actin binding 
in cofilin are color-coded as in the sequence alignment. The residues conserved in coactosin are 
indicated with the same color scheme and the corresponding residues are labelled to cofilin and N-
twinfilin. Orange-colored circles schematically indicate positions of N-terminal residues of cofilin and N-
twinfilin involved in G-actin binding. Aligned secondary structure elements of the three proteins are 
equally colored. Taken from Hellman et al., FEBS Letters, 2004 [102]. 
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Biochemical analyses have demonstrated that Cotl1 has a different role in actin dynamics from 
the ones of ADF/cofilin, Twf or Abp1/debrin, since it does not affect actin polymerization. 
Instead, in D. discoideum, coactosin was shown to counteract the activity of capping proteins 
[103]. Moreover, Cotl1 was identified as a regulator of T cell activation. Mechanistically, Cotl1 
was shown to prevent cofilin-mediated depolymerization of actin filaments, thereby promoting 
lamellipodia formation at the immune synapse [104]. 
Besides its interaction with F-actin, Cotl1 was shown to bind 5-lipoxygenase (5-LO) in a yeast-
two-hybrid assay [105]. 5-LO is a key enzyme in leukotriene (LT) biosynthesis, since it 
catalyzes two of the initial steps, which is the oxygenation of arachidonic acid (AA) to 5(S)-
hydroperoxy-6-trans-8,11,14-cis-eicosatetraenoic acid (5-HPETE) and the subsequent 
dehydration into the epoxide LTA4 (Fig. 7). LTs are inflammatory lipid mediators, which cause 
leukocyte chemotaxis and increased vascular permeability. The effects of LTs are well 
established in the pathogenesis of asthma, and accumulating data indicated a role for LTs in 
atherosclerosis.  
 
 
Figure 7. The 5-LO pathway. 
Different enzymes metabolize AA: (1) 
5-LO catalyzes the oxygenation of AA 
to 5-HPETE, which results in the 
production of LTs. (2) Cox metabolizes 
AA to Prostaglandins and TxA2. AA, 
arachidonic acid; 5-HPETE, 
5(S)hydroperoxy-6-trans-8,11,14-cis-
eicosatetraenoic acid; LT, leukotriene; 
TxA2, thromboxane A2, 5-LO, 5-
lipoxygenase, Cox, Cyclooxy-genase. 
 
 
In addition, 5-LO products are implicated in cancer cell survival, as recently shown in leukemia 
stem cells [106-109]. Cotl1 and another accessory protein, 5-lipoxygenase-activating protein 
(FLAP), can upregulate and modulate 5-LO activity [110] . Additional results showed that Cotl1 
functions as a chaperone for 5-LO, stabilizing 5-LO in resting cells and serving as a scaffold 
protein during Ca2+-induced 5-LO activity [111]. However, its defined cell biological role as well 
as the mechanisms by which Cotl1 contributes to cytoskeletal dynamics in general remain 
enigmatic. 
1.4.2 Actin-sequestering proteins  
The availability of G-actin is tightly regulated by the two main monomer-binding proteins Pfn1 
and Tβ4. β-thymosins are short peptides that can completely sequester G-actin, whereas 
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profilins can both sequester G-actin in isolation as well as actively participate in barbed end 
elongation in the presence of actin nucleation and elongation machineries [47, 48].  
1.4.2.1 Profilin1 
Pfn1 is a 14 kDa protein initially isolated from platelets in 1977 [112]. In mammals, four different 
Pfn isoforms are described: the well-characterized ubiquitously expressed Pfn1, the brain-
specific Pfn2 (with two sub-isoforms Pfn2a and 2b), and the mainly testis-specific Pfn3 and 4 
[112-116]. Pfn harbors, besides its actin-binding domain, a phosphatidyl-inositide binding site, 
with a strong preference towards PIP2 and a poly-L-proline (PLP) binding domain, which is 
required for its interaction with other ligands (Fig. 8) [49, 117].  
 
Figure 8. Domain architecture and interacting proteins of Pfn1 (not all interaction partners are 
depicted). Pfn1 consists of an N- and C-terminal PLP binding domain, a central actin binding site with 
an overlapping binding site for phosphatidylinositides, exhibiting a strong preference for PIP2 and 
another PIP2-binding site that overlaps with the PLP-binding domain in the C-terminus. The N- and C-
terminal PLP-binding sites allow the association with numerous interaction partners, such as WASp, 
mDia, Mena, dynamin, WAVE or Hem2 [118]. Binding of Pfn to PIP2 on the one hand prevents 
phospholipase-mediated hydrolysis to IP3 and DAG and on the other hand inhibits the association with 
actin monomers. W3A, Y6D, R74D, H133S, and R136D highlight point mutants of profilin that 
specifically disrupt the function of single domains [119, 120]. Hem2, hematopoietic protein 2; Mena, 
mammalian Enabled; PLP, poly-L-proline; WAVE, WASp family verprolin-homologous protein. Adapted 
from [121]. 
 
Pfn was first identified as a small actin-binding protein (molar ratio of 1:1) and was initially 
thought to function as an ATP-G-actin sequestering protein, thus interfering with F-actin 
assembly. However, this hypothesis was questioned over time, since Pfn1 concentrations of 
around 0.5 µM in platelets are too low to account for all the sequestered G-actin molecules. In 
fact, Pfn1 acts as an ATP exchange factor for actin, recharging ADP- bound G-actin monomers 
to ATP-G-actin [122]. Moreover, Pfns were shown to regulate the addition of new monomers 
to growing actin filaments [123, 124]. Additionally, Pfn interacts with a huge number other PLP-
stretch-containing proteins, among these are proteins involved in membrane trafficking like 
synapsin, clathrin, and dynamin, or proteins present in focal contacts, such as mammalian 
enabled orthologue (Mena) or vasodilator-stimulated phosphoprotein (VASP) [118, 125, 126]. 
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Furthermore, Pfn is involved in the regulation of small Rho-GTPases, e.g. by the interaction 
with the WIP complex, downstream of Cdc42 or mDia1, a known effector of RhoA [119]. 
Pfn plays an essential role for development. In Drosophila, constitutive deletion of Pfn1 
resulted in late, in mice in early embryonic lethality, indicating an essential biological function 
in mitosis and signaling [127, 128]. In 2014, Bender, Stritt et al., studied a conditional MK- and 
platelet-specific Pfn1 KO mouse (Pfn1fl/fl-Pf4Cre). Surprisingly, these mice fully reproduced key 
features of WAS patients (see section 1.4). They displayed a microthrombocytopenia due to 
accelerated turnover of platelets and premature platelet release into the bone marrow.  
Pfn1fl/fl-Pf4Cre MKs produced less and smaller-sized platelets into the circulation, which had a 
thicker marginal band and a partially disrupted actin cytoskeleton. These severely misarranged 
and hyperstable microtubules were also found in platelets isolated from WAS patients, which 
established Pfn1 as a new regulator of microtubule stability and reorganization [129].  
1.4.2.2 Thymosin β4 
β-thymosins are a family of 5 kDa peptides. Tβ4 was first isolated from calf thymus and 
therefore thought to exert hormone-like activities [130, 131]. Indeed, until now, various 
paracrine effects have been reported, including cardiac protection, angiogenesis, wound 
healing and immunomodulatory effects [129]. Besides its paracrine effects, Tβ4 is, together 
with Pfn1, the major G-actin sequestering protein within cells of higher eukaryotes. Of the 15 
existing, highly homologous β-thymosins, Tβ4 is the most abundant form [129]. Nuclear 
magnetic resonance (NMR) studies on Tβ4 in aqueous solution revealed that it is highly 
unstructured. This lack of defined secondary structure element is also referred to as intrinsically 
unstructured proteins (IUPs). Mostly, IUPs obtain a defined tertiary structure only upon binding 
to their interaction partners. IUPs are often involved in various cellular activities and therefore 
interact with many different proteins, which is enabled by their ability to attain different 
conformations, thus adapting to their target interactions partners. Since it exerts intra- and 
extracellular functions, Tβ4 is a so-called moonlighting protein [132].  
1.4.2.2.1 Intracellular function of thymosin β4 
Tβ4 can be found in the cytoplasm of many different cell types in concentrations ranging from 
100 to 500 µM. Its intracellular concentration is particularly high, in the range of 300–600 µM, 
in cells that rapidly respond to external signals by increased motility like polymorphonuclear 
leukocytes (neutrophils) and macrophages or by profound shape changes like platelets [133]. 
Its main intracellular function is to bind G-actin in a 1:1 stoichiometry (KD = 0.4-0.7 µM), thereby 
inhibiting actin polymerization. In resting cells, Tβ4 complexes about half of the total actin 
amount.  Due to a lack of any regulatory site on Tβ4, it has been speculated that actin release 
from Tβ4 after cellular activation is enabled by a drop in the cc of actin polymerization below 
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the KD of Tβ4 to G-actin. This is possibly due to a stimulus-dependent increase in barbed end 
concentrations, e.g. by removal of capping proteins from or severing of existing filaments or 
the action of actin polymerization nucleating proteins, suggesting that the affinity of Tβ4 
towards actin does not change [132]. 
 
Figure 9. Structure of the Tβ4-actin complex. The 
protein complex was purified from Pichia (P.) pastoris. 
Actin is shown as a surface, with the subdomains 
indicated by numbers, and Tβ4 as a rainbow-colored 
cartoon with sticks. Tβ4 makes extensive contact with 
actin, spanning the nucleotide binding cleft from the 
barbed to the pointed face of the actin monomer. 
Taken from Xue et al., PNAS, 2014 [134].  
 
 
 
 
Tβ4 makes extensive contacts with actin, its N-terminal helix elongates into the cleft between 
subdomain 1 and 3 and its C-terminus stretches between subdomains 2 and 4, resulting in 3 
contact regions (Fig. 9), the N- and C-terminal part and the extended region in between 
containing a widely spread actin binding consensus sequence (17LKLTET22) [134]. The 
extended region with its actin-binding consensus sequence is essential for actin binding, the 
structural topology is termed the β-thymosin (βT) domain or, more frequently, the WASP-
homology (WH2)-domain [135].  
   
Figure 10. Structural-based sequence alignment of WH2/Tβ domains. Tβ4-like residues within the 
C-terminal half are depicted in yellow. Functionally analogous residues in both gelsolin and WH2/Tβ 
domain families are shown in pink. Tβ4-like residues within the N-terminal half are marked in gray. Blue 
highlights conserved residues throughout the WH2 family, except for Tβ4. Accession numbers are: 
gelsolin (X04412), Tβ4 (NM_021109), ciboulot (Cib, NM_167001), TTβ (NM_077029), actobindin (Act, 
A36614), N-WASP (NM_003941), WASP (U12707), WAVE1 (BC044591), WAVE2 (AB026542), and 
WAVE3 (AB026543). Taken from Aguda et al., Structure, 2006 [136]. 
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The common feature of WH2-containing proteins is their ability to bind to the barbed end of 
actin, although WH2-domains from different proteins share only 15% sequence identity (Fig. 
10) [136]. In contrast to Tβ4, most of the depicted proteins support actin polymerization. This 
is due to a differential binding affinity of Tβ4, which is promoted by single residues. Therefore, 
some point mutations are sufficient for the switch from actin sequestration to nucleation [137].  
Since a considerable amount of Tβ4 has been detected intranuclearly, it has been speculated 
to act as transcription factor, however, its function in the nucleus has not been further 
elucidated so far [138].  
1.4.2.2.2 Extracellular function of thymosin β4 
Tβ4 is present in extracellular body fluids. For example, plasma concentrations of Tβ4 are 
0.03-0.4 µg mL-1 [139]. A recent study by Huff et al. showed that platelets release Tβ4 upon 
activation. The released Tβ4 is partially crosslinked to fibrin by FXIIIa, a transglutaminase, 
which might represent a mechanism to maintain Tβ4 at sites of injury (Fig. 11) [133]. However, 
possible secretion pathways remain elusive so far. Interestingly, Tβ4 is synthesized without a 
signal peptide, thus excluding a secretory pathway.  
 
Figure 11. Integration of Tβ4 into blood coagulation and wound repair. As blood enters a wound, 
clotting proteins and enzymes such as fibrinogen, thrombin and complement are activated. Fibrinogen 
is converted to fibrin and a clot is formed. Cells such as granulocytes, macrophages, platelets and 
lymphocytes enter the wound. At the same time, platelets co-release other proteins including FXIIIa 
which crosslinks Tβ4 with the aC domains of fibrin. Granulocytes, macrophages and other cells at the 
wound site also release significant amounts of Tβ4. Tβ4, which is bound covalently to the clot matrix, is 
a chemoattractant for endothelial cells (ECs) and keratinocytes. These cells migrate rapidly into the 
wound site and the healing process begins. Taken from Goldstein et al., Trends Mol Med, 2005 [129]. 
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Besides blood, Tβ4 has been found in wound, lacrimal and oral human fluids [140-142]. Tβ4 
concentrations are highest in platelets and polymorphonuclear monocytes (PMNs), which are 
among the first cells to enter a site of injury and recruit additional cells to the wound site. Tβ4 
concentrations in wound fluids are around 13 µg mL-1, most likely released from platelets. 
Extracellular Tβ4 has multiple biological functions. It was identified as an angiogenic factor in 
a screen of early genes induced during endothelial cell (EC) differentiation. Accordingly, it 
promotes EC migration, tubule formation and angiogenesis in vitro [143]. Moreover, it was 
shown to promote angiogenesis and wound repair in vivo [144, 145]. It has been reported that 
monocytes produce an oxidized form of Tβ4 (Tβ4 sulfoxide) that blocks neutrophil chemotaxis 
in vitro and has anti-inflammatory properties in vivo [146]. Additionally, in the eye, topical 
application of Tβ4 promotes corneal wound repair through increase of the cell-cell and cell-
matrix contacts and promoting of conjunctival epithelial cell migration [147]. In septic shock 
models, e.g. upon treatment of mice with lethal doses of endotoxins, Tβ4 significantly 
increased the survival of mice in a dose- and time-dependent manner [148]. Direct 
administration of Tβ4 following a myocardial infarction in mice protected heart tissue from cell 
death and enabled heart myocytes to survive after hypoxia by upregulating PINCH-ILK-Akt 
survival pathway [144]. After coronary artery ligation in mice, Tβ4 treatment resulted in 
upregulation of ILK and Akt activity, which enhanced early myocyte survival and improved 
cardiac function [143]. Figure 12 summarizes the moonlighting properties of Tβ4. 
All these observations make Tβ4 a potential therapeutic agent, although its mode of action 
remains largely unknown [129].  
Figure 12. Moonlighting 
properties of Tβ4. Tβ4 has 
many functions in addition to its 
role as major actin sequestering 
molecule. It stimulates the 
migration of endothelial cells 
and has anti-inflammatory and 
anti-microbial properties. More-
over, it protects the heart from 
damage following myocardial 
infarction and accelerates the 
process of healing and re-
modeling of tissues such as 
dermis or cornea [129]. 
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2. AIM OF THE STUDY 
Rearrangements of the actin cytoskeleton play a crucial role for platelet formation and reactivity 
and several actin-binding proteins have already been reported to be importantly involved in 
these processes, such as the ADF-H family members Cofilin and Twf2a. Therefore, we were 
interested to investigate the role of two additional actin-binding proteins, the ADF-H family 
protein Cotl1 and the actin-sequestering protein Tβ4, in platelet formation and function by 
analyzing a conditional (Cre-loxP system) Cotl1fl/lf-Pf4Cre and a constitutive Tβ4-/- knock-out 
mouse line. Moreover, although the role of the second major actin-sequestering protein Pfn1 
for platelet formation has already been described, we aimed to further investigate the loss of 
Pfn1 for platelet function and reactivity using a conditional Pfn1fl/f-Pf4Cre mouse.  
Given the fact that platelets exert key roles in hemostasis under physiological conditions as 
well as during thrombotic events under pathological conditions, progress in elucidating platelet 
signaling pathways is essential to identify new potential targets for antithrombotic therapy. 
Exogenous Tβ4 has been shown to protect heart tissue from cell death after myocardial 
infarction. It is thought to exert its various beneficial effects by upregulation of the survival 
kinase Akt. However, the distinction between endo- and exogenous protein function, its release 
mechanisms, its uptake and its mode of action is mostly unknown. Therefore, with the analysis 
of a constitutive knockout of Tβ4, we aimed to investigate its effect on platelet physiology, 
hemostasis, thrombosis and ischemia and to shed light on the underlying signaling network by 
analyzing the effect of recombinant Tβ4. 
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3. MATERIALS AND METHODS 
3.1 Materials 
3.1.1 Chemicals and Reagents 
A23187       AppliChem (Darmstadt, Germany) 
Acetic acid       Roth (Karlsruhe, Germany) 
Adenosine diphosphate (ADP)    Sigma-Aldrich (Steinheim, Germany) 
Adenosine triphosphate (ATP)   NEB (Frankfurt am Main, Germany) 
Agarose       Roth (Karlsruhe, Germany) 
Alexa F488       Molecular Probes (Eugene, USA) 
Alexa F647       Molecular Probes (Eugene, USA) 
Ammonium persulfate (APS)    Roth (Karlsruhe, Germany) 
Apyrase (grade III)      Sigma-Aldrich (Steinheim, Germany) 
Aspirin       Bayer (Wuppertal, Germany) 
β-mercaptoethanol      Roth (Karlsruhe, Germany) 
Botrocetin       Pentapharm Ltd. (Basel, CH) 
Bovine serum albumin (BSA)    Sigma-Aldrich (Steinheim, Germany) 
Bromophenol blue (3’,3”,5’,5”-tetrabromophenol- Sigma-Aldrich (Steinheim, Germany) 
sulfonphthalein)       
Cacodylate       AppliChem (Darmstadt, Germany) 
Calcium chloride (CaCl2)     Roth (Karlsruhe, Germany) 
Chloroform       AppliChem (Darmstadt, Germany) 
Collagen Horm® suspension + SKF sol.   Takeda (Linz, Austria) 
Coomassie Brilliant Blue G-250   Roth (Karlsruhe, Germany) 
Complete protease inhibitors (#11836153001) Roche Diagnostics (Mannheim, Germany) 
Convulxin (CVX)      Enzo Life Sciences (New York, USA) 
Cryo-Gel       Leica Microsystems (Wetzlar, Germany) 
Cytochalasin D      AppliChem (Darmstadt, Germany) & 
       Abcam (Cambridge, UK) 
4',6-diamidino-2-phenylindole (DAPI)   Invitrogen (Karlsruhe, Germany) 
Dade® Innovin (tissue factor)   Siemens Healthcare Diagnostics 
(Deerfield, IL, USA)  
Dimethyl sulfoxide (DMSO)     Sigma-Aldrich (Steinheim, Germany) 
Disodiumhydrogenphosphate (Na2HPO4 x 2H2O) Roth (Karlsruhe, Germany) 
Dithiothreitol (DTT)     Roth (Karlsruhe, Germany) 
DreamTaq DNA Polymerase (5 U L-1)  Life Technologies (Darmstadt, Germany) 
DreamTaq Green PCR Master Mix, 2x   Life Technologies (Darmstadt, Germany  
Dry milk, fat-free      AppliChem (Darmstadt, Germany) 
Deoxynucleotide triphosphates (dNTP) mix  Life Technologies, Darmstadt, Germany  
DNAse I   NEB (Frankfurt am Main, Germany) 
DyLight-488       Pierce (Rockford, USA) 
DyLight-649       Pierce (Rockford, USA) 
Epinephrine      Sigma-Aldrich (Steinheim, Germany) 
Ethylenediaminetetraacetic acid (EDTA)   AppliChem (Darmstadt, Germany) 
Ethylene glycol tetraacetic acid (EGTA)   Sigma-Aldrich (Steinheim, Germany) 
Eukitt® quick-hardening mounting medium   Sigma-Aldrich (Steinheim, Germany) 
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Enhanced chemiluminescence (ECL)   MoBiTec (Göttingen, Germany) 
detection substrate 
Eosin        Roth (Karlsruhe, Germany) 
Ethanol       Roth (Karlsruhe, Germany) 
Fentanyl       Janssen-Cilag GmbH (Neuss, Germany) 
Fetal calf serum (FCS)    Gibco (Karlsruhe, Germany) 
Fibrinogen from human plasma (F3879+ F4883)  Sigma-Aldrich (Steinheim, Germany) 
Fluorescein-isothiocyanate (FITC)    Molecular Probes (Oregon, USA) 
Fluoroshield™      Sigma-Aldrich (Steinheim, Germany) 
Fluorshield™ with DAPI     Sigma-Aldrich (Steinheim, Germany) 
Fura2/acetoxymethyl ester (AM)  Invitrogen (Karlsruhe, Germany) 
GeneRuler DNA Ladder Mix   NEB (Frankfurt am Main, Germany)  
Glucose       Roth (Karlsruhe, Germany) 
Glutaraldehyde      EMS (Hatfield, USA) 
Glycerol       Roth (Karlsruhe, Germany) 
Glycine      AppliChem (Darmstadt, Germany) 
Hematoxylin       Sigma-Aldrich (Steinheim, Germany) 
High molecular weight heparin    Ratiopharm (Ulm, Germany) 
Hydrochloric acid (HCl)    Roth (Karlsruhe, Germany)   
N-2-Hydroxyethylpiperazine-N'-2-ethane sulfonic  Roth (Karlsruhe, Germany) 
acid (HEPES)    
Igepal® CA-630      Sigma-Aldrich (Steinheim, Germany) 
Immobilon® PVDF transfer membrane  Merck Millipore (Darmstadt Germany) 
Indomethacin  Alfa Aesar (Karlsruhe, Germany) 
Integrilin® (Eptifibatide)   Millennium Pharmaceuticals Inc. 
(Cambridge, USA) 
Ionomycin      Invitrogen (Karlsruhe, Germany) 
Isopropyl-β-D-thiogalactopyranoside (IPTG)  Roth (Karlsruhe, Germany) 
Iron-III-chloride hexahydrate (FeCl3 x 6 H2O) Roth (Karlsruhe, Germany) 
Isofluran CP®       cp-pharma (Burgdorf, Germany) 
Isopropanol       Roth (Karlsruhe, Germany) 
Kanamycin sulfate      Roth (Karlsruhe, Germany) 
Latrunculin A       AppliChem (Darmstadt, Germany) & 
       Abcam (Cambridge, UK) 
Lysozym      Roth (Karlsruhe, Germany)   
Magnesium chloride (MgCl2)    Roth (Karlsruhe, Germany) 
Magnesium sulfate      Roth (Karlsruhe, Germany) 
Manganase chloride      Roth (Karlsruhe, Germany) 
MDL-28170       Sigma-Aldrich (Steinheim, Germany) 
Medetomidine (Dormitor)     Pfizer (Karlsruhe, Germany) 
Methanol       Roth (Karlsruhe, Germany) 
Midazolam (Dormicum)     Roche (Grenzach-Wyhlen, Germany) 
Midori Green™      Biozym Scientific (Oldenburg, Germany) 
3-(N-morpholino) propanesulfonic acid (MOPS) AppliChem (Darmstadt, Germany) 
NuPAGE® LDS Sample Buffer (4x)    Life Technologies (Darmstadt, Germany) 
Osmium tetroxide      Merck Millipore (Darmstadt, Germany) 
PageRuler® Prestained Protein Ladder   Fermentas (St. Leon-Rot, Germany) 
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Paraformaldehyde (PFA)     Roth (Karlsruhe, Germany) 
Phalloidin       AppliChem (Darmstadt, Germany) 
Phalloidin-Atto647N      Sigma-Aldrich (Steinheim, Germany) 
Phalloidin-FITC      Enzo Life Sciences (New York, USA) 
Phenol/chloroform/isoamyl alcohol    AppliChem (Darmstadt, Germany) 
Phenylmethylsulfonyl fluoride (PMSF)  Life Technologies, Darmstadt, Germany 
Piperazine-N,N′-bis(2-ethanesulfonic acid)  Roth (Karlsruhe, Germany)  
(PIPES) 
Poly-L-lysine       Sigma-Aldrich (Steinheim, Germany) 
Potassium acetate      Roth (Karlsruhe, Germany) 
Potassium chloride (KCl)    Roth (Karlsruhe, Germany) 
Pluronic F-127     Invitrogen (Karlsruhe, Germany) 
Propidium iodide (PI)     Invitrogen (Karlsruhe, Germany) 
Prostacyclin (PGI2)      Calbiochem (Bad Soden, Germany)  
Proteinase K   NEB GmbH, Frankfurt am Main, Germany 
RNase A (# R4875)  Sigma-Aldrich (Steinheim, Germany) 
R-phycoerythrin (PE)     EUROPA (Cambridge, UK) 
Rotiphorese Gel 30% (PAA)     Roth (Karlsruhe, Germany) 
SeeBlue® Plus2 pre-stained standard   Life Technologies (Darmstadt, Germany)  
Sodium azide (NaN3)     Sigma-Aldrich (Steinheim, Germany) 
Sodium bicarbonate (NaHCO3)   Roth (Karlsruhe, Germany) 
Sodium chloride (NaCl)    AppliChem (Darmstadt, Germany) 
Sodium citrate      AppliChem (Darmstadt, Germany) 
Sodiumdihydrogenphosphate (NaH2PO4)   Roth (Karlsruhe, Germany) 
Sodium dodecyl sulfate (SDS)    Sigma-Aldrich (Steinheim, Germany) 
Sodium hydroxide (NaOH)    AppliChem (Darmstadt, Germany) 
Sodium orthovanadate (Na3VO4)   Sigma-Aldrich (Steinheim, Germany) 
Sucrose       Sigma-Aldrich (Steinheim, Germany) 
Spectra™ Multicolor Low Range Protein Ladder  Thermo Scientific (Rockford, lL, USA) 
Sulfuric acid (H2SO4)     Roth (Karlsruhe, Germany) 
10x Taq Buffer (+KCl, -MgCl2)   NEB (Frankfurt am Main, Germany) 
Taq-Polymerase   NEB (Frankfurt am Main, Germany) 
Taxol        AppliChem (Darmstadt, Germany) 
Tetramethylethylenediamine (TEMED)   Roth (Karlsruhe, Germany) 
3,3,5,5-tetramethylbenzidine (TMB)    EUROPA (Cambridge, UK) 
Thrombin from human plasma    Roche Diagnostics (Mannheim, Germany) 
Sigma-Aldrich (Steinheim, Germany) 
Thymosin β4 (recombinant)    Peprotech (Rocky Hill, USA) 
Tris(hydroxymethyl)aminomethane (Tris)   Roth (Karlsruhe, Germany) 
Triton X-100       Sigma-Aldrich (Steinheim, Germany) 
TRIzol®       Invitrogen (Karlsruhe, Germany) 
Tryptone      Roth (Karlsruhe, Germany) 
Tween 20®       Roth (Karlsruhe, Germany) 
U46619       Alexis Biochemicals (San Diego, USA) 
Uranyl acetate      EMS (Hatfield, USA) 
Vectashield hardset mounting medium   Vector Labs, Inc. (Burlingame, USA) 
Water, nuclease-free      Roth (Karlsruhe, Germany) 
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Yeast extract      AppliChem (Darmstadt, Germany) 
Rhodocytin (Rhd) was kindly provided by J. Eble (University Hospital Frankfurt, Germany). 
Collagen-related peptide (CRP) was a generous gift from Paul Bray (Baylor College, USA). 
Annexin V (Anxa5) was generously provided by Jonathan F. Tait (Medical Center Washington, 
USA) and conjugated in our lab. 
3.1.2 Consumables, Kits 
NucleoSpin® Gel and PCR Clean-up kit   Macherey-Nagel (Düren, Germany) 
NucleoSpin® Plasmid     Macherey-Nagel (Düren, Germany) 
SuperScript® First-Strand Synthesis System  Invitrogen (Karlsruhe, Germany) 
NuPAGE® Novex® 4-12% Bis-Tris Gels, 1mm,  Life Technologies (Darmstadt, Germany)  
15 well 
NuPAGE® Novex® 16% Tricine Gels, 1mm,  Life Technologies (Darmstadt, Germany) 
15 well 
TxB2 ELISA Kit     DRG (Marburg, Germany) 
Total LT ELISA Kit (MSB747931)   My Biosource (San Diego, USA) 
Nunc® 96 DeepWell™ plate, MediSorb  Nunc (Roskilde Denmark) 
CHRONO-LUME #395 Luciferin-Luciferase  CHRONO-LOG (Havertown, USA) 
3.1.3. Molecular cloning 
Fast-Alkine Phosphatase   NEB (Frankfurt am Main, Germany) 
Quick Ligation™ Kit   NEB (Frankfurt am Main, Germany) 
FastDigest® Restriction Enzymes   NEB (Frankfurt am Main, Germany) 
5x Phusion® buffer HF  NEB (Frankfurt am Main, Germany) 
Phusion® High-Fidelity DNA polymerase   NEB (Frankfurt am Main, Germany) 
3.1.4. Plasmids 
pETM-52: E. coli expression vector providing N-terminal DsbA, hexahistidine (6x His)-tobacco 
etch virus (TEV) protease recognition site and a C-terminal 6x His sequence; resistance: 
Kanamycin. European Molecular Biology Laboratory (Heidelberg, Germany) [149]. 
3.1.5. Escherichia (E.) coli strains 
Competent TOP10 E. coli     Iba Lifesciences (Göttingen, Germany) 
(E. coli F- mcrA (mrr- hsdRMS- mcrBC) 80lacZ M15 lacX74 recA1 ara139 (ara-leu)7697 galU galK rpsL 
(StrR) endA1 nupG) 
 
BL21-CodonPlus R (DE3)    Stratagene (San Diego, USA) 
(E. coli B F- ompT hsdS(rB- mB-) dcm+ Tetr gal λ (DE3) endA Hte[argU ileY leuW Camr]*) 
*Concentration of antibiotic used for selection: chloramphenicol 34 μg mL-1 
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3.1.6 Antibodies 
3.1.6.1 Commercial antibodies 
Antibody Origin  Manufacturer 
anti-α-tubulin (B-5-1-2) mouse Sigma-Aldrich (Steinheim, Germany) 
anti-β-actin rabbit Sigma-Aldrich (Steinheim, Germany) 
anti-β-tubulin mouse Sigma-Aldrich (Steinheim, Germany) 
anti-CD105 rat BioLegend (San Diego, USA) 
anti-Cofilin rabbit Cell Signaling (Denver, USA) 
anti-Cotl1 (10781-1-AP) rabbit Proteintech (Manchester, UK) 
anti-Cdc42 (# ACD03-S) mouse Cytoskeleton (Denver, USA) 
anti-FlnA (EP2405Y) rabbit Epitomics (Burlingame, USA) 
anti-GAPDH (G5262) rabbit Sigma-Aldrich (Steinheim, Germany) 
anti-Itgb3 (β3 integrin) Ab762 und 
AbΔ747 rabbit * 
anti-LAT (#5347) rabbit Cell Signaling (Denver, USA) 
anti-phospho-Cofilin Ser 3  rabbit Cell Signaling (Denver, USA) 
anti-phospho-LAT (Y132) ab4476 rabbit Abcam (Cambridge, UK) 
anti-phospho-tyrosine (clone 4G10) mouse Merck Millipore (Darmstadt, Germany) 
anti-phospho-PLCγ2 (Y759)  
(#3874)  rabbit Cell Signaling (Danvers, MA; USA)  
anti-total-PLCγ2 (Q-20) (#sc-407)  rabbit Santa Cruz (Heidelberg, Germany) 
anti-Profilin1 (#sc-137235) mouse Santa Cruz (Heidelberg, Germany) 
anti-phospho-Syk (Y525/526) 
(clone C87C1) (#2710)  rabbit Cell Signaling (Danvers, MA; USA) 
anti-total-Syk (clone D1I5Q) 
(#12358)  rabbit Cell Signaling (Danvers, MA; USA) 
anti-Thymosin β4 (A 9522.1) rabbit Immundiagnostik (Bensheim, Germany) 
anti-Tln1 (C-20, #sc-7534) & (A-11, 
#sc-365460) goat Santa Cruz (Dallas, USA) 
anti-Twf1 rabbit ** 
anti-Twf1/2 rabbit ** 
anti-vWF mouse DAKO (Hamburg, Germany) 
platelet depletion antibody rat Emfret Analytics (Eibelstadt, Germany) 
*Anti-Itgb3 Ab762 und AbΔ747 were kindly provided by Xiaoping Du (University of Illinois, 
Chicago IL 60612, USA) 
**Anti-Twf1 and anti-Twf1/2 antibodies were generously provided by Pekka Lappalainen 
(Helsinki, Finland). 
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Antibody conjugate Origin  Manufacturer 
anti-α-tubulin-Alexa F488 mouse Invitrogen (Karlsruhe, Germany) 
anti-CD29-FITC (HMβ1-1) hamster BioLegend (San Diego, USA) 
anti-mouse IgG-Cy3 donkey Jackson Immuno (Suffolk, UK) 
anti-mouse IgG-Alexa F405 donkey Jackson Immuno (Suffolk, UK) 
anti-mouse IgG-Alexa F488 goat Invitrogen (Karlsruhe, Germany) 
anti-mouse IgG-HRP rat DAKO (Hamburg, Germany) 
anti-goat IgG-Cy3 donkey BioLegend (San Diego, USA) 
anti-rabbit IgG-Cy3 goat Jackson Immuno (Suffolk, UK) 
anti-rabbit IgG-Alexa F647 goat Invitrogen (Karlsruhe, Germany) 
anti-rabbit IgG-Alexa F488 donkey Invitrogen (Karlsruhe, Germany) 
anti-rabbit IgG-HRP goat Cell Signaling (Denver, USA) 
anti-rabbit IgG-HRP donkey Jackson Immuno (Suffolk, UK) 
anti-rat IgG-Cy3 goat BioLegend (San Diego, USA) 
anti-rat IgG-Cy3 donkey Jackson Immuno (Suffolk, UK) 
anti-rat IgG-Alexa F405 donkey Jackson Immuno (Suffolk, UK) 
anti-rat IgG-Alexa F488 goat Invitrogen (Karlsruhe, Germany) 
anti-rat IgG-HRP goat Dianova 
 
3.1.6.2 Home-made antibodies 
The monoclonal antibodies listed below were generated in our laboratory and labeled with 
either fluorescein isothiocyanate (FITC) or with phycoerythrin (PE) using commercial kits 
following manufacturer’s instructions. Annexin-A5 was purified in our laboratory and coupled 
to DyLight488. 
Antibody  Clone Isotype Antigen Described in 
p0p3 7A9 IgG2a GPIbα [150] 
p0p4 15E2 IgG2b GPIbα [151] 
p0p5 13G12 IgG1 GPIbα [152] 
p0p/B 57E12 IgG2b GPIbα [153] 
p0p1 3G6 IgG1 GPIbβ [150] 
DOM2 89H11 IgG2a GPV [151] 
p0p6 56F8 IgG2b GPIX [151] 
JAQ1 98A3 IgG2a GPVI [154] 
INU1 11E9 IgG1 CLEC-2 [155] 
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ULF1 97H10 IgG2a CD9 [151] 
JER1 10B6 IgG1 CD84 [156] 
LEN1 12C6 IgG2b α2 [157] 
MWReg30 5D7 IgG1 αIIb [150] 
BAR-1 25B11 IgG1 α5 [157] 
EDL-1 57B10 IgG2a β3 [151, 157] 
JON/A 4H5 IgG2b αIIbβ3 [152, 157] 
JON6 14A3 IgG2b αIIbβ3 unpublished 
WUG 1.9 5C8 IgG1 P-selectin unpublished 
HB.197™ 2.4G2 IgG2b FcgR [158] 
 
3.1.7. Buffers and Media 
All buffers were prepared using deionized water obtained from a MilliQ Water Purification 
System (Millipore, Schwalbach, Germany). pH was adjusted using HCl or NaOH.  
Acid-Citrate-Dextrose (ACD) Buffer, pH 4.5 
Trisodium citrate dehydrate        85 mM 
Anhydrous citric acid        65 mM 
Anhydrous glucose         110 mM 
 
Blocking Buffer (Western Blot) 
Washing Buffer (1x)        — 
BSA or fat-free dry milk        5% 
 
Blocking Buffer (Immunohistochemistry) 
PBS (1x)         — 
Tween 20®          0.1% 
BSA           3% 
Rat serum          0.3% 
 
Coating Buffer, pH 9.6 
Na2CO3          15 mM 
NaHCO3          85 mM 
 
Coomassie Staining Solution 
Acetic acid          10% 
Methanol          40% 
Coomassie Brilliant blue        0.01% 
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Coomassie Destaining Solution 
Acetic acid          10% 
Methanol          40% 
H2O           50% 
 
Cytoskeleton Extraction Buffer 
1x PHEM         — 
Triton X-100          0.75% 
Phalloidin          1 μM 
Taxol           1 μM 
 
Decalcification Buffer, pH 7.4 
PBS (1x)         — 
EDTA           10% 
 
Fixation Buffer I (Electron microscopy) 
Cacodylate, pH 7.2         0.1 M 
Glutaraldehyde         2.5% 
Formaldehyde         2% 
 
Fixation Buffer II (Electron microscopy) 
Sodium cacodylate, pH 7.2        50 mM 
Osmium tetroxid         2% 
 
Fluorescent Thrombin Substrate 
 Z-GGR-AMC          2.5 mM 
 HEPES         20 mM 
 NaCl          140 mM 
 CaCl2          200 mM 
BSA          6% 
 
Gel Filtration Buffer 
Tris base, pH 8.0        50 mM 
NaCl          150 mM 
DTT          5 mM 
 
IP Buffer (Phosphorylation studies) 
Tris base, pH 8.0        15 mM 
NaCl          155 mM 
EDTA          1 mM 
NaN3          0.005% 
Na3VO4         4 mM 
Protease Inhibitor Mix       1x 
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 Igepal®CA-630        1% 
 
Karnovsky Fixation Buffer, pH 7.2 
Paraformaldehyde         2% 
Glutaraldehyde         2.5% 
Cacodylate          0.1 M 
 
Laemmli Buffer (SDS-PAGE) 
Tris base          40 mM 
Glycine          0.95 M 
SDS           0.5% 
 
LB Medium 
Peptone (pancreatic digested)       10 g L-1 
Yeast extract          5 g L-1 
NaCl           171 mM 
 
LB Plates 
LB-Medium         — 
Agar           15 g L-1 
 
Lysis Buffer (DNA Lysis) 
Tris base          100 mM 
EDTA          5 mM 
NaCl           200 mM 
SDS           0.2% 
Freshly added Proteinase K (20 mg mL-1)      100 μg mL-1 
 
Lysis Buffer (Protein Purification) 
Tris base, pH 8.0        50 mM 
NaCl          150 mM 
Lysozym         100 mg 
DNAse I         1 U mL-1 
DTT          1 mM 
 
PBS/EDTA (Platelet Lysates) 
PBS (1x)         — 
EDTA           5 mM 
 
PBS Fixation Buffer 
PBS (1x)         — 
PFA           4% 
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PHEM Buffer, pH 6.8 
PIPES          100 mM 
HEPES          5.25 mM 
EGTA           10 mM 
MgCl2           20 mM 
 
PHEM Complete Buffer 
PHEM Fixation Buffer       — 
Igepal®CA-630         0.1% 
 
PHEM Fixation Buffer 
PHEM (1x)         — 
PFA           4% 
 
Phosphate-Buffered Saline (PBS), pH 7.14 
NaCl           137 mM 
KCl           2.7 mM 
KH2PO4          1.5 mM 
Na2HPO4 x 2H2O         8 mM 
 
PRP Reagent (Thrombin generation assay) 
 HEPES         20 mM 
 NaCl          140 mM 
 BSA          0.5% 
 Tissue Factor         3 pM 
 
Sample Buffer (Agarose Gels), 6x 
Tris base (150 mM)         33% 
Glycerol          60% 
Bromophenol blue        0.04%  
 
SDS Sample Buffer, 4x 
Tris base (1 M), pH 6.8        20% 
Glycerol          40% 
SDS           4% 
β-mercaptoethanol (reducing conditions)      20% 
Bromophenol blue         0.04% 
 
Separating Gel Buffer (Western Blot), pH 8.8 
Tris base         1.5 M 
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Stacking Gel Buffer (Western Blot), pH 6.8 
Tris base         0.5 M 
 
Stripping Buffer (Western Blot), pH 2.0 
PBS (1x)          — 
Glycine          25 mM 
SDS           1% 
 
Sodium-Citrate-Buffer, pH 7.0 
Sodium Citrate         0.129 M 
 
TAE, 50x, pH 8.0 
Tris base          0.2 M 
Acetic acid          5.7% 
EDTA           50 mM 
 
TE-Buffer, pH 8.0 
Tris base          10 mM 
EDTA           1 mM 
 
Transfer-Buffer (Western Blot) 
Tris Ultra          50 mM 
Glycine          40 mM 
Methanol          20% 
 
Tris-Buffered Saline (TBS), pH 7.3 
NaCl           137 mM 
Tris base         20 mM 
 
Tyrode’s Buffer, pH 7.3 
NaCl           137 mM 
KCl           2.7 mM 
NaHCO3          12 mM 
NaH2PO4          0.43 mM 
HEPES          5 mM 
CaCl2           2 mM 
MgCl2           1 mM 
BSA           0.35% 
Glucose          0.1% 
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Washing Buffer PBS-T (ELISA) 
PBS (1x)         — 
Tween 20®          0.1% 
 
Washing Buffer TBS-T (Western Blot) 
TBS (1x)         — 
Tween 20®          0.1% 
3.1.8 Chromatography columns and media 
Superdex Increase 75 10/300 GL (Analytical SEC FPLC column) and Ni-NTA Agarose were 
purchased from GE Healthcare (Munich, Germany). 
3.1.9 Genetically modified mice 
Cotl1+/- mice were created by injection of embryonic stem cell clone Cotl1tm1a(EUCOMM)Hmgu 
(European Conditional Mouse Mutagenesis Program (EUCOMM)) into C57Bl/6 blastocysts. 
Germline transmission was achieved by backcrossing of the resulting chimeric mice with 
C57Bl/6 mice. These mice were further intercrossed with mice carrying the Flp-recombinase 
to generate Cotl1fl/fl mice, which were, in a final step, intercrossed with mice carrying the Cre-
recombinase under the platelet factor 4 (PF4) promoter [159] to generate animals lacking Cotl1 
specifically in MKs and platelets. Conditional Pfn1fl/f-Pf4Cre mice have been generated by 
intercrossing Pfn1fl/fl mice (obtained from EUCOMM, Strain ID EM: 03711) with mice carrying 
the Cre-recombinase under the platelet factor 4 (Pf4) promoter [159]. Tβ4-/- mice were created 
by MRC mouse network by injection of embryonic stem cell clone Tmsb4xtm2a(EUCOMM)Wtsi into 
C57Bl/6/129/SvJ blastocysts and afterwards transferred to our animal facility where the KO 
mice were kept on the mixed background.  
If not stated otherwise, 8- to 16-week-old mice of either sex were used in experiments. Animal 
studies were approved by the district government of Lower Frankonia (Bezirksregierung 
Unterfranken). 
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3.2 Methods 
3.2.1 Genotyping of mice 
3.2.1.1 Isolation of genomic DNA from mouse ears 
A 5 mm2 piece of mouse ear was incubated in 500 μL lysis buffer under constant shaking at 
900 rpm o/N or at 1,400 rpm for 3 h at 56°C. Cellular proteins and lipids were removed by the 
addition of 500 μL of phenol/chloroform/isoamyl alcohol (25:24:1). Samples were mixed and 
centrifuged for 10 min at 10,000 rpm in an Eppendorf 5417R tabletop centrifuge at RT. After 
centrifugation, the aqueous nucleic acid containing upper phase was transferred into a new 
tube containing 500 μL isopropanol to precipitate the DNA. Subsequently, the nucleic acids 
were spun down at 14,000 rpm for 15 min. The pellet was washed and dehydrated by the 
addition of 500 μL 70% ethanol with subsequent centrifugation at 14,000 rpm for 10 min. Before 
dissolving the pellet in 50 μL TE buffer, the pellet was dried for 30 min at 37°C. 
3.2.1.2 Polymerase Chain Reaction (PCR) 
The pipetting scheme shown is representative for 1 sample (final volume: 25 μL) for the below 
described genotyping PCRs. 
2.0 μL DNA sample 
2.5 μL 2 x Dream Taq Buffer (+KCl, +MgCl2)  
0.5 μL dNTPs [10 mM]     
1 μL forward Primer [1 μg mL-1]    
1 μL reverse Primer [1 μg mL-1]    
0.25 μL Dream Taq-Polymerase [5 U μL-1]   
18.75 μL H2O       
Detection of the Pfn1 floxed allele 
• Primer 
Pfn1_i2_f2: 5’ TTC TGA CTC TGG CTC CCC AG 3’ 
Pfn1_i2_r2: 5’ GCT AGG AAC GGC TGT GAT GC 3’ 
• Program 
Temperature 
[°C]  
Time 
[s] 
Repeats 
96 180 1 
94 30 35 
55.5 30 35 
72 60 35 
72 300 1 
22 ∞ 1 
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• Expected band sizes 
WT: 187 bp 
Floxed allele: 221 bp 
Detection of the Cotl1 floxed allele 
• Primer 
Cotl1_for: 5´ GGA GGA CGT GAG TGG ACT GCA GCG 3´ 
Cotl1_rev: 5´ TGA ACT GAT GGC GAG CTC AGA CC 3´ 
Cotl1_5´arm: 5´ GGGACATCGTCACCATGGGAACGG 3´ 
Cotl1_3´: 5´ TAG CTG GCG TAG ATG CAC ACC ACC 3´ 
Cotl1_LAR3: 5´ CAA CGG GTT CTT CTG TTA GTC C 3´ 
• Program 
Temperature 
[°C]  
Time 
[s] 
Repeats 
96 180 1 
94 30 35 
60 30 35 
72 60 35 
72 300 1 
22 ∞ 1 
 
• Expected band sizes 
WT: 224 bp 
Floxed allele: 354 bp & 450 bp for the LAR3 cassette 
Detection of the Tβ4 transgene allele 
• Primer 
Tβ4_fw: 5´ GTG CTT TTG GAA CTG GGA GA 3´ 
Tβ4_rev: 5´ AGC CCG TTC TGA AAA TGG 3´ 
Tβ4_GT: 5´ GGC CTT CTT GAC GAG TTC TT 3´ 
• Program 
Temperature 
[°C]  
Time 
[s] 
Repeats 
96 180 1 
94 30 35 
63.5 30 35 
72 60 35 
72 300 1 
22 ∞ 1 
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• Expected band sizes 
WT: 190 bp 
Genetrap+: 600 bp 
Detection of the PF4 Cre transgene 
• Primer 
PF4_for: 5´ CCC ATA CAG CAC ACC TTT TG 3´ 
PF4_ rev: 5´ TGC ACA GTC AGC AGG TT 3´ 
• Program 
 
 
 
 
 
 
 
 
 
 
 
• Expected band sizes 
WT allele: no PCR product 
PF4-Cre+: 450 bp 
3.2.1.3 Semiquantitative reverse transcription PCR (RT-PCR) 
For reverse transcription of RNA, two different Mastermixes were prepared: 
• Mastermix 1 pipetting scheme 
1.0 μg RNA 
2.0 μL oligo dT Primer [0.5 μg μL-1] 
add 20 μL H2O 
Mastermix 1 was denaturated for 10 min at 70°C and subsequently cooled on ice. 
• Mastermix 2 pipetting scheme 
5.0 μL 5x first strand buffer 
2.0 μM DTT [0.1 M] 
1.0 μL dNTPs [10 mM] 
0.1 μL RNAse inhibitors [5 U mL-1] 
Mastermix 1 and 2 were pooled and 1 μL of SuperScript® II Reverse Transcriptase                      
[200 U μL-1] was added. Amplification was performed for 1 to 2 h at 42°C in a thermomixer and 
afterwards the reaction was aborted by incubation of the samples for 10 min at 70°C. The 
generated cDNAs were stored at -20°C. The mRNA expression levels were determined by 
Temperature 
[°C]  
Time 
[s] 
Repeats 
96 300 1 
94 30 35 
54.1 30 35 
72 45 35 
72 30 1 
22 ∞ 1 
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PCR, optimal annealing temperature for the used primers was identified via gradient PCR. 
Gapdh expression was determined as control. 
• Mastermix for semi-quantitative RT-PCR 
2.0 μL cDNA sample 
2.0 μL 10x Taq Buffer (+KCl, -MgCl2) 
1.2 μL MgCl2 [25 mM] 
0.4 μL dNTPs [10 mM] 
0.1 μL forward Primer [1 μg mL-1] 
0.1 μL reverse Primer [1 μg mL-1] 
0.125 μL native Taq-Polymerase [5 U μL-1] 
14.075 μL H2O 
• Primer 
Tβ4_RT_for: 5´ GAG CAG ATC AGA CTC TCC TCG 3´ (annealing temperature 45°C) 
Tβ4_RT_rev: 5´ GAA GGC AAT GCT CGT GGA ATG 3´ (annealing temperature 60.8°C) 
GAPDH_RT_for: 5‘ GCA AAG TGG AGA TTG TTG CCA T 3‘ 
GAPDH_RT_rev: 5‘ CCT TGA CTG TGC CGT TGA ATT T 3‘ 
• Program 
Temperature 
[°C]  
Time 
[s] 
Repeats 
96 180 1 
94 30 35 
45-61 30 35 
72 60 35 
72 300 1 
22 ∞ 1 
 
• Expected band sizes 
Tβ4: 280 bp. 
GAPDH: 108 bp. 
 
3.2.1.4 Agarose gel electrophoresis 
PCR products were separated on agarose gels. A molecular weight marker with a range from 
100 to 10,000 bp was run on the gels to control the size of the products. For a 1% agarose gel, 
1.0 g of agarose per 100 mL TAE buffer was boiled in microwave until it was dissolved. The 
cooled (60°C) agarose was submitted with the DNA marker Midori Green™ [50 μL L-1] and 
poured into a sleigh containing a comb. The cast gel was then laid into a chamber filled with 
1x TAE buffer. 20 μL of the PCR products were loaded onto the gels. The samples were 
separated for 30-45 min at 140 V. For big gels, 4 g agarose in 400 mL TAE buffer were used. 
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The big gels were run at 160 V. Finally, the DNA was visualized under ultra violet (UV) light 
and pictures were taken with a GelDoc system (Herolab GmbH, Germany). 
3.2.2 Biochemical analyses 
3.2.2.1 UV/Vis spectrophotometry 
The concentrations of purified DNA and proteins were determined by measuring the UV 
absorbance using a spectrophotometer (NanoDrop™, Thermo Scientific). Absorbance spectra 
in the wavelength range of 220-350 nm were recorded and corrected for the reference 
spectrum of the buffer solution devoid of DNA or protein. For DNA, the concentration was 
calculated based on the absorbance at 260 nm and the ratio of the absorbance at 260 nm and 
280 nm was used to control for the purity of the DNA. For proteins, the concentration was 
calculated based on the absorbance at 280 nm and the specific extinction coefficient of the 
respective protein, which was calculated based on the amino acid sequence using the 
ProtParam tool (Expasy). 
3.2.2.2 Sodium Dodecyl Sulfate (SDS)-Polyacrylamide Gel Electrophoresis (PAGE) 
For SDS-PAGE under denaturing conditions, samples were mixed with an equal volume of 
reducing 2x Loading Dye and boiled for 5 min at 95°C. Afterwards, samples were separated 
by their molecular weight following the protocol described by Laemmli [160]. Protein samples 
and a molecular-weight size marker were loaded to the gel installed in the electrophoresis 
chamber filled with running buffer. Electrophoresis was performed at 25 mA per gel until the 
dye had nearly traversed the gel. For staining, gels were first stained in Coomassie staining 
solution for up to 30 min and afterwards destained in Destaining solution. 
3.2.2.3 Immunoblotting 
Samples were separated by SDS-PAGE as described above and afterwards blotted onto 
polyvinylidene difluoride (PVDF) membranes and incubated with the respective primary 
antibodies (section 3.1.6) o/N at 4°C. For visualization, horseradish peroxidase (HRP)-
conjugated secondary antibodies were used and membranes were developed using an 
enhanced chemiluminescence (ECL) detection system with autoradiography films or digitally 
on a MultiImage® II FC Light Cabinet (Alpha Innotech cooperation) device.  
3.2.3 Molecular Cloning 
Classical cloning using restriction endonucleases was chosen as cloning strategy. For this, 
fragments with suitable overhangs containing the restriction endonuclease recognition site 
were amplified from cDNA by PCR. 
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3.2.3.1 PCR 
• Pipetting scheme (25 μL) 
10 ng template DNA 
1 x HF-buffer 
0.5 μM forward Primer 
0.5 μM reverse Primer 
0.5 μL dNTP mix 
1 U Phusion® polymerase high-fidelity 
• Primer 
Tβ4_NcoI: 5´ TTC AGG GCG CCA TGG GCT CCG ATA AGC CTG ATA TGG CAG 3´ 
Tβ4_XhoI: 5´ GTG GTG GTG CTC GAG TTA AGA CTC TCC AGC TTG TTT C 3´ 
• Program 
Temperature 
[°C]  
Time 
[s] 
Repeats 
96 180 1 
94 30 35 
60 30 35 
72 60 35 
72 300 1 
22 ∞ 1 
 
• Expected band size 
180 bp 
The PCR product was purified using the NucleoSpin® Gel and PCR Clean-up kit according to 
the manufacturer’s instructions.  
3.2.3.2 Restriction Digestion 
• Pipetting scheme (50 μL) 
1 µg Tβ4 Insert  
or 800 ng pETM-52 
3 µL XhoI-HF®  
3 µL NcoI-HF® 
5 µL CutSmart buffer 
Add H2O to 50 µL 
The DNA was digested for 4 h at 37°C. 10 U Fast Alkaline Phosphatase were added to the 
vector digestion reaction 15 min prior to the end of incubation. The products were separated 
by agarose gel electrophoresis and extracted using the NucleoSpin® Gel and PCR Clean-up 
kit.  
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3.2.3.3 Ligation  
For ligation the digested Insert and the linearized vector were mixed in a 8:2 or 9:1 ratio (insert: 
vector), and incubated for 5 min at 45°C, followed by 3 min on ice. Subsequently, the ligation 
mix was combined with Quick Ligation Buffer and 2,000 U Quick T4 DNA Ligase, and 
incubated for 30 min at RT. Ligation products were either directly transformed into E. coli 
TOP10 cells or stored at -20°C. 
3.2.3.4 Transformation of competent E. coli cells 
For transformation, chemically competent TOP10 E. coli were incubated with 10 ng of the 
ligation for 30 min on ice. Transformation was triggered by a 90 s heat shock at 42°C with 
subsequent incubation for 3 min on ice. Thereafter, bacteria were supplied with 500 µL LB-
medium and incubated at 450 rpm for 1.5 h at 37°C. Positive clones were selected by plating 
the transformation mixture on LB-agar plates containing the respective antibiotics.  
3.2.3.5 Colony-PCR 
To probe for positive clones, single colonies were studied in an analytical PCR following the 
protocol depicted below.  
• Pipetting scheme (50 μL) 
1 colony 
2.5 μL 2x DreamTaq Buffer (+KCl, +MgCl2)  
0.5 μL dNTPs [10 mM] 
0.1 μL forward Primer [1 μg mL-1] 
0.1 μL reverse Primer [1 μg mL-1] 
0.25 μL Dream Taq-Polymerase [5 U μL-1] 
21.55 μL H2O 
• Primer 
Tβ4_NcoI: 5´ TTC AGG GCG CCA TGG GCT CCG ATA AGC CTG ATA TGG CAG 3´ 
Tβ4_XhoI: 5´ GTG GTG GTG CTC GAG TTA AGA CTC TCC AGC TTG TTT C 3´ 
• Program 
Temperature 
[°C]  
Time 
[s] Repeats 
98 30 1 
98 10 30 
60 30 30 
72 10 30 
72 300 1 
22 ∞ 1  
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• Expected band size 
180 bp fpr positive clones 
Finally, all recombinant plasmids were verified by dideoxy sequencing executed by the 
company MWG (Eurofins Genomics, Ebersberg, Germany). 
3.2.3.6 Amplification and isolation of plasmid DNA 
Following sequencing, the desired clone was transformed into E. coli TOP10 cells and plated 
onto LB plates containing the respective antibiotics. On the next day, a single colony was 
transferred to 5 mL sterile LB medium with antibiotics and incubated under constant shaking 
at 220 rpm o/N at 37°C in an incubator shaker. Subsequently, cells were separated from the 
medium by centrifugation at 6,000 rpm for 15 min at 4°C. The plasmid DNA was isolated 
following the manufacturer’s instructions with the NucleoSpin® Plasmid kit. The DNA content 
of the samples was determined using a NanoDrop (Thermo Scientific) device. For long-term 
storage, glycerol stocks of the respective plasmids were created. For this, 800 µL of an o/N 
culture was added to 200 µL of sterile 10% glycerol, shock-frozen in liquid N2 and stored 
afterwards at -80°C. 
3.2.4 Protein expression and purification 
3.2.4.1 Small-scale expression 
To test the influence of different temperatures and durations on the protein yield, small-scale 
expressions (125 mL) were performed. For this, the E. coli expression strains BL21 (DE3), 
BL21 (DE3) pLysS and Rosetta 2™ pRARE2 were transformed with the plasmid and used to 
inoculate 5 mL sterile LB medium containing the appropriate antibiotics. Cultures were 
incubated under constant shaking at 220 rpm o/N at 37°C. Expression cultures were started 
by transferring pre-cultured cells to fresh LB-medium containing antibiotics (125 mL). Cultures 
were grown under constant shaking at 220 rpm at 37°C, while the optical density at 600 nm 
(O.D.600) was monitored. When the desired O.D.600 of 0.4-0.6 was reached, expression was 
induced by addition of IPTG [0.5 mM], and the cultures were incubated at 220 rpm o/N at 20°C. 
At the end of the expression phase, the cells were harvested by centrifugation at 4,000 rpm 
for 10 min at 4°C (Beckman Coulter centrifuge, Rotor type JLA-16.250) and the cell pellets 
were stored at -80°C until further use.  
3.2.4.2 Purification of small-scale expression 
The harvested cell pellets were resuspended in 10 mL per g lysis buffer supplemented with 1 
mM DTT. To separate the soluble and insoluble protein fraction, cells were first lysed 
mechanically by sonification (3x 30 sec) on ice. After centrifugation at 14,000 rpm for 15 min 
at 4°C, soluble and insoluble fractions were separated. The soluble fraction was subsequently 
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incubated with 0.1 mL Ni-NTA Agarose, which was previously washed 3x with lysis buffer, for 
1 h at 4°C. The Ni-NTA Agarose was spun down by centrifugation at 1,000 rpm for 1 min at 
4°C and the bound protein was eluted with 200 µL lysis buffer containing 250 mM Imidazol.   
50 µL sample was taken at every step of the purification and thereafter all samples were 
analyzed by SDS-PAGE and staining with Coomassie. As these initial purification tests already 
indicated a strong overexpression in E. coli BL21 (DE3) cells at 20°C, further optimization was 
dispensable. 
3.2.4.3 Large-scale expression 
For larger expressions, E. coli BL21 (DE3) cells were transformed with the plasmid and used 
to inoculate 125 mL sterile LB medium containing the appropriate antibiotics. Cultures were 
grown o/N as described in section 3.2.4.1 and transferred to 2 L LB medium containing the 
appropriate antibiotics. After induction of expression at an O.D.600 of 0.4-0.6 with 0.5 mM IPTG, 
cells were grown as described in section 3.2.4.1. At the end of the expression phase, cells 
were harvested by centrifugation at 6,000 rpm for 15 min at 4°C (Beckman Coulter centrifuge, 
Rotor type JA-10)  
3.2.4.4 Purification of large-scale expression 
Cell pellets of the large-scale expression were resuspended as described in section 3.2.4.2 
and lysed mechanically by sonification (5x 30 sec) on ice. The cell lysate was centrifuged at 
16,000 rpm for 1 h at 4°C (Beckman Coulter centrifuge, Rotor type JA 25.50). The supernatant 
was subsequently subjected to Immobilized Metal Affinity Chromatography (IMAC), which was 
performed in a batch procedure. For this, 1 mL Ni-NTA Agarose, washed 3x in lysis buffer, 
was incubated with the supernatant under constant stirring for 1 h at 4°C. The Ni-NTA agarose 
was transferred to an Econo-Column® 2.5x 20 cm column body (Bio-Rad Laboratories), 
washed intensively with at least 100 mL lysis buffer before the bound protein was eluted with 
25 mL lysis buffer supplemented with 250 mM Imidazol. The protein tag was cleaved off o/N 
at 4°C under constant stirring using 10 µg TEV Protease per mg protein. Next day, the 
untagged protein was separated from the cleaved His-DsbA tag by reverse IMAC. The protein 
was concentrated using Amicon Ultra® centrifugal filter units to a volume of 1 mL and further 
purified using size exclusion chromatography with a Superdex 75 10/300 GL column on an 
Äkta pure 25 system (GE Healthcare). Because of the potential in vivo use of the purified Tβ4, 
the size exclusion chromatography was performed in 1x PBS, pH 7.0. Afterwards the purified 
protein was concentrated using Amicon Ultra® centrifugal filter units and protein concentration 
was determined using a NanoDrop™ device (Thermo Scientific). The protein was stored until 
further usage at -80°C.  
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3.2.5 In vitro analysis of platelet function 
3.2.5.1 Platelet preparation and washing 
Mice were anesthetized using isoflurane and bled from the retro-orbital plexus up to 1 mL in 
300 μL heparin [20 U mL-1] or ACD buffer. 300 μL of heparin [20 U mL-1] were added and the 
samples were centrifuged at 800 rpm for 6 min. Subsequently, the upper phase and the buffy 
coat with some erythrocytes were transferred into 300 μL heparin [20 U mL-1]. To further purify 
the platelets, centrifugation was repeated (800 rpm, 6 min) and only the upper phase without 
any erythrocytes was pipetted into a new Eppendorf tube containing 2 μL of apyrase 
[0.02 U mL-1, f.c.] and 5 μL PGI2 [0.1 μg mL-1, f.c.]. Platelets were spun down at 2,800 rpm for 
5 min, resuspended in 1 mL of Tyrode’s buffer without Ca2+, containing 2 μL of apyrase 
[0.02 U mL-1, f.c.] and 5 μL PGI2 [0.1 μg mL-1, f.c.] and allowed to rest for 5 min at 37°C. The 
washing step was repeated twice, before the pellet was resuspended in an appropriate volume 
of Tyrode’s buffer without Ca2+ containing apyrase [0.02 U mL-1, f.c.] and the platelets were 
allowed to rest for 30 min prior to experiments. 
3.2.5.2 Plasma preparation 
Mice were bled to 1 mL as described above. The heparinized blood was centrifuged at         
2,800 rpm for 5 min and the supernatant was transferred into a new tube. After a second 
centrifugation step at 14,000 rpm for 5 min, the supernatant was collected. The plasma was 
either used directly or stored at -80°C. 
3.2.5.3 RNA preparation from platelets 
Animals were bled to 1 mL into 300 μL heparin [20 U mL-1] and washed platelets were prepared 
(see 3.2.5.1). The platelet pellets were resuspended in a total volume of 250 μL IP-buffer 
supplied with 1% NP-40, vortexed and incubated for 10 min at RT. After the addition of 1 mL 
TRIzol® reagent, the samples were incubated for 10 min at RT. Then, 250 μL of chloroform 
were added and the samples were incubated for 10 min at RT and afterwards centrifuged at 
10,000 rpm for 10 min at 4°C. The upper phase was then transferred into a tube containing     
1 mL chloroform/isoamyl alcohol (24:1), vortexed for 2 min and centrifuged again at 10,000 
rpm for 10 min at 4°C. Subsequently, the upper phase was pipetted into a new tube containing     
1 mL of ice cold isopropanol, mixed well and incubated for 30 min on ice. The nucleic acids 
were pelleted by centrifugation at 14,000 rpm for 10 min at 4°C, washed once with 70% ethanol 
(14,000 rpm, 10 min, 4°C), dried at RT for 30 min and finally resuspended in 20 μL RNase free 
water. The RNA content of the samples was determined using a NanoDrop (Thermo Scientific) 
device. 
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3.2.5.4 Determination of platelet size and count 
Mice were bled to 50 μL in 300 μL heparin [20 U mL-1] as described in section 3.2.5.1. The 
sample was filled up with 650 μL Tyrode’s buffer without Ca2+. Platelet count and size were 
assessed by incubating diluted, heparinized blood with fluorophore-conjugated antibodies 
directed against platelet-specific epitopes and subsequently analyzed by flow cytometry 
(FACSCalibur, BD Biosciences). Forward scatter (FSC) and the counts per second were 
determined. Alternatively, platelet count and size were measured in heparinized blood using a 
Sysmex analyzer (Sysmex KX-21N automated hematology analyzer; Sysmex Corp., Kobe, 
Japan). 
3.2.5.5 Platelet glycoprotein expression 
Mice were bled to 50 μL in 300 μL heparin [20 U mL-1] as described in 3.2.5.1 and blood was 
diluted using 650 μL Tyrode’s buffer without Ca2+. The expression levels of the most abundant 
platelet glycoproteins were determined by incubating the heparinized blood with fluorophore-
conjugated monoclonal antibodies and mean fluorescence intensities (MFI) were analyzed by 
flow cytometry.  
3.2.5.6 Platelet integrin activation and degranulation 
50 μL of blood in 300 μL heparin [20 U mL-1] were withdrawn, diluted and washed twice at 
2,800 rpm for 5 min with 1 mL of Tyrode’s buffer without Ca2+. After the final washing step, the 
washed blood was resuspended in an appropriate volume of Tyrode’s buffer with Ca2+ and 
incubated with fluorophore-conjugated antibodies directed against activated β1-integrins 
(9EG7-FITC) or αIIbβ3 integrins (PE-conjugated JON/A) and against P-selectin (FITC-labeled 
WUG 1.9). Subsequently, the samples were activated with different agonists. The reaction was 
stopped after an incubation for 7 min at 37°C and 7 min at RT by the addition of 500 μL PBS. 
Where stated, samples were pretreated with the calpain inhibitor MDL-28170 [200 μM] or the 
actin polymerization inhibitor cytochalasin D [5 μM].  
3.2.5.7 Platelet fibrinogen binding 
1 mL of blood in 300 μL heparin [20 U mL-1] was withdrawn and platelets were washed as 
described (see section 3.2.5.1). Binding of fluorescently labeled fibrinogen [50 μg mL-1] to 
washed platelets (18.000 per μL) was assessed over time in resting or activated samples. After 
the indicated time points the reactions were stopped by the addition of 500 μL of Tyrode´s 
buffer containing 3 mM Ca2+.  
3.2.5.8 Aggregometry 
Mice were bled to 1 mL into 300 μL heparin [20 U mL-1] and platelets were washed as described 
before in section 3.2.5.1. The light transmission of a washed platelet suspension 
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(1.5x 105 platelets per μL) in 150 μL Tyrode’s buffer with Ca2+ supplied with 100 μg mL-1 human 
fibrinogen was monitored for 10 min using a four-channel aggregometer (APACT, Laborgeräte 
und Analysensysteme, Hamburg) following activation with different agonists. For stimulation 
with thrombin, Tyrode’s buffer without human fibrinogen was used. Aggregation studies with 
ADP were performed in platelet-rich plasma (1.5x 105 platelets per μL). Aggregation is 
displayed as arbitrary units with the light transmission of 160 μL Tyrode’s buffer with Ca2+ and 
fibrinogen set as 100%. 
3.2.5.9 Western Blot analysis of platelets 
For Western blotting of platelets, mice were bled and platelets were prepared as described in 
section 3.2.5.1, but washed twice in PBS/EDTA [5 mM] to remove residual serum albumin. 
Platelet counts were adjusted to 1.0 x 106 platelets per μL in IP Buffer using a Sysmex KX 21-
N cell analyzer (Sysmex Deutschland GmbH). After an incubation time of 30 min on ice, the 
samples were mixed with an equal volume of reducing 2x Loading Dye and boiled for 5 min at 
95°C and then subsequently were subjected to SDS-PAGE and immunoblotting as described 
in section 3.2.2.2 and 3.2.2.3. 
3.2.5.10 Tyrosine phosphorylation studies  
For identification of tyrosine phosphorylated proteins in platelets, washed platelets 
(1.4x 108 platelets per µL) were used. Platelets were prepared as described in section 3.2.5.1, 
but were washed only once with Tyrode’s buffer containing BSA, whereas all subsequent 
washing steps were carried out in Tyrode’s buffer without BSA. To prevent aggregation, 
apyrase [2 U mL-1], EDTA [5 mM] and indomethacin [10 µM] were added to the platelet 
suspension. Platelets were stimulated with different agonists under stirring. Reaction was 
stopped at different time points by the addition of ice-cold 2x lysis buffer and samples were 
lysed for 30 min on ice. Afterwards, the samples were mixed with an equal volume of reducing 
2 x Loading Dye, boiled for 5 min at 95°C and were subsequently subjected to SDS-PAGE and 
immunoblotting as described in section 3.2.2.2 and 3.2.2.3. Densitometry was conducted by 
volume analysis using ImageJ (version 1.46r, ImageJ software, National Institutes of Health, 
Bethesda, MD, USA). 
3.2.5.11 Determination of platelet vWF content and secretion by ELISA  
For the determination of total vWF levels, platelet lysates were prepared as described in 
section 3.2.5.9. Samples were stored at -80°C until further use. For the determination of vWF 
secretion, washed platelets were prepared as described in section 3.2.5.1, diluted in Tyrode’s 
buffer with Ca2+ (5x 105 µL-1) and stimulated with thrombin [0.1 U mL-1] under stirring conditions 
for 15 min at 37°C. Samples were centrifuged at 2,800 rpm for 5 min and platelet aggregate-
free supernatants were spun down at 14,000 rpm for 5 min. Supernatants were stored at  
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-80°C. vWF levels were subsequently assessed by ELISA. For this, Nunc® 96 DeepWell™ 
plates MediSorb (Nunc, Roskilde, Denmark) were coated with 10 µg mL-1 rabbit anti-human 
antibody o/N at 4°C and blocked with 5% BSA for 90 min at 37°C on the next day. Serial 
sample dilutions were incubated for 2 h at 37°C. After extensive washing with TBS-T, samples 
were incubated with an HRP-coupled rabbit anti-human vWF antibody, which was shown to 
cross-react with mouse vWF. After washing, ELISA plates were developed using TMB 
substrate and the reaction was stopped by the addition of 0.5 M H2SO4.  
3.2.5.12 Determination of TxB2 and total LT release 
Washed platelets were obtained as described in section 3.2.5.1, adjusted to a concentration 
of 5x 105 platelets per μL and stimulated with different agonists for 5 min. The reaction was 
stopped by adding 5 mM EDTA and 1 mM aspirin. Platelets were removed by centrifugation at 
14,000 rpm for 5 min and the supernatant was collected. TxB2 concentrations in the 
supernatant were measured using the TxB2 ELISA kit according to the manufacturer’s 
instructions (DRG, Marburg, Germany). Total LT concentrations in the supernatant were 
measured with the total LT ELISA kit according to the manufacturer’s instructions (My 
Biosource, San Diego, USA). 
3.2.5.13 Determination of ATP release  
Washed platelets were resuspended to a concentration of 5x 105 per µL in Tyrode’s buffer 
without Ca2+. 80 µL of this platelet suspension were diluted into 160 µL Tyrode’s buffer with     
2 mM Ca2+. After addition of 25 µL Chrono-lume luciferase reagent, agonists were added to 
the continuously stirred (1,000 rpm) platelet suspension. Light transmission and luminescence 
were recorded on a 700 Whole Blood/Optical Lumi-Aggregometer (Chrono-log) over 10 min. 
Results were shown in arbitrary units with buffer representing 100% transmission and washed 
platelet suspension 0% transmission. ATP release was calculated using an ATP standard and 
the AggroLink 8 software. 
3.2.5.14 Intracellular Ca2+ measurements 
For intracellular calcium measurements, washed platelets (0.6x 106 per µL) were prepared in 
Tyrode’s buffer without Ca2+ and loaded with Fura-2/AM [5 μM] together with Pluronic F-127 
[0.2 μg mL-1] for 30 min at 37°C. After labeling, platelets were washed once and resuspended 
in Tyrode’s buffer containing 0.5 mM EGTA to measure store release or 1 mM Ca2+ to assess 
Ca2+ entry. Platelets were activated with the indicated agonists and the fluorescence signal 
was measured with a fluorimeter (LS 55; PerkinElmer). Each measurement was calibrated 
using Triton X-100 (Roth) and EGTA. 
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3.2.5.15 Platelet adhesion under flow conditions 
For flow adhesion experiments on collagen, rectangular coverslips (24x 60 mm) were coated 
o/N at 37°C with 70 μg mL-1 fibrillar type I collagen and prior to the experiment blocked for 1 h 
with 1% BSA. Mice were bled up to 1 mL in 300 μL heparin [20 U mL-1], the blood was diluted 
3:1 with Tyrode’s buffer with Ca2+ and incubated for 5 min at 37°C with a DyLight488-
conjugated anti-GPIX derivative [0.2 μg mL-1]. A transparent flow chamber with a slit depth of 
50 μm was covered with the prepared cover slip and perfused for 4-10 min with the blood using 
a pulse-free pump with different shear rates (150, 1,000, 1,700 and 3,000 s-1), reflecting the 
blood flow in different vessel types. Subsequently, the chamber was perfused under the same 
conditions with Tyrode’s buffer with Ca2+ and at least five phase-contrast and fluorescent 
pictures were taken using a Zeiss Axiovert 200 inverted microscope (40x/0.60 objective) 
equipped with a CoolSNAP-EZ camera (Visitron). The recorded phase-contrast and 
fluorescence pictures were analyzed using Metavue software. 
For experiments on immobilized vWF, rectangular coverslips (24x 60 mm) were coated o/N at 
4°C with 200 µL 1:500 diluted polyclonal rabbit anti-human vWF antibody (A0082; Dako) in 
coating buffer. Prior to the experiment slides were blocked for 1 h with 1% BSA and incubated 
with 200 µL heparinized wild-type mouse plasma for 2 h at 37°C and placed within the flow 
chamber. Afterwards, mice were bled up to 1 mL in 300 μL heparin [20 U mL-1], the blood was 
diluted 2:1 with Tyrode’s buffer with Ca2+ and subsequently perfused over the slides for 4 min 
at 1,700 s-1. Afterwards, the chamber was perfused for the same time and at the same shear 
rate with Tyrode’s buffer and at least five phase-contrast and fluorescent pictures were taken. 
3.2.5.16 Analysis of PS exposing platelets  
Under flow conditions  
Rectangular cover slips (24x 60 mm) were coated with 70 μg mL-1 fibrillar type I collagen o/N 
at 37°C and blocked with 1% BSA. Heparinized whole blood was supplemented with additional 
5 U mL-1 heparin and perfused over the coverslips through a transparent flow chamber at a 
shear rate of 1000 s-1 as described above. The flow chamber was rinsed for 4 min with Tyrode’s 
buffer supplemented with 5 U mL-1 heparin and 0.25 µg mL-1 Annexin A5-DyLight488. After 
additional washing for 2 min with Tyrode’s buffer containing Ca2+ and 5 U mL-1 heparin, phase-
contrast and fluorescence images were taken. Procoagulant activity was defined as the ratio 
of surface coverage of PS-exposing platelets (Annexin A5-DyLight488 staining of platelets) to 
the total surface covered by platelets.  
Under static conditions  
Washed platelets were diluted into Tyrode’s buffer with Ca2+ (50 µL with 0.5x 105 platelets per 
µL) and incubated with different agonists for 15 min at 37°C in the presence of saturating 
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amounts of Alexa F488-coupled Annexin A5. Reactions were stopped by the addition of          
500 µL Tyrode’s buffer with Ca2+, and data were immediately collected on a FACSCalibur (BD 
Biosciences, Heidelberg, Germany) and analyzed using FlowJo v7 software (FlowJo, LLC, 
Ashland OR, USA). 
3.2.5.17 Platelet clot retraction 
Mice were bled up to 700 μL in 70 μL sodium citrate [0.129 mM] and PRP was isolated by 
centrifugation at 1,800 rpm for 5 min. Plasma was collected and platelets were resuspended 
in 1 mL Ca2+-free Tyrode’s buffer supplemented with 2 μL of apyrase [0.02 U mL-1] and 5 μL 
PGI2 [0.1 μg mL-1]. Platelet count was determined and 7.5x 107 platelets were resuspended in 
250 μL plasma. PRP (3x 105 platelets per μL) was recalcified by adding 20 mM CaCl2 and 
supplemented with 1 μL of red blood cells to visualize the clot. Clot formation was initiated by 
the addition of 4 U mL-1 thrombin (Sigma). Clot formation and retraction was recorded up to      
4 h and the residual serum volume was determined. 
3.2.5.18 Measurement of coagulation factors (Central Laboratory) 
Mice were bled under isoflurane anesthesia from the retro-orbital plexus to 700 µL blood into 
70 µL sodium citrate. Plasma was prepared as described above. For measurement of PTT and 
for single measurements of FVIII, FIX, FXI and FXII, undiluted samples were used. For the 
Quick index, samples were diluted 1:3 in 0.9% NaCl. Measurements were performed in 
collaboration with Dr. Sabine Herterich from the Central Laboratory. 
3.2.5.19 Thrombin generation assay  
Thrombin generation was quantified in citrate-anticoagulated PRP (1 x 105 platelets per µL), 
which was prepared as described above and measured according to the calibrated automated 
thrombogram method as previously described [161]. Assays were performed in collaboration 
with Sarah Beck in our laboratory.  
3.2.5.20 Platelet spreading on fibrinogen 
Rectangular coverslips (24x 50/60 mm) were coated with 100 μL of 100 μg mL-1 human 
fibrinogen o/N at 4°C in a humid chamber. Slides were blocked with 1% BSA for 1 h at RT.  
30-50 μL of washed platelets (3x 105 per μL) were mixed with 50-70 μL Tyrode’s buffer with 
Ca2+, activated with 0.01 U mL-1 thrombin and immediately allowed to spread on the fibrinogen-
coated coverslips. After different time intervals, the adherent platelets were fixed with 300 μL 
4% PFA in PBS for 5 min and differential interference contrast (DIC) microscopy pictures were 
taken using an inverted microscope Zeiss HBO 100 (Axiovert 200M, Zeiss). For analysis, the 
phase abundance of the different spreading stages (1, resting; 2, formation of filopodia; 
 3, formation of filopodia and lamellipodia; 4, fully spread) was determined.  
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3.2.5.21 Immunofluorescence (IF) stainings of platelets 
After the spreading assays on fibrinogen or vWF, platelets were fixed and permeabilized in 
PHEM complete buffer for 20 min at RT and blocked for at least 30 min at 37°C with 5% BSA. 
Slides were further incubated o/N with primary antibodies or for 2 h with fluorophore-labeled 
primary antibodies (section 3.1.6). After intense washing unlabeled primary antibodies were 
detected with the respective fluorophore-conjugated secondary antibodies. Analysis was 
performed by confocal microscopy with a 100x oil objective on a Leica TCS SP5. Where 
indicated, washed platelets were pretreated (10 minutes at 37°C) with the calpain inhibitor 
MDL-28170 [200 μM]. To visualize the cytoskeleton of resting platelets, 30 μL washed platelets 
(3x 105 per μL) were mixed with 70 μL PHEM complete buffer and allowed to adhere to 
poly-L-lysine-coated coverslips and processed as described above. Images were further 
processed using Image J software (National Institute of Health, USA). 
3.2.5.22 F-actin assembly 
The ability of platelets to incorporate G-actin monomers into F-actin filaments was assessed 
using the F-actin assembly assay. Washed platelets (5x 105 per μL) were prepared as 
described before, diluted (1:1) in Tyrode’s buffer with Ca2+ and stained with 10 μL DyLight649-
labeled anti-GPIX antibody derivative by incubation at 400 rpm for 3 min at 37°C in a 
thermomixer (Eppendorf). Subsequently, the samples were divided into two sets: a resting 
control and an activated sample. Activation was induced by different agonists at 400 rpm for 2 
min at 37°C. After activation, the platelets were fixed with 10% PFA at 400 rpm for 10 min at 
37°C and spun down by centrifugation at 2,800 rpm for 5 min. The pellets were permeabilized 
in 55 μL of Tyrode’s buffer supplied with Ca2+ and 0.1% Triton X-100 and stained with 10 μM 
phalloidin-FITC for 30 min at RT. The reaction was stopped by addition of 500 μL PBS. 
Platelets were spun down at 2,800 rpm for 5 min, resuspended in 500 μL PBS, stored on ice 
and measured immediately. MFI was assessed by flow cytometry using a FACSCalibur (BD 
Biosciences, Heidelberg, Germany). To assess the ability of platelets to assemble F-actin after 
stimulation, the ratio between resting and activated sample was calculated.  
3.2.5.23 Sedimentation of the actin and microtubule cytoskeleton 
Washed platelets (3x 105 per μL) were prepared as described in section 3.2.5.1. 190 μL of 
resting platelets in Tyrode´s without Ca2+ were lysed by addition of 20 μL 10x PHEM buffer 
containing 1% Triton X-100, 60 μM taxol, 20 μM phalloidin and protease inhibitors. One set 
(105 μL) served as whole cell lysate. The other set (105 μL) was separated into polymerized 
and soluble fraction by centrifugation at 56,000 rpm (microtubules) or 75,000 rpm (actin) for 
30 min at 37°C in a TLA-100 rotor (Beckman Coulter). Total platelet lysates (T), soluble 
supernatant (S) and insoluble pellets (P) were supplemented with 2x Loading Dye and 
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subjected to subjected to SDS-PAGE and immunoblotting as described in section 3.2.2.2 and 
3.2.2.3.  
3.2.5.24 Cold-induced microtubule disassembly 
Washed platelets (3x 105 per μL) were prepared as described before and microtubules were 
depolymerized by incubation of platelets in Tyrode´s without Ca2+ for 3 h at 4°C. Microtubule 
reassembly was then allowed by subsequent rewarming at 37°C for 30 min. Samples 
maintained at 4°C and 37°C, as well as rewarmed platelets were allowed to adhere to             
poly-L-lysine-coated coverslips and subsequently fixed and permeabilized in PHEM buffer 
supplemented with 4% PFA and 0.1% TritonX-100. Samples were stained with the respective 
antibodies as described in section 3.2.5.21 and visualized with a Leica TCS SP5 confocal 
microscope (Leica Microsystems). 
3.2.6 In vivo analysis of platelet function 
3.2.6.1 Determination of platelet life span 
The clearance of platelets from the circulation was determined by the retro-orbital injection of 
5 μg DyLight488-labeled anti-GPIX derivative in PBS per mouse. The percentage of labeled 
platelets was determined by daily blood withdrawal (50 μL) and subsequent analysis by flow 
cytometry. 
3.2.6.2 Anesthesia (Triple narcotics) 
Mice were anesthetized by intraperitoneal injection of a combination of Midazolam, 
Medetomidine and Fentanyl [5, 0.5 and 0.05 mg kg-1 body weight]. Mice were placed on a 
heating mat to prevent hypothermia. Before performing any experiment, absence of corneal 
and crossed extensor reflexes was ensured. 
3.2.6.3 Tail bleeding time 
Mice were anesthetized by intraperitoneal injection of triple narcotics and a 1 mm segment of 
the tail tip was removed using a scalpel. Tail bleeding was monitored by gently absorbing blood 
on filter paper at 20 s intervals without touching the wound site. Bleeding was determined to 
have ceased when no blood was observed on the paper. Experiments were stopped at latest 
after 20 min by euthanization. 
3.2.6.4 FeCl3-induced injury of mesenteric arterioles 
The mesentery of 3- to 4-week old anesthetized mice (triple narcotics) was exteriorized by a 
midline abdominal incision. Endothelial damage in mesenteric arterioles was induced by 
application of a 3 mm2 filter paper soaked with 20/13% FeCl3. Arterioles were visualized using 
a Zeiss Axiovert 200 inverted microscope equipped with a 100-W HBO fluorescent lamp source 
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and a CoolSNAP-EZ camera (Visitron). Digital images were recorded and analyzed using the 
Metavue software. Adhesion and aggregation of fluorescently labeled platelets (Dylight488-
conjugated anti-GPIX derivative) was monitored until complete occlusion occurred (blood flow 
stopped for > 2 min). Experiments were performed in collaboration with Sarah Beck. 
3.2.6.5 Mechanical injury of the abdominal aorta 
The abdominal cavity of 12-weeks-old anesthetized mice was opened by a longitudinal 
incision. An ultrasonic flow probe (Transonic Flowprobe 0.5, Transonic Systems) was placed 
around the exposed abdominal aorta. Thrombosis was induced by a single firm compression 
of the aorta using forceps. Blood flow was monitored until complete blood vessel occlusion 
occurred for a minimum of 5 min. Otherwise the experiment was stopped after 30 min. Aorta 
injury experiments shown in this study were performed and evaluated in collaboration with 
Sarah Beck in our laboratory. 
3.2.6.6 Transient Middle Cerebral Artery Occlusion (tMCAO) model 
tMCAO was induced in 12 weeks-old male mice under isoflurane inhalation anesthesia using 
the intraluminal filament technique [162]. Briefly, a midline neck incision was made and a 
standardized silicon rubber-coated 6.0 nylon monofilament (6021PK10, Doccol, Redlands, CA, 
USA) was inserted into the right common carotid artery and advanced via the internal carotid 
artery to occlude the origin of the middle cerebral artery. After 60 min, the filament was 
removed to allow reperfusion. 24 h after tMCAO the global neurological status was assessed 
using the Bederson score [163], motor function and coordination were evaluated using the grip 
test [164]. For determination of the ischemic brain infarct volume, mice were euthanized 24 h 
after induction of tMCAO and brain sections were stained with 2%                                                             
2,3,5-triphenyltetrazoliumchloride (TTC). Planimetric measurements were performed using 
ImageJ software to calculate lesion volumes, which were corrected for brain edema as 
described [165]. Experiments were conducted in collaboration with Dr. Michael Schumann in 
the group of Prof. Dr. Guido Stoll (Department of Neurology, University Hospital, Würzburg) 
according to the recommendations for research in mechanism-driven basic stroke studies 
[166]. 
3.2.7 MK analysis 
3.2.7.1 Sample preparation for histology 
Spleen and femora of 12-week-old KO and wild-type mice were isolated and fixed in 4% PFA 
in PBS o/N at 4°C. Femora were decalcified for 3 d in decalcification buffer. Afterwards, 
spleens and femora were dehydrated in an automated tissue processor (Leica ASP200S) and 
embedded in paraffin.  
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3.2.7.2 Hematoxylin and Eosin (H&E) staining on paraffin sections 
After embedding in paraffin, 3 μm thick sections of the formalin-fixed paraffin embedded 
spleens and femora were prepared, immobilized on glass slides and allowed to dry o/N at 
37°C. On the following day, deparaffinization and rehydration was performed using xylene        
(2 x 5 min), followed by a graded alcohol series (100%, 96%, 90%, 80% and 70%, each 2 min) 
and finally the slides were transferred into H2O bidest (2 min). Sections were stained with 
hematoxylin for 15 s and washed intensively at least for 10 min with tap water. 0.05% Eosin 
was used as counterstaining. Slides were washed once with H2O bidest and dehydrated by a 
graded alcohol series (70%, 80%, 90%, 96% and 100%, each 2 min) followed by xylene                
incubation (2 times 5 min). The sections were mounted using Eukitt®, a xylene-based mounting 
medium. Analysis was performed with an inverted Leica DMI 4000 B microscope. 
3.2.7.3 IF staining on cryosections 
Femora and spleen of mice were isolated, fixed with 4% PFA and 5 mM sucrose for 1 h under 
agitation, transferred into 10% sucrose in PBS and dehydrated using a graded sucrose series 
(each 24 h in 10%, 20% and 30% sucrose in PBS, respectively). Subsequently, the samples 
were embedded in Cryo-Gel and shock frozen in liquid nitrogen. Frozen samples were stored 
at -20°C. 7 μm thick cryosections were generated using the CryoJane tape transfer system 
(Leica Biosystems) and probed with AlexaF488-conjugated anti-GPIb antibodies (7A9 and 
13G12 [1.33 μg mL-1]), to specifically label platelets and MKs, and AlexaF647-conjugated anti-
CD105 antibody [3.33 μg mL-1] to stain the endothelium. Nuclei were stained using DAPI            
[1 μg mL-1]. Samples were visualized with a Leica TCS SP5 confocal microscope (Leica 
Microsystems). 
3.2.8 Transmission electron microscopy (TEM) 
3.2.8.1 TEM analysis of resting platelets in suspension 
PRP was prepared as described before and mixed in a 1:2 ratio with 5% glutaraldehyde in 
PBS for 10 min at 37°C and for 1 h at RT. Platelets were spun down at 2,800 rpm for 5 min, 
washed three times with cacodylate buffer and incubated for 1 h at RT with 1% OsO4 in 
cacodylate buffer. Afterwards, the samples were washed twice with cacodylate buffer and H2O 
bidest and 2% uranyl acetate (in H2O) was added for 1 h at 4°C. Then, platelets were 
dehydrated by a graded ethanol series (3x 70%, 5 min; 3x 95%, 15 min; 3x 100%, 15 min), 
incubated twice for 10 min with propylenoxide and afterwards transferred in a 1:1 mixture of 
propylenoxide and epon for 1 h under rotation. After this step, epon was added twice and 
samples were incubated o/N at RT. Epon was hardened for 48 h at 60°C. Ultrathin sections 
were prepared, stained with 2% uranyl acetate (in ethanol) and lead citrate (in H2O) and 
examined at 80 kV under a EM900 (Zeiss). 
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3.2.8.2 TEM analysis of BM MKs in situ  
For TEM on BM samples, the femora of 12-weeks old mice were isolated and fixed o/N at 4°C 
in Karnovsky fixation buffer. Subsequently, femora were decalcified for three consecutive days. 
Contrasting, embedding and analysis of the samples was performed as described above for 
platelets. 
3.2.9 Data analysis 
The presented results are mean ± standard deviation (SD) from at least three independent 
experiments per group, if not stated otherwise. Differences between wild-type and KO mice 
were statistically analyzed using the unpaired Student’s t-test. Infarct volumes and functional 
data obtained from tMCAO experiments were tested for Gaussian distribution with the 
D’Agostino and Pearson omnibus normality test and then analyzed using the two-tailed 
Student’s t test. Differences between more than two groups were analyzed by one-way 
analysis of variance (ANOVA) with Dunnetts T3 as post-hoc test. P-values < 0.05 were 
considered as statistically significant: ***P< 0.001; **P< 0.01; *P< 0.05. Results with a P-value 
> 0.05 were considered as non-significant (NS). 
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4. RESULTS 
4.1 Coactosin-like 1 is a regulator of thrombosis and hemostasis in mice 
4.1.1 Cotl1 is dispensable for platelet production and structure 
Rearrangements of the actin cytoskeleton play a crucial role for platelet formation and reactivity 
and thus several actin-binding proteins have already been reported to be critically involved in 
these processes, e.g. the ADF-H family members Cof and Twf2a [82, 99]. Therefore, we were 
interested to investigate another ADF-H family member, Coactosin-like 1 (Cotl1) and its 
implication in thrombopoiesis and platelet reactivity using transgenic mice.  
Preliminary experiments had indicated that the constitutive Cotl1 depletion was perinatally 
lethal between day P14 and P17 (Stritt et al., unpublished observations). Conditional MK- and 
platelet-specific Cotl1-deficient (Cotl1fl/fl-Pf4Cre) mice, however, were viable and fertile and were 
therefore used in this study. Absence of Cotl1, which was confirmed by Western Blotting (Fig. 
11 A), did not alter the expression of prominent platelet surface receptors (Table 1). 
 
 
Table 1. Platelet surface glycoprotein expression 
in Cotl1-/- platelets. Diluted whole blood was stained 
with fluorophore-labeled antibodies and analyzed on 
a FACSCalibur (Becton Dickinson, Heidelberg). 
Platelets were gated by FSC/SSC characteristics. 
Results are given as the mean fluorescence intensity 
(MFI) ± SD of 6-12 mice per group.  
 
 
In contrast to Twf2a- or Cof-deficient platelets, depletion of Cotl1 did not affect peripheral 
platelet count and size as assessed by flow cytometry (Fig. 11 B). Analysis of the morphology 
of resting platelets (Fig. 11 C) using transmission electron microscopy (TEM) confirmed the 
unaltered platelet size and revealed no differences in the distribution of α- and dense granules 
in Cotl1-/- mice. In agreement with these observations, MK numbers in spleen and BM were 
unaltered in Cotl1-/- mice (data not shown). Consistently, the life span of Cotl1-/- platelets was 
comparable to wild-type platelets (Fig. 11 D).  
Thus, Cotl1-/- mice represent the first KO mouse model of an ADF-H family member with 
unaltered platelet number and size.  
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Figure 11. Cotl1 is dispensable for platelet formation, survival and structure. (A) Immunoblot on 
platelet lysates proved the complete loss of Cotl1 in mutant platelets. GAPDH served as loading control. 
(B) Peripheral platelet count and size was assessed by flow cytometry (n= 6 per group). 
(C) Representative TEM pictures of wild-type and Cotl1-/- platelets. Bar, 2 µm. (D) Platelet life span was 
assessed by i.v. injection of a Dylight488-coupled anti-GPIX-IgG derivative [0.5 µg g-1 body weight] and 
monitoring of fluorescently-labeled platelets over 5 days by flow cytometry. 
 
4.1.2 Cotl1-deficiency does not affect cytoskeletal dynamics in platelets 
A common feature of ADF-H family members is, besides their ability to bind actin, their 
involvement in cytoskeletal dynamics. Cof-deficiency was shown to downregulate stimulus-
dependent F-actin assembly, whereas Twf2a-deficient mice displayed enhanced actin 
dynamics [82, 99]. Therefore, it was assumed that a deletion of Cotl1 would have effects on 
the cytoskeletal organization, too.  
First, agonist-induced actin polymerization was assessed and found to be unaltered in Cotl1-
deficient platelets (Fig. 12 A). In line with this, total tubulin and actin content was unaltered in 
Cotl1-/- platelets (Fig. 12 C, D), which was further confirmed by immunofluorescence stainings 
of resting platelets on poly-L-lysine (Fig. 12 B, left). Consistently, actin and tubulin 
reorganization of Cotl1-deficient platelets during spreading on fibrinogen was comparable to 
wild-type platelets (Fig. 12 B, right). Together, these results suggest that Cotl1 has no impact 
on cytoskeletal dynamics in platelets in vitro.  
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Figure 12. Cotl1-deficiency does not affect cytoskeletal function in platelets. (A) F-actin content of 
resting and agonist-stimulated platelets was measured by flow cytometry after incubation with phalloidin-
FITC. The ratio of MFI from activated and resting platelets ± SD of 4 mice per group is shown.  
(B) Visualization of the cytoskeleton of resting platelets on poly-L-lysine and spread platelets (15 min) 
on fibrinogen, which were stained with Phalloidin-atto647N (red) and α-tubulin antibody-AlexaF488 
(green) and analyzed by confocal microscopy. Bar, 2 µm. (C, D) The tubulin (C) and actin (D) 
cytoskeleton was isolated by ultracentrifugation, immunoblotted with anti-α-tubulin and anti-β-actin 
antibodies and analyzed for the content of monomeric/polymeric tubulin (C) or monomeric/polymeric 
actin (D) using densitometry. GAPDH served as loading control. Values are mean ± SD (n= 3). P: pellet, 
S: supernatant, T: total protein. 
4.1.3 Increased Cofilin phosphorylation in Cotl1-/- platelets 
Since Cotl1-deficiency did not affect cytoskeletal dynamics, the hypothesis arises that other 
actin-binding proteins compensated for the lack of Cotl1. To test a possible effect of Cotl1-
deficiency on other cytoskeletal regulators, expression levels of the ADF-H members Twf and 
Cof, the Cof upstream effector Cdc42, as well as the actin-sequestering protein Pfn1 were 
assessed by western blotting.  
Analysis of total protein expression revealed no differences in Twf, Cof, Pfn1 or Cdc42 levels 
between wild-type and Cotl1-/- platelets. Since Cof is known to be regulated by (de)-
phosphorylation at the highly conserved amino acid serine 3, phosphorylation levels were 
assessed in addition. In platelets, approximately 90% of n-cofilin is phosphorylated at position 
serine 3 in the resting state [82]. 
  RESULTS 
 
57 
 
Figure 13. Increased Cofilin phosphorylation in Cotl1-/- platelets. Western blots of lysates from 
resting wild-type and Cotl1-/- platelets using antibodies against (A) Pfn1, (B) Twf1/2a, (C) Cdc42 and (D) 
Cofilin´s Phospho-Ser as well as total Cofilin. GAPDH served as loading control. (E) Densitometric 
analysis of relative expression levels of Phospho-Cofilin (left) and total Cofilin (right) in unstimulated 
wild-type and Cotl1-/- platelets. 
 
Strikingly, a strong, 2-fold increase in expression of the (inactive) phosphorylated form of Cof 
could be detected in Cotl1-deficient platelets. As described by Kim et al. Cotl1 antagonizes 
Cof´s actin severing function, resulting in reduced F-actin depolymerization [104]. Therefore, 
the increased phosphorylation of Cof in the absence of Cotl1, ultimately causing reduced F-
actin severing, might act as a compensatory mechanism.  
4.1.4 Unaltered integrin activation in Cotl1-deficient platelets 
Next it was tested whether Cotl1-deficiency might affect platelet reactivity as it was shown for 
Twf2a-/- platelets [99]. Therefore, agonist-induced αIIbβ3 integrin activation using the JON/A-
PE antibody [152], which specifically binds to activated αIIbβ3 integrins, as well as 
degranulation-dependent surface exposure of P-selectin, a marker for α-granule release, were 
determined by flow cytometry. Interestingly, Cotl1-/- platelets showed unaltered αIIbβ3 integrin 
activation in response to all tested agonists (Fig. 14 A). Likewise, agonist-induced P-selectin 
exposure was indistinguish-able between wild-type and Cotl1-/- platelets (Fig. 14 B).  
In line with this data, Cotl1-/- platelets showed unaltered aggregation in response to all tested 
agonists (Fig. 14 C). Spreading assays on fibrinogen showed the functionality of αIIbβ3 integrin 
outside-in signaling, which is critically important for cytoskeletal rearrangements upon platelet 
activation. Although Cotl1 was recently described as a regulator of T cell spreading at the 
immune synapse by preventing cofilin-mediated depolymerization of actin filaments [104], 
Cotl1-deficiency in platelets did not affect their spreading ability on fibrinogen (Fig. 14 D). In 
summary, these results showed that Cotl1 is dispensable for platelet reactivity in vitro under 
static conditions.  
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Figure 14. Unaltered integrin activation in Cotl1-deficient platelets. (A) Activation of platelet αIIbβ3 
integrin (JON/A-PE) and (B) degranulation (α-P-selectin-FITC) in Cotl1-/- platelets as determined by flow 
cytometry. (C) Aggregation responses in turbidometric aggregometry after stimulation with the indicated 
agonists. (D, E) Washed platelets were stimulated with 0.01 U mL-1 thrombin and allowed to spread on 
fibrinogen. (D) Representative Differential Interference Contrast (DIC) microscopy images of 3 individual 
experiments at t= 15 min and (E) statistical evaluation of the percentage of spread platelets at different 
spreading stages. Bar, 3 µm.  
 
4.1.5 Unaltered thromboxane secretion in Cotl1-/- platelets 
Besides its interaction with F-actin, Cotl1 was shown to upregulate 5-lipoxygenase (5-LO) 
activity, a key enzyme in leukotriene (LT) biosynthesis [110]. LTs are derivatives of arachidonic 
acid (AA) and act as inflammatory lipid mediators, which cause leukocyte chemotaxis and 
increased vascular permeability. 5-LO catalyzes the two initial steps of LT biosynthesis, (1) the 
oxygenation of AA to 5-HPETE and (2) the subsequent dehydration into the epoxide LTA4 [106, 
167]. Likewise, 5-HPETE can be reduced to 5-HETE, which is metabolized to 5-oxo-ETE. 
Moreover, AA is converted to thromboxanes (TxA/B2), prostacyclin (PGI2) and prostaglandines 
(PGE/F2) by cyclooxygenases [168, 169]. 
To test the effect of Cotl1-deficiency on LT and TxA/B2 production, their resting levels as well 
as the amount of released LT and TxB2 were assessed in Cotl1-deficient platelets using 
commercially available ELISA kits. As shown in Figure 15, neither resting thromboxane levels 
nor TxB2 release upon platelet stimulation was altered in Cotl1-deficient platelets as compared 
to wild-type levels. 
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Figure 15. Unaltered TxA2 and LT production in Cotl1-deficient mice. TxA2 levels were measured 
in the supernatant of resting (A) and stimulated washed platelets (B) by ELISA. Results are expressed 
as mean TxB2 generation [ng mL-1] ± SD of 4 mice per group. 
 
LT levels of resting or agonist-stimulated platelets (A23187, CRP, thrombin) were not 
detectable with the ELISA kit used in this study, presumably due to low concentration of these 
mediators in platelets. A study from Evangelista et al. detected 52.7 ng LTB4 after stimulation 
of 5 mL rabbit whole blood with the calcium ionophore A23187 [170]. Thus, more sensitive 
methods are necessary to detect LT levels in platelets. To this end, analysis of the LT content 
of wild-type and Cotl1-deficient platelets is meanwhile performed by our collaboration partner 
Dr. Robert Ahrends from ISAS (Düsseldorf, Germany) using a Lipidomics approach.  
4.1.6 Decreased aggregate formation of Cotl1-/- platelets under flow 
At sites of vessel wall injury, release of secondary mediators from activated platelets at the 
exposed subendothelium plays a crucial role for the recruitment and activation of further 
platelets to promote thrombus formation.  
To study the effect of Cotl1 on aggregate formation under flow, whole blood was perfused over 
a collagen-coated surface at different shear rates, reflecting the blood flow in different vessel 
sizes. Interestingly, less Cotl1-/- platelets adhered to the collagen-coated surface (Fig. 16 A, B) 
and thrombus formation was significantly reduced (Fig. 16 C). Notably, the reduction in 
aggregate formation was most striking at medium and high shear rates as surface coverage 
and thrombus formation of Cotl1-/- platelets at a low shear rate of 150 s-1 was unaltered as 
compared to wild-type platelets (data not shown). 
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Figure 16. Impaired adhesion and thrombus formation of Cotl1-/- platelets on collagen under flow. 
Heparinized whole blood of Cotl1-/- and wild-type mice was perfused over a collagen-coated surface for 
4 min at shear rates of 1,000, 1,700 and 3,000 s-1. (A) Representative phase contrast images taken at 
the end of the perfusion time, (B) analysis of the surface area covered by platelets (%) and  
(C) the relative thrombus volume ± SD (n= 6 per group) are depicted. Unpaired Student’s t-test:  
**P< 0.01; *P< 0.05. Bar, 50 µm. 
 
4.1.7 Cotl1-/- mice are protected from arterial thrombus formation and ischemic stroke  
To test whether the observed thrombus formation defect on collagen in vitro translates into an 
in vivo phenotype, Cotl1-/- and wild-type mice were subjected to the thrombosis model of the 
mechanically injured abdominal aorta, where blood flow is monitored until vessel occlusion 
using an ultrasonic perivascular Doppler flow meter (Fig. 17 A, B). After a transient increase 
directly following injury, blood flow progressively decreased for several minutes in all animals. 
In all wild-type mice (8/8), this decrease resulted in complete and irreversible occlusion of the 
vessel within maximally 7 min after injury (mean occlusion time 3.37 ± 0.72 min). In sharp 
contrast, while a progressive reduction in blood flow was observed during the first minutes after 
injury in Cotl1-/- mice, blood flow afterwards normalized and 9 of 11 mice displayed normal flow 
rates through the injured vessel at the end of the observation period (30 min). Notably, 
thrombus formation of Cotl1-/- mice in smaller arterioles was unaltered as compared to wild-
type mice, which was assessed using a second thrombosis model, the FeCl3-induced injury of 
the mesenteric arterioles (data not shown). This is in line with the observed in vitro data under 
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flow, as it is well documented that collagen is the main driver of thrombus formation in bigger 
vessels, whereas in smaller vessels thrombosis is predominantly driven via TF-dependent 
mechanisms [171]. Supporting the reduced thrombotic activity in Cotl1-/- mice, these animals 
also exhibited mildly prolonged bleeding times (Fig. 17 C). Notably, bleeding times were highly 
variable suggesting thrombus instability.  
To analyze whether Cotl1-deficiency would also improve outcome in a model of thrombo-
inflammatory brain infarction, wild-type and Cotl1-/- mice were subjected to the transient middle 
cerebral artery occlusion (tMCAO) model of acute stroke, where the origin of the middle 
cerebral artery is occluded by a filament [162]. After 60 min, the filament was removed to allow 
reperfusion. 24 h after tMCAO the global neurological status was assessed using the Bederson 
score [163], motor function and coordination were evaluated using the grip test [164]. 
Additionally, 2,3,5-triphenyltetrazolium chloride (TTC) staining of the brains was performed to 
differentiate between metabolically active and inactive tissue. Of note, infarct volumes of  
Cotl1-/- mice were significantly reduced (Fig. 17 D, E). The neurological outcome and motoric 
function, however, was not improved in Cotl1-deficient mice (Fig. 17 F).  
 
Figure 17. Cotl1-/- mice are protected from arterial thrombus formation. (A, B) Aorta thrombosis 
model. (A) Representative graph of blood flow of a wild-type and a Cotl1-/- mouse after mechanical injury 
of the abdominal aorta at t= 0. (B) Occlusion time after mechanical injury of the abdominal aorta. 
Experiments were performed in collaboration with Sarah Beck in our laboratory. (C) Tail bleeding times 
on filter paper in wild-type and Cotl1-/- mice. Each symbol represents one individual. (D) Brain infarct 
volumes of wild-type and Cotl1-/- mice which were subjected to 1 h tMCAO. Data are mean ± SD of 8 
mice per group. (E) Neurological outcome tested by Grip test and Bederson score 24 h after tMCAO. 
Experiments were performed in collaboration with Dr. Michael Schumann (Department of Neurology, 
University Hospital, Würzburg). Unpaired Student’s t-test: ***P< 0.001; *P< 0.05. 
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Taken together, it was shown that Cotl1-deficiency had no effect on cytoskeletal dynamics and 
platelet function under static conditions. Nevertheless, in vitro under flow lack of Cotl1 resulted 
in reduced thrombus formation, which translated into protection from arterial thrombus 
formation in vivo. Overall, these findings show that Cotl1 contributes to thrombotic activity and 
hemostasis. However, the underlying mechanism remains elusive, which was addressed in 
further experiments. The protection from thrombus formation of Cotl1-deficient mice in the 
mechanically injured aorta model as well as the decreased aggregate formation, especially 
under high shear rates, in the in vitro flow chamber model, pointed towards altered GPIb-vWF 
interactions in Cotl1-/- platelets. 
4.1.8 Altered GPIb-vWF interaction of Cotl1-deficient platelets 
GPIbα is part of the GPIb-V-IX complex and plays a crucial role for the initial platelet tethering 
at sites of vascular injury through binding to its ligand vWF [172]. Upon blockade of GPIb-vWF 
interactions, a reduced lesion progression after experimentally induced tMCAO has been 
described [162, 173]. Moreover, blockade of the vWF binding site on GPIbα by p0p/B-Fab 
treatment significantly reduced platelet tethering and thus abolished aggregate formation at 
sites of vascular injury [153].  
Platelet tethering to vWF-coated surfaces under flow was assessed to analyze GPIb-vWF 
interactions in Cotl1-deficient platelets. Strikingly, adhesion of Cotl1-/- platelets was significantly 
reduced, which was most prominent at a shear rate of 3000 s-1 (Fig. 18). Of note, this defect 
was not caused by altered GPIb expression levels (see Table 1). 
 
Figure 18. Impaired adhesion of Cotl1-/- platelets to vWF under flow. Heparinized whole blood of 
Cotl1-/- and wild-type mice was perfused over a vWF-coated cover slip for 4 min at 1,700 and  
3,000 s-1. (A) Representative phase contrast images taken at the end of the perfusion time and (B) 
analysis of the number of adherent platelets per mm2 ± SD (n= 6 per group). Bar, 50 µm. Unpaired 
Student’s t-test: **P< 0.01; *P< 0.05. 
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These results demonstrate that Cotl1 is an important mediator of GPIb-vWF-interactions under 
shear flow suggesting that the decreased GPIb-vWF interaction may account for the observed 
in vivo phenotypes.  
4.1.9 Slightly altered granule content and release in Cotl1-deficient platelets  
Second wave mediators, such as ADP or TxA2, potentiate thrombus formation at sites of 
vascular injury by further recruitment of platelets into the growing thrombus [14]. To assess 
whether impaired release of second wave mediators contributed to the defective thrombus 
formation of Cotl1-/- mice, agonist-induced granule secretion of wild-type and Cotl1-deficient 
platelets was assessed. Unexpectedly, dense granule ATP release was significantly enhanced 
in Cotl1-deficient platelets (Fig. 19 A), but, indeed, α-granular vWF secretion was slightly 
decreased in Cotl1-deficient platelets (Fig. 19 B). To elucidate granule secretion of Cotl1-
deficient platelets further, it will be interesting to determine ADP and P-selectin content as well 
as the amount of released serotonin. 
 
Figure 19. Moderately altered granule release of Cotl1-/- platelets. (A) Luminometric measurement 
of released ATP of activated wild-type and Cotl1-/- platelets. Results are given as mean ATP 
concentration [µM] ± SD (n= 3 per group). (B) Platelet α-granular vWF content in wild-type and Cotl1-/- 
platelets as assessed by ELISA. Results are expressed as mean O.D.450/0.04 x 106 platelets ± SD of 4 
mice per group. (C) vWF release upon platelet activation. Results are expressed as mean O.D.450/0.04x 
106 platelets ± SD of 3 mice per group. Unpaired Student’s t-test: *P< 0.05. 
 
4.1.10 Addition of second wave mediators partially restores the defective thrombus 
formation of Cotl1-/- mice 
To assess whether the observed altered second wave mediator release of Cotl1-deficient 
platelets contributed to the defective thrombus formation, ADP and the TxA2 analogue U46619 
were co-infused into Cotl1-/- blood using the in vitro flow chamber model [174].  
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Figure 20. Defective thrombus formation of Cotl1-/- mice under shear flow is partially restored by 
exogenous addition of second wave mediators. Heparinized whole blood of Cotl1-/- and wild-type 
mice was perfused over a collagen-coated surface for 4 min at a shear rate of 1700 s-1. Where stated, 
10 µM ADP and 1 µM U46619 were co-infused into the blood. (A) Representative phase contrast images 
taken at the end of the perfusion time, (B) analysis of the surface area covered by platelets (%) and (C) 
relative thrombus volume ± SD (n= 6 per group) are depicted. Unpaired Student’s t-test:  
**P< 0.01. Bar, 50 µm. 
 
Strikingly, exogenous addition of these agonists could restore the thrombus formation defect 
of Cotl1-/- platelets as Cotl1-deficient platelets were able to build larger thrombi compared to 
untreated Cotl1-/- platelets (Fig. 20 A, C), although the defect could not be restored to wild-type 
levels. These results suggest that both the altered GPIb-vWF interaction and a decreased 
second wave mediator release contribute to the protection from thrombus formation of Cotl1-
deficient mice in vitro under flow and in vivo.  
4.1.11 Increased procoagulant activity of Cotl1-/- platelets under shear flow 
Platelet adhesion at high shear rates to sites of vascular injury depend on GPIb-vWF 
interactions. Platelet deceleration subsequently enables the binding of collagen to GPVI, which 
initiates a powerful intracellular signaling cascade characterized by a rise in cytosolic Ca2+ 
concentration, cytoskeletal rearrangements, mobilization of α- and dense granules and 
subsequent release of secondary platelet agonists as well as surface exposure of negatively 
charged procoagulant phosphatidylserine (PS) [175, 176]. PS exposure further enhances TF-
triggered thrombin generation and second wave mediators together with locally generated 
thrombin reinforce cellular activation and recruit additional circulating platelets to the growing 
thrombus.  
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Figure 21. Cotl1-deficiency increases platelet procoagulant activity under flow. (A) Washed 
platelets were stimulated with the indicated agonists, stained with saturating amounts of Annexin A5-
DyLight488 and analyzed by flow cytometry. Results are expressed as MFI ± SD (n= 4 mice per group). 
(B) Whole blood was perfused over a collagen-coated surface at a shear rate of 1,700 s−1 for 4 min. 
Adherent platelets were stained with Annexin A5-AlexaF488 [0.25 mg mL-1]. Representative phase 
contrast and fluorescence images and mean relative amount of Annexin-A5 positive platelets ± SD of at 
least 6 mice. Unpaired Student’s t-test: *P< 0.05. 
 
Since Cotl1-/- platelets displayed impaired GPIb-vWF interactions as well as altered second 
wave mediator release, it was assessed whether procoagulant activity might be affected by 
Cotl1-deficiency. To this end, binding of fluorescently-labeled Annexin A5 to PS exposed on 
the platelet surface upon stimulation was analyzed by flow cytometry [177]. Notably, no 
differences in procoagulant activity between wild-type and Cotl1-deficient platelets could be 
observed (Fig. 21 A). However, under flow, procoagulant activity of Cotl1-deficient platelets as 
assessed by binding of Annexin A5 to PS was significantly increased, although collagen-
induced platelet adhesion was decreased in Cotl1-deficient blood (Fig. 21 B). This result again 
emphasizes that the effect of Cotl1-deficiency is most prominent under shear flow in vitro and 
in vivo suggesting reduced thrombus stability. 
In summary, it was very surprising to find that Cotl1 as a member of the ADF-H protein family 
and regarding its actin-binding capability [68] was dispensable for thrombopoiesis and actin 
dynamics, but that it shows major impact on thrombosis and hemostasis. 
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4.2 Profilin 1 regulates integrin function in mouse platelets by mediating cyto-
skeletal rearrangements 
4.2.1 Pfn1-deficiency leads to microthrombocytopenia 
The MK- and platelet-specific Pfn1 KO mouse model (Pfn1fl/fl-Pf4Cre) has previously been 
described. Briefly, Pfn1-deficiency resulted in a microthrombocytopenia due to cytoskeletal 
alterations, an accelerated platelet clearance as well as premature platelet release into the 
BM. Pfn1-deficient platelets displayed a thicker marginal band and a partially disrupted actin 
cytoskeleton. The severely misarranged and hyperstable microtubules detected in Pfn1-
deficient platelets were also found in platelets isolated from WAS patients, which established 
Pfn1 as a new regulator of microtubule stability and reorganization [178]. However, the impact 
of Pfn1-deficiency on platelet function has not been addressed in this study. Therefore, 
platelets from Pfn1fl/fl-Pf4Cre mice were investigated concerning platelet reactivity, aggregation 
and thrombotic activity.  
Western Blot analysis of platelet lysates confirmed effective ablation of Pfn1 expression in 
mutant platelets (Fig. 22 A). Assessment of platelet count and size by flow cytometry revealed 
a microthrombocytopenia, which was already described by Bender, Stritt et al. [178] 
(Fig. 22 B, C) and is caused by accelerated clearance and premature release of platelets into 
the BM compartment. In line with the decreased platelet size, the surface expression of major 
platelet glycoproteins was decreased (Fig. 22 D). 
 
Figure 22. Pfn1fl/fl-Pf4Cre mice display microthrombocytopenia. (A) Immunoblot on platelet lysates 
proved lack of Pfn1 expression in mutant platelets. GPIIIa served as loading control. (B-D) Platelet count 
(B), size (C) and surface prevalence of major platelet glycoproteins (D) were assessed by flow 
cytometry. Values are ± SD (n= 6 vs. 6). Unpaired Student’s t-test: ***P< 0.001; **P< 0.01; *P< 0.05. 
(Stritt, Birkholz et al., Blood Adv, 2018 [179]) 
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4.2.2 Impaired inside-out integrin activation in Pfn1fl/fl-Pf4Cre platelets 
To study whether the smaller sized platelets show altered reactivity, agonist-induced platelet 
β1 (9EG7-FITC)- and β3 (JON/A-PE)-integrin activation was assessed by flow cytometry (Fig. 
23 A, B). Strikingly, Pfn1fl/fl-Pf4Cre platelets showed impaired activation of β1- and β3-integrins in 
response to all tested agonists. Degranulation as assessed by P-selectin exposure was, 
however, unaltered in Pfn1-deficient platelets (Fig. 23 C).  
 
Figure 23. Impaired integrin activation in Pfn1fl/fl-Pf4Cre platelets. Activation of platelet (A) αIIbβ3- 
(JON/A-PE) and (B) β1-integrins (9EG7-FITC), as well as (C) α-granule release (α-P-selectin-FITC) and 
(D) platelet fibrinogen-binding (Fibr-AF488) in response to different agonists were assessed by flow 
cytometry. Values are presented as mean ± SD (n= 6 per group). (E) Aggregation responses in 
turbidometric aggregometry. Unpaired Student’s t-test: ***P< 0.001; **P< 0.01; *P< 0.05. (Stritt, Birkholz 
et al., Blood Adv, 2018 [179]) 
 
In line with the decreased integrin activation, agonist-stimulated Pfn1fl/fl-Pf4Cre platelets showed 
reduced binding to AlexaF488-conjugated fibrinogen (Fig. 23 D). Unexpectedly, aggregation 
responses of Pfn1fl/fl-Pf4Cre platelets were only slightly affected by the impaired integrin activation 
(Fig. 23 E). 
4.2.3 Defective outside-in signaling in Pfn1fl/fl-Pf4Cre platelets 
Integrin outside-in signaling was assessed in a spreading assay on fibrinogen to further assess 
the integrin activation defect of Pfn1-deficient platelets (Fig. 24). Consistently, Pfn1-deficient 
platelets displayed severely reduced outside-in activation, which was characterized by 
significantly impaired filopodia and lamellipodia formation. Strikingly, Pfn1-deficient platelets 
displayed only few “normal looking” filo- and lamellipodia, hence, two new spreading phases, 
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“leaky” (a stage between filopodia and lamellipodia formation) and “rough” (the stage between 
lamellipodia formation and fully spread platelets) were defined. Of note, this spreading defect 
is probably not only caused by impaired integrin signaling, but can additionally be attributed to 
the grossly disrupted actin cytoskeleton as described by Bender, Stritt et al. [178]. 
 
Figure 24. Impaired filopodia and lamellipodia formation of Pfn1fl/fl-Pf4Cre platelets. Washed wild-
type and Pfn1fl/fl-Pf4Cre platelets were allowed to spread on fibrinogen-coated coverslides after stimulation 
with 0.01 U mL-1 thrombin. (A) Representative DIC images at t= 30 min after thrombin stimulation. Bars, 
3 μm. (B) Overview of newly defined spreading phases. (C) Quantification of the different spreading 
phases after 15 (C) and 30 min (D) from DIC images (Zeiss Axiovert 200 inverted microscope (100x/1.4 
oil objective, Zeiss)). Images are representative of at least 6 animals per group. Values are mean ± SD. 
(E) Platelet clot retraction was determined over time in response to 5 U mL-1 thrombin. Values are mean 
± SD (n= 6 mice per group). ***P< 0.001. (Stritt, Birkholz et al., Blood Adv, 2018 [179]) 
 
In line with the defective spreading of Pfn1fl/fl-Pf4Cre platelets, they showed severely delayed and 
less effective clot retraction (Fig. 24 E), further reflecting impaired integrin function.  
4.2.4 Pfn1 is a regulator of thrombosis and hemostasis 
To investigate whether the integrin activation defect of Pfn1fl/fl-Pf4Cre platelets does translate into 
a thrombus formation defect under flow, aggregate formation on collagen using the in vitro flow 
chamber model, was assessed. Indeed, Pfn1-deficient platelets displayed markedly reduced 
adhesion and aggregate formation (Fig. 25 A, B) at an intermediate shear rate of 1000 s-1. This 
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translated into a profound protection from in vivo thrombus formation as upon induction of 
arterial thrombosis by mechanical injury of the abdominal aorta all control mice formed 
occlusive thrombi, whereas 5 out of 6 Pfn1fl/fl-Pf4Cre mice did not form stable occlusions  
(Fig. 25 C, D). In line with the in vitro data, Pfn1fl/fl-Pf4Cre mice displayed prolonged bleeding 
times as compared to wild-type mice, since two out of nine Pfn1fl/fl-Pf4Cre mice failed to cease 
bleeding within the observation period (Fig. 25 D). Altogether, these results highlight Pfn1 as 
a critical factor for platelet integrin activation and thus as regulator of hemostasis and 
thrombosis.  
 
Figure 25. Impaired thrombosis and hemostasis in Pfn1fl/fl-Pf4Cre mice. Assessment of platelet 
adhesion and aggregate formation on collagen-coated coverslides under flow (1,000 s-1) of wild-type 
and platelet count-adjusted Pfn1fl/fl-Pf4Cre samples. (A) Representative phase contrast images taken at 
the end of the perfusion time, (B) analysis of the surface area covered by platelets (%) and the relative 
thrombus volume ± SD (n= 6 per group) are depicted. Values are mean ± SD (n= 12 mice per group).  
(C) Aorta thrombosis model. Representative graph of blood flow of a wild-type and a Pfn1fl/fl-Pf4Cre mouse 
after mechanical injury of the abdominal aorta at t= 0. (B) Occlusion time after mechanical injury of the 
abdominal aorta (n= 7 vs. 6 mice). Experiments were performed in collaboration with Sarah Beck in our 
laboratory. (E) Hemostasis as assessed by a tail bleeding time assay (n= 9 mice per group). Unpaired 
Student’s t-test (B, E) and Fisher’s exact test (D): ***P< 0.001. (Stritt, Birkholz et al., Blood Adv, 2018 
[179]) 
4.2.5 Altered β3-integrin and Talin-1 localization in Pfn1fl/fl-Pf4Cre platelets 
Talin-1 (Tln1) recruitment to the tails of β-integrin subunits represents a key step in integrin 
activation. To analyze if altered Tln1 recruitment causes the defective integrin activation 
observed in Pfn1fl/fl-Pf4Cre platelets, Tln1 and β3-integrin localization was assessed by 
immunostaining of platelets spread on fibrinogen. Whereas in wild-type platelets Tln1 and β3-
integrins localized mainly at the cell cortex (Fig. 26 A, upper part, B), Pfn1fl/fl-Pf4Cre platelets 
displayed a diffuse localization pattern throughout the entire platelet cytoplasm (Fig. 26 A, 
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lower part, B). These results suggested that lack of Pfn1 impairs Tln1 and β3-integrin 
localization, possibly due to an integrin defect or the disrupted actin cytoskeleton, also 
interfering with proper spreading of the platelets, or both.  
 
Figure 26. Altered integrin and Tln1 localization in Pfn1fl/fl-Pf4Cre platelets. (A) Tln1 localization to β3-
integrin tails was assessed by immunostaining and confocal microscopy (Leica TCS SP5, 100x/1.4 oil 
STED WHITE objective, Leica Microsystems) of spread platelets on fibrinogen (t= 30 min) of 6 vs. 6 
animals. Bar, 3 μm. (B) Assessment of the Tln1 and β3-integrin distribution pattern in at least 70 platelets 
of 6 animals per group. Values are mean ± SD. ***P< 0.001. (Stritt, Birkholz et al., Blood Adv, 2018 
[179]) 
4.2.6 Accelerated integrin closure in Pfn1fl/fl-Pf4Cre platelets 
The integrin activation defect in Pfn1-deficient platelets was further addressed by analysis of 
the activation status of β3-integrins. It has previously been reported that the switch of β3-
integrin from its high- to low-affinity state, the so-called integrin closure, is triggered by 
activation of the Ca2+-dependent cytosolic cysteine proteinase calpain, which cleaves off the 
β3-integrin tail. Sustained Ca2+ signaling, in turn, leads to exposure of PS on the outer leaflet 
of platelets, which critically links PS exposure and integrin closure [99, 180-182].  
To assess the role of Pfn1 in the dynamics of integrin closure, time course experiments were 
performed and the percentages of platelets with activated β3-integrins (measured by JON/A-
PE binding, quadrant Q1), PS exposure (assessed by Annexin A5-FITC binding, Q3), or both 
(Q2), were determined. In line with the increased Ca2+ signaling (data not shown), Pfn1fl/fl-Pf4Cre 
platelets displayed a significantly increased percentage of PS-positive platelets with 
inactivated integrins (JON/A- Annexin A5+; lower right quadrant Q3) after 5 minutes  
(Fig. 27 A, B) which was further increased 30 min after stimulation (Fig. 27 A, C).  
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Figure 27. Accelerated integrin closure in Pfn1fl/fl-Pf4Cre mice. (A) Washed platelets were stimulated 
for 5 or 30 minutes with 0.1 U mL-1 Thr and 10 µg mL-1 CRP. Activation of β3-integrins and PS exposure 
on the outer leaflet of the platelet membrane were determined by JON/A-PE antibody and Annexin A5 
protein (Anx A5-FITC). Analysis was performed by flow cytometry. Plots are representative of at least 6 
animals per group. (B, C) Percentage of platelets (mean ± SD of 6 vs. 7 animals) per quadrant (Q); Q1, 
JON/A+ Anxa5- (upper left); Q2, JON/A+ Anxa5+ (upper right); Q3, JON/A- Anxa5+ (lower right); Q4, 
JON/A- Anxa5- (lower left). Unpaired Student’s t-test: ***P< 0.001; **P< 0.01; *P< 0.05. (Stritt, Birkholz 
et al., Blood Adv, 2018 [179]) 
 
These results revealed that Pfn1-deficiency leads to accelerated integrin closure and is 
consequently a reason for the integrin activation defect observed in Pfn1-deficient platelets.  
4.2.7 Increased calpain activity in Pfn1fl/fl-Pf4Cre platelets 
Stritt et al. previously showed that altered calpain activity can impair integrin closure [99]. 
Therefore, it was assessed next whether accelerated integrin closure in Pfn1-deficient platelets 
was the reason of increased calpain activity. Immunoblotting of stimulated wild-type and 
Pfn1fl/fl-Pf4Cre platelets showed that cleavage of β3-integrin tails and hence dissociation of the 
integrin-cytoskeleton linkage was increased in stimulated Pfn1fl/fl-Pf4Cre platelets independent of 
the used agonist. A23187 (Fig. 28 A, lane 2), a Ca2+ ionophore which increases Ca2+ levels 
and hence activates calpain, served as activation-independent control. Increased calpain 
cleavage of β3-integrin in Pfn1fl/fl-Pf4Cre platelets was detectable upon stimulation with thrombin 
and CRP. As control, the cleavage of two additional calpain targets, Tln1 and Filamin A (Fln 
A) was assessed in Pfn1-deficient platelets. Again, similar results were obtained as increased 
calpain cleavage of these targets was observed in Pfn1fl/fl-Pf4Cre platelets (Fig. 28 B, C, lanes 
2+3). Of note, when calpain was chemically inhibited using the compound MDL-28170, the 
accelerated cleavage of calpain targets in Pfn1-deficient platelets was reversed to wild-type 
levels (Fig. 28 A-C, lane 4). 
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Figure 28. Increased calpain-mediated cleavage of β3-integrin, Talin and Filamin A in Pfn1fl/fl-Pf4Cre 
platelets. (A-C) Where indicated, platelets were pre-incubated for 10 min with the calpain inhibitor MDL-
28170 [200 μM]. Subsequently, resting platelets were left untreated or were stimulated with A23187  
[10 μM] or thrombin [0.1 U mL-1] and CRP [10 μg mL-1] (T+C), lysed and processed for immunoblotting. 
Full-length (Ab762) and calpain-cleaved (AbΔ747) β3-integrin, as well as Tln1 and Fln A were probed 
with the respective antibodies and analyzed by densitometry (n = 7 vs. 6 animals). Immunoblots are 
representative of at least 6 animals per group. (Stritt, Birkholz et al., Blood Adv, 2018 [179]) 
 
As pretreatment with MDL-28170 could revert the enhanced calpain-mediated cleavage of β3-
integrins in Pfn1-deficient platelets, it was assessed next whether it would also restore the 
impaired β3-integrin localization. To this end, platelets were pre-treated with MDL-28170 10 
min prior to spreading on fibrinogen. Inhibition of calpain could indeed restore β3-integrin and 
Tln1 localization (Fig. 29) and significantly improved spreading of Pfn1fl/fl-Pf4Cre platelets.  
 
Figure 29. Restored integrin and Tln1 localization in Pfn1fl/fl-Pf4Cre platelets upon MDL-28170 
treatment. Platelets were pretreated with the calpain inhibitor MDL-28170 [200 µM] and localization of 
β3-integrin (cyan) and Tln1 (magenta) was assessed by immunostaining and confocal microscopy 
(Leica TCS SP5, 100x/1.4 oil STED WHITE objective, Leica Microsystems) of spread platelets on 
fibrinogen (t= 30 min) of 4 animals per group. Bar, 3 μm. (Stritt, Birkholz et al., Blood Adv, 2018 [179]) 
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In summary, accelerated integrin closure caused by enhanced calpain activity, leads to 
reduced levels of activated integrins in Pfn1-deficient platelets. Moreover, these results support 
the previously described mechanism of calpain-mediated integrin closure.  
4.2.8 Defective actin dynamics in Pfn1fl/fl-Pf4Cre platelets modulate calpain activity  
Stritt et al. proposed that the organization of the circumferential actin cytoskeleton modulates 
calpain-mediated β3-integrin closure and thereby also controls their localization [99]. 
Therefore, it was assessed whether pretreatment with the actin polymerization inhibitor 
Latrunculin A could normalize the increased calpain activity of Pfn1-deficient platelets. 
Strikingly, inhibition of actin polymerization could revert the increased calpain-mediated 
cleavage of β3-integrin tails in Pfn1-deficient platelets to wild-type levels as assessed by 
immunoblotting of stimulated platelets pretreated with Latrunculin A (Fig. 30, A, B). 
 
Figure 30. Increased calpain-mediated cleavage of β3-integrin and Talin-1 is restored by 
inhibition of actin polymerization. Latrunculin A-pretreated platelets ([2.5 μM], 10 min) were left 
untreated or pre-incubated for 10 min in the presence of the calpain inhibitor MDL-28170 [200 μM]. 
Subsequently, samples were stimulated with A23187 [10 μM] or thrombin [0.1 U mL-1] and CRP  
[10 μg mL-1], lysed and processed for immunoblotting. Full-length β3-integrin (Ab762) and Talin-1 (Tln) 
was probed with the respective antibody and analyzed by densitometry. Immunoblots are representative 
of 3 animals per group. Values are mean ± SD. Unpaired Student’s t-test: **P< 0.01; *P< 0.05. (Stritt, 
Birkholz et al., Blood Adv, 2018 [179]) 
 
In summary, these findings reveal that lack of Pfn1 in platelets perturbs the organization of the 
adhesion-dependent circumferential actin network and thereby causes accelerated integrin 
closure translating into defective hemostatic and thrombotic function in vitro and in vivo.   
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4.3 Thymosin β4 regulates reactivity and procoagulant activity of platelets 
4.3.1 Tβ4-deficient mice show a mild thrombocytopenia 
Tβ4 is a moonlighting protein as it exerts various paracrine effects on the one hand, including 
cardiac protection, angiogenesis, wound healing and immunomodulatory effects [129]. On the 
other hand, it is, together with Pfn1, the major G-actin sequestering protein within cells of 
higher eukaryotes. While intensive research has investigated the beneficial impact of 
recombinant Tβ4 in a variety of disease models, its function for cytoskeletal dynamics is still 
poorly studied. Moreover, a distinction between endo- and exogenous protein function, its 
uptake and release mechanisms and its mode of action have remained elusive. Therefore, the 
aim was to investigate the effect of a constitutive Tβ4 KO on platelet physiology and thrombosis 
and to shed light on the underlying signaling network by analyzing the effect of recombinant 
Tβ4 in wild-type and Tβ4-deficient mice. Constitutive deletion of X-chromosomal Tβ4 (Tβ4y/- 
(male), Tβ4-/- (female)) in mice has previously been described by Rossdeutsch et al. [183]. 
Briefly, Tβ4-deficiency induced hemorrhages in the vessel wall (referred to as vascular 
hemorrhage) and reduced smooth muscle cell coverage [183], which reveals Pfn1 as regulator 
of mural cell development and vessel wall stability. The constitutive Tβ4y/- and Tβ4-/- mice 
(further referred to as Tβ4-/-) were further investigated in this thesis to assess the effect of Tβ4 
deletion for cytoskeletal dynamics and its other moonlighting properties.  
Deletion of Tβ4 was confirmed by RT-PCR (Fig. 32 A), as a detection of protein levels using 
western blotting was not possible so far due to the small protein size of 5 kDa.  
 
Table 2. Platelet membrane glycoprotein 
expression in Tβ4-/- platelets. Diluted whole 
blood was stained with fluorophore-labeled 
antibodies at saturating concentrations for 15 
min at RT and analyzed on a FACSCalibur 
(Becton Dickinson, Heidelberg). Platelets were 
gated by FSC/SSC characteristics. Results are 
given as mean fluorescence intensity (MFI) ± SD 
of 6-12 mice per group. Basal blood parameters 
were assessed using the Sysmex automated 
hematology analyzer (Sysmex KX-21N, Sysmex 
Corp., Kobe, Japan). 
 
 
Tβ4-deficiency did affect neither viability or fertility nor expression of prominent surface 
receptors or basal blood parameters (Table 2). Analysis of platelet count and size by flow 
cytometry revealed a moderate thrombocytopenia in Tβ4-/- mice, resulting in a 30% reduction 
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of platelet count compared to wild-type animals. However, the size of Tβ4-/- platelets was only 
slightly increased (Fig. 31 B). To test whether the thrombocytopenia was associated with 
altered MK numbers, H&E staining of spleen and BM sections was performed, which revealed 
normal MK numbers and morphology in Tβ4-/- mice compared to wild-type mice (Fig. 31 C)  
 
Figure 31. Tβ4-deficient platelets display a mild macrothrombocytopenia. (A) Agarose gel of RT-
PCR products from wild-type and Tβ4-/- platelet lysates proved the efficient ablation of Tβ4 expression 
in mutant platelets. Platelet size and count (B) were assessed by flow cytometry (n= 6 per group).  
(C) Representative pictures and analysis of MK numbers on H&E stained BM and spleen sections from 
wild-type and Tβ4-/- mice. Bar, 50 µm. Unpaired Student’s t-test: **P< 0.01. 
 
This suggested that the thrombocytopenia was not attributed to BM failure. Reduced platelet 
numbers in Tβ4-/- mice could also result from accelerated platelet clearance or impaired platelet 
production. Hence, it will be interesting to determine in vivo platelet life span, platelet clearance 
and proplatelet-formation of Tβ4-/- mice, which have not been addressed here. 
4.3.2 Altered cytoskeletal structure and function of Tβ4-deficient platelets 
Tβ4 is, together with Pfn1, one of the major actin-sequestering molecules in cells. Pfn1-
deficient platelets displayed severely misarranged, hyperstable microtubules and a partially 
disrupted actin cytoskeleton, as described by Bender, Stritt et al. [178]. Therefore, a detailed 
analysis of the actin and tubulin cytoskeleton of Tβ4-/- platelets was performed. 
First, agonist-induced actin polymerization was assessed and, strikingly, Tβ4-/- platelets 
exhibited an increased F-actin content already in the resting state and assembled significantly 
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less F-actin after platelet stimulation (Fig. 32 A). Of note, pretreatment of platelets with the 
actin polymerization inhibitor Latrunculin A, diminished the differences between Tβ4-/- and wild-
type platelets (Fig. 32 B).  
 
Figure 32. Increased levels and altered assembly of F-actin in Tβ4-/- platelets. (A-B) F-actin content 
of resting platelets and agonist-induced F-actin assembly was measured by flow cytometry after 
incubating the platelets with phalloidin-FITC and, where stated, with Latrunculin A (LatA) [2.5 µM] or 
with the same volume DMSO as control. The ratio of MFI from activated and resting platelets ± SD of 4 
mice per group is shown. A: ADP; U: U46619; AU: arbitrary units. (C) The actin cytoskeleton was isolated 
by ultracentrifugation, immunoblotted with anti-β-actin antibody and analyzed for the content of 
monomeric vs. polymeric actin using densitometry. GAPDH served as loading control. Values are mean 
± SD (n= 3). P: pellet, S: supernatant, T: total protein. (D) Visualization of the cytoskeleton of spread 
platelets (15 minutes) on fibrinogen, which were stained with DNase I-AlexaF488 (green) to label G-
actin and Phalloidin-atto647N (red) for visualization of F-actin and analyzed by confocal microscopy. 
Bar, 2 µm. Unpaired Student’s t-test: ***P< 0.001; **P< 0.01; *P< 0.05; NS = non-significant. 
 
In a sedimentation assay, the above-mentioned results were confirmed. Resting Tβ4-deficient 
platelets contained 30% more F-actin compared to wild-type platelets, which was accompanied 
by a concomitant decrease in G-actin levels (Fig. 32 C). These observations are in line with 
studies suggesting that Tβ4 complexes about half of the total amount of G-actin in resting cells 
[184]. Moreover, specific G-actin staining of spread platelets on fibrinogen with fluorescently 
labelled DNase I [185], revealed a similar reduction in the content of monomeric actin (Fig. 32 
D). In summary, this data shows that lack of Tβ4 impairs the equilibrium between actin 
monomers and polymers in platelets as Tβ4-deficient platelets displayed a decreased G-actin 
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pool concomitant with increased F-actin levels. Hence, due to the lack of actin monomers, less 
F-actin is assembled upon agonist-induced stimulation in Tβ4-deficient platelets. 
Analysis of the tubulin cytoskeleton revealed a significant increase in microtubule numbers 
(Fig. 33 A) in Tβ4-/- platelets.  
 
Figure 33. Increased levels of polymeric tubulin in Tβ4-/- platelets. (A) The tubulin cytoskeleton was 
isolated by ultracentrifugation, immunoblotted with an anti-α-tubulin antibody and analyzed for the 
content of monomeric vs. polymeric tubulin using densitometry. GAPDH served as loading control. 
Values are mean ± SD (n= 3). P: pellet, S: supernatant, T: total protein. (B) Platelets were either 
incubated at 37 or 4°C or were first incubated at 4°C and then allowed to reassemble their microtubules 
at 37°C. Platelets were subsequently fixed on a poly-L-lysine-coated surface. F-actin is shown in red 
and α-tubulin in green. Bars, 2 μm. Images are representative of at least 3 individuals. Unpaired 
Student’s t-test: **P< 0.01. 
Notably, this phenomenon was also described for Pfn1-deficient platelets [178], suggesting 
that impaired actin dynamics additionally affect the microtubule cytoskeleton. However, 
microtubule structure (Fig. 33 B and 36 B) as well as their cold-induced depolymerization (Fig. 
33 B) was unaltered in Tβ4-/- platelets, indicating a minor role of Tβ4 for microtubule 
functionality. The increased number of microtubules might rather act as a compensatory 
mechanism to guarantee a grossly normal platelet structure and shape. 
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4.3.3 Unaltered expression of other actin-binding proteins in Tβ4-/- platelets 
To exclude compensatory mechanisms of other actin-binding proteins in Tβ4-/- platelets, 
expression levels of the actin-sequestering protein Pfn1, and the ADF-H family members 
Twf1/2a and Cof were assessed by Western Blot analysis (Fig. 34). Interestingly, Tβ4-
deficiency did not affect the expression of any of these proteins.  
 
Figure 34. Unaltered expression levels of other cytoskeletal regulators in Tβ4-/- platelets. Western 
blots of lysates from unstimulated wild-type and Tβ4-/- platelets using antibodies against Pfn1, Twf1/2a 
or Cof. GAPDH served as loading control. 
 
4.3.4 Altered integrin activation of Tβ4-deficient platelets 
As altered cytoskeletal dynamics have been shown to influence platelet reactivity, e.g. for 
Twf2a-/- platelets [99], integrin activation was assessed next. To this end, β1- and β3-integrin 
activation as well as degranulation were assessed by flow cytometry (Fig. 35 A-C).  
Tβ4-/- platelets showed impaired activation of β3-integrins (JON/A-PE) in response to all tested 
agonists, whereas β1-integrin activation (9EG7-FITC) was only moderately decreased after 
high doses of thrombin and CRP (Fig. 35 A, B). Degranulation as assessed by P-selectin 
exposure (Fig. 35 C) was generally slightly increased, despite a significant decrease upon high 
doses of CRP. In line with this, Tβ4-/- platelets showed impaired aggregation in response to 
thrombin and the GPVI-coupled agonists CRP and CVX, whereas aggregation in response to 
ADP and U46619 was unaltered (Fig. 35 D). Surprisingly, Tβ4-/- platelets showed a profound 
hyper-responsiveness towards collagen, which was most evident at low and intermediate 
concentrations. To exclude that this effect was caused by altered second wave mediator 
release, platelets were pre-incubated with apyrase [2 U mL-1] and indomethacin [10 μM] to 
block these mediators and then stimulated with high concentrations of collagen  
[20 μg mL-1]. This could, however not revert the hyperresponsiveness of Tβ4-/- platelets towards 
collagen. Moreover, a blockade of the collagen-binding receptor α2β1 using the antibody 
23C11, did not affect the hyperreactivity either (data not shown). 
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Figure 35. Altered integrin activation in Tβ4-/- platelets. Activation of platelet (A) αIIbβ3- (JON/A-PE) 
and (B) β1-integrins (9EG7-FITC), as well as (C) α-granule release (α-P-selectin-FITC) in response to 
different agonists were assessed by flow cytometry. Values are mean ± SD (n= 6 mice per group). (D) 
Aggregation responses of wild-type and Tβ4-/- platelets to different agonists. Values are mean ± SD of 
at least 4 mice per group. Unpaired Student’s t-test: **P< 0.01; *P< 0.05. 
 
Next, the impact of Tβ4-deficiency on platelet integrin outside-in signaling was assessed in a 
clot retraction assay (Fig. 36 A) and spreading experiments on fibrinogen-coated surfaces (Fig. 
36 B, C). Tβ4-/- platelets displayed significantly accelerated clot retraction, as well as faster 
lamellipodia formation already after 5 min and a higher abundance of fully spread platelets 
after 15 min. Pre-incubation of Tβ4-/- platelets with apyrase [2 U mL-1] and indomethacin  
[10 μM] could not slow down the accelerated spreading back to wild-type levels (data not 
shown). 
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Figure 36. Altered integrin outside-in signaling in Tβ4-/- platelets. (A) Clot retraction of wild-type and 
Tβ4-deficient PRP was determined in response to 5 U mL-1 thrombin and monitored over time. Values 
are mean ± SD (n= 6 per group). (B) Visualization of the cytoskeleton of resting platelets on poly-L-
lysine and spread platelets (t= 15 min) on fibrinogen, which were stained with Phalloidin-atto647N (red) 
and α-tubulin antibody-Alexa 488 (green) and analyzed by confocal microscopy microscopy (Leica TCS 
SP5, 100x/1.4 oil STED WHITE objective, Leica Microsystems). Bars, 2 µm. (C) Quantification of the 
different spreading phases at 5, 15 and 30 min after stimulation with 0.01 U mL-1 thrombin from DIC 
images. Images are representative of at least 6 animals per group. Unpaired Student’s t-test: *P< 0.05.  
 
4.3.5 Defective thrombus formation of Tβ4-deficient platelets on collagen under flow 
Platelet adhesion and thrombus formation of Tβ4-/- platelets on collagen using the in vitro flow 
chamber model was assessed to investigate whether the altered reactivity of Tβ4-/- platelets in 
vitro under static conditions would affect thrombus formation under flow. Indeed, Tβ4-
deficiency resulted in a markedly reduced (up to 50%) adhesion and thrombus formation 
compared to wild-type levels at both low and high shear rates (Fig. 37 A, B).  
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Figure 37. Impaired adhesion and defective thrombus formation of Tβ4-/- platelets on collagen 
under flow. (A) Representative phase contrast images taken at the end of the perfusion time after 
heparinized whole blood of Tβ4-/- and wild-type mice was perfused over a collagen-coated surface for 
10 min at shear rates of low (150 s-1) and for 4 min at shear rates of intermediate shear forces  
(1000, 1,700 s-1). (B) Analysis of the surface area covered by platelets (%) and the relative thrombus 
volume ± SD of at least 6 animals per group. Unpaired Student’s t-test: ***P< 0.001; **P< 0.01;  
*P< 0.05. Bar, 50 µm. 
 
4.3.6 Tβ4-deficient mice are protected from arterial thrombus formation in vivo 
To test whether the observed thrombus formation defect translates into an in vivo phenotype, 
Tβ4-/- and wild-type mice were subjected to two well-established in vivo thrombosis models. In 
the first model, mesenteric arterioles were injured by topical application of FeCl3. The time to 
appearance of first thrombi, as well as the time to stable vessel occlusion was slightly 
prolonged in Tβ4-/- mice compared to wild-type animals (Fig. 38 A). 
In the second model, injury is mechanically induced in the aorta. Notably, it is well established 
that thrombus formation occurs mainly through collagen-dependent mechanisms under these 
experimental conditions [171]. After a transient increase directly after injury, blood flow 
progressively decreased for several minutes in all animals. In all wild-type mice, this decrease 
resulted in complete and irreversible occlusion of the vessel within 7 min after injury  
(Fig. 38 B). Out of the 14 tested Tβ4-/- mice, 7 displayed a transient decrease in blood flow, 
which increased again to normal and led to essentially normal flow rates through the injured 
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vessel at the end of the observation period. The other group of Tβ4-/- mice showed a 
progressive decrease in blood flow, which resulted in full occlusion of the vessel transient 
within 8 minutes after injury, almost comparable to wild-type mice. Consistent with the in vitro 
data under flow, the protection of Tβ4-/- mice was more pronounced when using the collagen-
dependent in vivo model.  
 
Figure 38. Tβ4-/- mice are protected from arterial thrombus formation in vivo. (A) FeCl3-induced 
arterial thrombus formation of the mesenteric arterioles. Adhesion and thrombus formation of 
fluorescently-labeled platelets was monitored in vivo by fluorescence microscopy and time to 
appearance of first thrombus as well as time to occlusion was assessed. Each symbol represents one 
individual. (B) Aorta occlusion model. Representative graph of blood flow of a wild-type and two Tβ4-/- 
mice after mechanical injury of the aorta at t= 0 and occlusion time after injury of the aorta. Fisher´s 
exact test: **P< 0.01. Experiments were performed in collaboration with Sarah Beck in our laboratory. 
 
4.3.7 Altered secretion of Tβ4-deficient platelets 
At sites of vessel wall injury, release of secondary mediators from activated platelets at the 
exposed subendothelial matrix plays a crucial role for the recruitment and activation of further 
platelets to promote thrombus formation. To test whether the impaired thrombus formation in 
vitro and in vivo was caused by altered second wave mediator release, agonist-induced 
granule secretion of Tβ4-deficient platelets was assessed. Strikingly, a profound increase in 
ATP secretion upon stimulation with U46619 and thrombin, as well as the GPVI agonist 
collagen could be detected in Tβ4-deficient platelets (Fig. 39). In contrast, as seen in other 
assays (Fig. 35 A, D), Tβ4-deficient platelets were hyporesponsive towards CRP-stimulation, 
which resulted in a significant decrease in dense granule ATP release (Fig. 39). Notably, in 
line with this, α-granule release was generally slightly increased in Tβ4-deficient platelets, 
despite a significant decrease after CRP stimulation (Fig. 35 C). Hence, it will be interesting to 
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determine ATP and P-selectin content in Tβ4-deficient platelets to exclude that the effects 
observed here are caused by increased storage of these mediators.  
 
Figure 39. Altered dense granule secretion of Tβ4-/- platelets. Luminometric measurement of 
released ATP of activated wild-type and Tβ4-/- platelets. Results are given as mean ATP concentration 
[µM] ± SD (n = 12 per group). Unpaired Student’s t-test: ***P< 0.001; **P< 0.01; *P< 0.05. 
 
4.3.8 Increased procoagulant activity in Tβ4-deficient platelets 
Sustained platelet activation leads to a marked increase in cytosolic Ca2+ concentrations, 
subsequent surface exposure of procoagulant PS and resultant thrombin generation [176] 
[186]. To assess whether the hyperresponsiveness towards collagen or the hypo-
responsiveness towards CRP would predominate the procoagulant potential of Tβ4-/- platelets, 
binding of fluorescently-labeled Annexin A5 to PS exposed on the platelet surface upon 
stimulation was analyzed by flow cytometry [177]. Notably, no differences in procoagulant 
activity between wild-type and Tβ4-/- platelets could be observed (Fig. 40 A). 
Next, whole blood from wild-type and Tβ4-/- mice was perfused over immobilized collagen at a 
shear rate of 1700 s-1 and PS exposure was determined by Annexin A5-staining. Although the 
surface covered by collagen-adherent platelets was strongly reduced in Tβ4-/- samples, PS 
exposure was markedly increased (Fig. 40 B), indicating that Tβ4 regulates procoagulant 
activity of platelets. 
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Figure 40. Increased procoagulant activity of Tβ4-/- platelets on collagen under shear flow. (A) 
Washed platelets were stimulated with the indicated agonists and stained with saturating amounts of 
Annexin A5-DyLight488 and directly analyzed by flow cytometry. Results are expressed as MFI ± SD 
(n= 4 mice per group). (B) Whole blood was perfused over a collagen-coated [0.2 mg mL-1] surface at a 
shear rate of 1,700 s−1 for 4 min. Adherent platelets were stained with Annexin A5-AlexaF488 [0.25 mg 
mL-1]. Representative phase contrast, fluorescence images and mean relative amount of Annexin A5 
positive platelets ± SD of at least 6 mice per group is shown. Unpaired Student’s t-test: ***P< 0.001. 
 
Surface-exposed PS triggers procoagulant activity of platelets and propagates coagulation by 
facilitating assembly and activation of the tenase and prothrombinase complexes [186] and 
leads to rapid thrombin generation [187]. In agreement with the enhanced PS exposure, lack 
of Tβ4 resulted in an altered maximal amount of generated thrombin (Fig. 41 B), which was 
signify-cantly accelerated upon stimulation with (hem)ITAM-specific agonists. The overall 
amount of produced thrombin (ETP), however, was comparable to wild-type samples (Fig. 41 
A). In line with this, Tβ4-deficient mice showed a shortened activated plasma thromboplastin 
time (aPTT), a global test for the intrinsic coagulation pathway. When single factors were 
assessed, levels of FXII as initiator of the intrinsic cascade were unaltered. Strikingly, however, 
levels of FXI, the second factor of the intrinsic coagulation pathway, and the subsequent factor 
IX together with its cofactor VIII were significantly increased in Tβ4-deficient mice (Fig. 41 D, 
F-H). The extrinsic coagulation pathway as assessed by Quick was, however, unaltered in 
Tβ4-deficient mice. Taken together, the results establish Tβ4 as an important regulator of 
thrombin generation and coagulation.  
In summary, the results of this thesis highlight Tβ4 as an important regulator of cytoskeletal 
dynamics on the one hand and of platelet reactivity, in vivo thrombus formation, granule 
release and procoagulant activity on the other hand. However, differences between endo- and 
exogenous protein function have not been addressed and therefore require further 
investigation.  
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Figure 41. Tβ4-deficiency resulted in accelerated thrombin formation and enhanced intrinsic 
coagulation. (A-C) Citrate-anticoagulated PRP was left unstimulated (PRP), or platelets were activated 
by incubation with CRP [20 μg mL-1], CVX [10 μg mL-1], Rhd [1 μg mL-1] or the Ca2+ ionophores A23187 
and ionomycin (Iono) [10 µM] for 10 min at 37°C. Thrombin generation was triggered with tissue factor. 
(A) Endogenous thrombin potential (ETP). (B) Quantification of thrombin peak height. (C) Quantification 
of time to peak. Results are mean ± SD of at least 4 animals per group. Experiments were performed in 
collaboration with Sarah Beck in our laboratory. (D-I) Coagulation was assessed using the two global 
tests aPTT (D) and Quick (E). Measurement of single factors FVIII (F), XI (G), IX (H), XII (I). Results are 
mean of two independent experiments with 5 vs. 5 animals. Experiments were performed in 
collaboration with Dr. Sabine Herterich from the Central Laboratory, University Clinics Würzburg. 
Unpaired Student’s t-test: **P < 0.01; *P < 0.05.  
 
4.3.9 Assessment of the function of recombinant Tβ4  
4.3.9.1 Recombinant Tβ4 rescues the thrombus formation defect of Tβ4-deficient 
platelets 
Several studies investigated the anti-inflammatory, angiogenic and cardioprotective function of 
recombinant Tβ4 in a variety of disease models. Administration of Tβ4 following myocardial 
infarction in mice protected heart tissue from cell death and enabled heart myocytes to survive 
after hypoxia by upregulating PINCH-ILK-Akt survival pathways [144]. However, a distinction 
between endo- and exogenous protein function and especially its release and uptake 
mechanisms have remained elusive. Therefore, the aim was to investigate whether 
exogenously added recombinant Tβ4 would revert (at least in part) some of the observed 
effects of Tβ4-deficiency. To this end, several of the previously described assays were 
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repeated after pre-incubation of wild-type and Tβ4-/- platelets with commercial recombinant 
Tβ4 (Peprotech; Rocky Hill, USA) in vitro. 
 
Figure 42. Recombinant Tβ4 rescued the thrombus formation defect of Tβ4-deficient platelets on 
collagen under flow. Heparinized whole blood of Tβ4-/- and wild-type mice was either pre-incubated 
with recombinant Tβ4 [1, 5, 10 µg mL-1] for 5 min at 37°C or left untreated and afterwards perfused over 
a collagen-coated surface [0.2 mg mL-1] for 4 min at an intermediate shear rate of 1000 s-1.  
(A) Fluorescent images taken at the end of the perfusion period. Images are representative of at least 6 
animals per group. (B) Analysis of the surface area covered by platelets (%) and the relative thrombus 
volume ± SD. Unpaired Student’s t-test: **P< 0.01; *P< 0.05; NS = non-significant. Bar, 50 µm. 
 
As the described Tβ4 concentration in human plasma was estimated to 0.03-0.4 µg mL-1 [139], 
a concentration range of 0.1 to 10 µg mL-1 was chosen for the in vitro pre-incubation of platelets 
and the working concentration was titrated for each experiment. Similarly, different incubation 
times (5-30 min) were tested and showed an effect of the protein as early as after 5 minutes. 
Since the effect of Tβ4-deficiency was most pronounced under flow, activity of the recombinant 
protein was first tested using the in vitro flow chamber system. At concentrations of 0.1, 0.5 
and 1 µg mL-1 recombinant Tβ4 showed no effect on thrombus formation under flow, strikingly, 
however, it could fully revert the thrombus formation defect of Tβ4-deficient blood to wild-type 
levels at a concentration of 5 and 10 µg mL-1 (Fig. 42 A, B and data not shown). Of note, 
although a concentration of 1 µg mL-1 was insufficient to fully restore thrombus volume, it could 
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rescue platelet adhesion to collagen in Tβ4-/- mice. In wild-type samples pre-incubation with 
recombinant Tβ4 had no obvious effect on surface coverage or thrombus formation (Fig. 42 A, 
B and data not shown). The results suggest a direct interaction between Tβ4 and collagen, 
which might be facilitated by its highly adoptive structure as an intrinsically unstructured protein 
IUP [132]. In line with this hypothesis, Tβ4 is released from activated platelets and partially 
crosslinked to fibrin by FXIIIa, a transglutaminase [133]. A possible interaction between 
collagen and Tβ4 will be addressed in further experiments.  
4.3.9.2 Recombinant Tβ4 has differential influence on αIIbβ3 integrin activation 
Besides the reduced thrombus formation in vitro under flow, Tβ4-/- platelets exhibited defective 
αIIbβ3 integrin activation. Therefore, it was investigated whether pre-incubation of Tβ4-/- 
platelets with recombinant Tβ4 (5 min at 37°C with 0.05, 0.1, 0.5, 1 and 5 µg mL-1) could revert 
the impaired integrin activation as assessed by flow cytometry and aggregometry.  
 
Figure 43. Recombinant Tβ4 cannot rescue the altered integrin activation of Tβ4-/- platelets. 
Washed platelets were pre-incubated with 5 µg mL-1 recombinant Tβ4 for 5 min or left untreated prior to 
stimulation. (A) Activation of platelet αIIbβ3-integrins (JON/A-PE) in response to different agonists was 
assessed by flow cytometry. Values are mean ± SD of 4 mice per group. (B) Aggregation responses to 
different agonists. Values are mean ± SD of at least 4 animals per group. Unpaired Student’s t-test:  
**P< 0.01; *P< 0.05. 
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At concentrations less than 0.1 µg mL-1 recombinant Tβ4 had no effect on wild-type or Tβ4-/- 
platelets (data not shown). However, at concentrations of 0.1 µg mL-1 or higher, αIIbβ3 integrin 
inside-out activation was decreased in comparison to untreated controls of both wild-type and 
Tβ4-/- platelets (Fig. 43 A and data not shown). Strikingly, the integrin activation defect of  
Tβ4-/- platelets pre-incubated with recombinant Tβ4 was even more pronounced. Similarly, pre-
incubation with 1 and 5 µg mL-1 recombinant Tβ4 could neither enhanced aggregation of  
Tβ4-/- platelets upon stimulation with CRP and thrombin nor revert the hyperresponsiveness of 
Tβ4-/- platelets towards collagen stimulation (Fig. 43 B). Interestingly, recombinant protein 
further enhanced aggregation of both wild-type and Tβ4-/- platelets in comparison to the 
untreated controls upon collagen stimulation. Next, the effect of recombinant Tβ4 on integrin 
outside-in signaling was assessed by performing spreading assays on fibrinogen. 
Recombinant Tβ4 could not slow down the enhanced spreading of Tβ4-/- platelets to levels of 
wild-type platelets.  
 
Figure 44. Recombinant Tβ4 accelerates spreading of wild-type and Tβ4-deficient platelets. 
Washed platelets were pre-incubated with 5 µg mL-1 recombinant Tβ4 or left untreated prior to 
stimulation with 0.01 U mL-1 thrombin. Platelets were allowed to spread on fibrinogen [100 µg mL-1]. (A) 
Representative DIC images of 2 individual experiments at t= 15 min and (B) statistical evaluation of the 
percentage of spread platelets at different spreading stages. Bar, 3 µm. 
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Pre-treatment of both wild-type and Tβ4-deficient platelets with recombinant Tβ4 at a 
concentration of 1 µg mL-1 and higher rather resulted in faster spreading, which was most 
striking at 15 minutes after thrombin stimulation, were significantly more wild-type and Tβ4-
deficient platelets already reached phase 4 (fully spread platelets) compared to untreated 
controls (Fig. 44 A, right part and B). 
In summary, on the one hand, recombinant Tβ4 does not rescue the impaired integrin inside-
out signaling of Tβ4-/- platelets to wild-type levels, but further decreases integrin activation. On 
the other hand, integrin outside-in signaling is enhanced by recombinant Tβ4, which resulted 
in a significant increase of fully spread platelets already after 15 minutes in both wild-type and 
Tβ4-/- platelets.  
4.3.9.3 Enhanced secretion of platelets treated with recombinant Tβ4  
Tβ4-/- platelets displayed enhanced granule secretion (Fig. 39). Therefore, it was tested 
whether pre-incubation with recombinant Tβ4 would normalize granule secretion back to wild-
type levels, which was assessed by measurement of agonist-induced ATP release (Fig. 45). 
In line with its effect on platelet aggregation, recombinant Tβ4 further enhanced the elevated 
ATP secretion in Tβ4-/- platelets, except after stimulation with CRP, where it even further 
decreased granule release. Tyrosine phosphorylation assays of known hem(ITAM) 
downstream signaling molecules, such as Syk, LAT and PLC will address the differential 
effects of CRP vs. collagen stimulation on GPVI signaling in Tβ4-/- platelets. 
 
Figure 45. Recombinant Tβ4 enhances ATP release of wild-type and Tβ4-/- platelets. Washed 
platelets were pre-incubated with 5 µg mL-1 recombinant Tβ4 or left untreated prior to the stimulation. 
Luminometric measurement of released ATP of activated wild-type and Tβ4-/- platelets. Results are 
given as mean ATP concentration [µM] ± SD (n= 6 mice per group). Unpaired Student’s t-test:  
**P< 0.01; *P< 0.05. 
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4.3.10 Construct design, expression and purification of recombinant Tβ4 
To further elucidate the effects of recombinant Tβ4 and the underlying signaling pathways, 
large amounts of recombinant protein will be needed, especially for in vivo experiments, which 
would not be feasible with commercial Tβ4. Therefore, the aim was to establish an expression 
and purification protocol for recombinant Tβ4 from E. coli. Successful overexpression of full-
length Tβ4 in E. coli had previously been described [188]. The herein described strategy was 
used as starting point and was partially adopted and optimized in the course of this thesis. Li 
et al. showed that expression of recombinant Tβ4 benefited from a DsbA-solubility tag, which 
is a feature of the pETM-52 vector [149] (see sections 3.1.4 and 8.2). Therefore, full-length 
Tβ4 was cloned into this vector using restriction endonucleases (described in the methods part 
in section 3.2.3). Restriction sites were introduced into the insert by PCR (Fig. 46 B), digested 
vector and insert were ligated and transformed into competent E. coli TOP10 cells and 
successful cloning was verified by Colony-PCR (Fig. 46 C) and sequencing approaches (data 
not shown).  
 
Figure 46. Cloning and expression tests of recombinant Tβ4. (A) Cartoon of the designed construct 
comprising the N-terminal DsbA-tag, followed by a 6x His-Tag, full-length Tβ4 and a stop codon. N- 
terminal Tag can be cleaved off by TEV protease. (B) Success of the Insert-PCR adding sites for 
restriction endonucleases was analyzed by agarose gel electrophoresis. The expected band size of the 
insert was 180 bp. (C) Successful ligation of the pETM-52 vector with the Tβ4 insert was verified by 
Colony-PCR of 7 clones per ligation approach (8:2 or 9:1, insert:vector). The expected band size was 
180 bp. (D) Expression test of a positive clone using different E. coli expression strains (Rosetta-2 
pRARE2 and pLysS, BL21 (DE3)). Expression was performed o/N at 20°C, cells were harvested and 
soluble expression was analyzed by a small-scale expression test where harvested cells were 
resuspended in lysis buffer, lysed by sonification and centrifuged to separate soluble from insoluble 
protein. Subsequently, soluble protein was incubated with Ni-NTA and eluted using lysis buffer 
supplemented with 250 mM imidazole. Sn: supernatant; P: pellet; W1: wash 1; E1, 2: eluate 1, 2. 
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Expression of the construct was tested by expression tests using different E. coli expression 
strains and two different temperatures (16°C (data not shown), 20°C (Fig. 46 D)). The DsbA-
tagged full-length Tβ4 was solubly expressed, with the highest protein yields from E. coli BL21 
(DE3) expression (Fig. 46 D). The tested temperatures during cultivation did not have a 
significant effect on protein yield. Therefore, further optimization was not necessary and 
expression in E. coli BL21 (DE3) at 20°C o/N under constant shaking at 200 rpm was applied 
for all following expressions.  
Initial purifications of small-scale expression tests succeeded with a simple Tris buffer at pH 8 
supplemented with 150 mM NaCl (Fig. 46 D). Harvested cells were resuspended in this buffer, 
lysed by sonification and centrifuged to separate soluble from insoluble protein. Subsequently, 
soluble protein was incubated with Ni-NTA Agarose and eluted using lysis buffer supplemented 
with 250 mM imidazole. Subsequent analysis of samples taken at every step of the small-scale 
purification revealed successful purification. Therefore, this protocol was used for upscaling.  
 
Figure 47. Purification of recombinant Tβ4. (A) Purification protocol including lysis of the cells by 
sonification, separation of soluble (Sn) and insoluble protein fraction by centrifugation, incubation of the 
soluble fraction with Ni-NTA Agarose followed by Immobilized Metal Affinity Chromatography (IMAC) 
(fractions FT, E1, E5), a subsequent cleavage of the DsbA-tag using TEV protease (TEV cleavage), a 
reverse IMAC (rev. IMAC) to separate the cleaved tag from the untagged protein and a final size 
exclusion chromatography (SEC) for improved purity. The arrow indicates the expected elution of 
untagged Tβ4. (B) Representative size exclusion chromatogram and Coomassie-stained tricine PAGE 
of a Tβ4 purification. Sn: supernatant; FT: flow-through; E1, 5: eluate 1, 5. 
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Large-scale purifications were performed in same buffer and comprised the following 
purification protocol: lysis of the cells by sonification, separation of soluble and insoluble protein 
fraction by centrifugation, incubation of the soluble fraction with Ni-NTA Agarose followed by a 
starting Immobilized Metal Affinity Chromatography (IMAC), subsequent cleavage of the DsbA-
tag using TEV protease, reverse IMAC to separate the cleaved tag from the untagged protein 
and a final size exclusion chromatography for improved purity. As the size of untagged Tβ4 (5 
kDa) was too small to detect it with the usual 15% SDS-PAGE, different gel systems were 
tested, among these were native PAGE or tricine PAGE. However, it was not possible to detect 
the untagged recombinant Tβ4. Further optimization is necessary to solve this problem and to 
successfully purify untagged recombinant Tβ4.  
Functionality of the purified protein will be tested using the in vitro flow chamber model with a 
shear flow of 1000 s-1. When an increase of the surface coverage of Tβ4-deficient blood to 
wild-type levels is detected, the protein will be considered as functional. 
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5. DISCUSSION  
Platelet activation and aggregation at sites of vascular injury is essential to limit blood loss, but 
under pathological conditions it may lead to complete vessel occlusion resulting in myocardial 
infarction or stroke. Therefore, platelet signaling has become an important field in clinical 
research over the last decades and many therapeutical drugs for prevention of cerebro- and 
cardiovascular diseases, such as aspirin and clopidogrel, act by inhibiting platelet function. 
However, application of those currently available antithrombotic agents is often associated with 
an increased bleeding risk; hence, new safe therapeutic options are urgently needed.  
Massive reorganization of the actin cytoskeleton is induced upon platelet activation. This 
enables adhesion and spreading of platelets on ligands immobilized at the injured vessel wall. 
Likewise, the actin and microtubule cytoskeleton plays a central role in megakaryo- and 
thrombopoiesis. Thus, cytoskeletal protein aberrations may cause many pathological 
phenotypes. Although intensive research is carried out to identify the key players, the signaling 
cascades orchestrating the complex process of cytoskeletal remodeling are still poorly 
understood. Among the vast number of actin-binding proteins, the ADF-H family members Cof 
and Twf2a, have been described as critical regulators of cytoskeletal rearrangements required 
for proper platelet formation and reactivity. However, another protein family member, Cotl1, 
has not been investigated. Deficiency of the actin-sequestering protein Pfn1 has been 
described to evoke cytoskeletal instability, which resulted in a partially disrupted cortical actin 
cytoskeleton. Its impact on platelet reactivity has, however, not been addressed so far. Finally, 
Tβ4 is a moonlighting protein and its cardioprotective, angiogenic and immunomodulatory 
effects are intensively studied. However, its function for cytoskeletal dynamics is still poorly 
understood.  
In the current thesis, the actin-binding proteins Cotl1, Pfn1 and Tβ4 have been investigated 
concerning platelet production and function using transgenic mice. Although effects of a 
deficiency in one of these proteins are diverse, a common feature is their influence on platelet 
reactivity. This further emphasizes the importance of a functional actin cytoskeleton for intact 
platelet function in vitro and in vivo and shows that actin-binding proteins may serve as new 
potential targets to treat cerebro- and cardiovascular diseases. 
5.1 A complex phenotype dominated by protection from arterial thrombus 
formation in mice lacking Cotl1  
Rearrangements of the actin cytoskeleton play a crucial role for platelet formation and 
reactivity, which has been demonstrated in several studies on actin-binding proteins, e.g. the 
ADF-H family members Cof and Twf2a [82, 99]. Therefore, we were interested to investigate 
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Cotl1, another member of this protein family and its implication in thrombopoiesis and platelet 
reactivity in vitro and in vivo using a knock-out approach (PF4-Cre/loxP). A common feature of 
ADF-H containing proteins is (1) their ability to bind actin and (2) their influence on cytoskeletal 
dynamics. However, each group of ADF-H family members shows unique actin-binding 
properties and biological activities, which can be attributed to their differential domain structure. 
Thus, ADF/cofilins contain one ADF-H domain and can bind both G- and F-actin [69], whereas 
Twfs consist of two ADF-H domains separated by a short linker region and are only able to 
bind monomeric actin [38, 66]. Hence, Cof-deficiency decreased stimulus-dependent F-actin 
assembly, whereas on the contrary, Twf2a-deficient mice displayed enhanced actin dynamics 
[82, 99]. A study from Kim et al. demonstrated that Cotl1 is essential for T cell spreading at the 
immune synapse by protecting F-actin from Cof-mediated severing [104]. Taken together, it 
was likely that a deletion of Cotl1 would interfere with cytoskeletal dynamics, too. Surprisingly, 
however, the results of this study clearly show that Cotl1 is not required for cytoskeletal function 
in vitro (Fig. 12). Moreover, in contrast to Cof and Twf2a, Cotl1 was dispensable for 
thrombopoiesis (Fig. 11 B) [82, 99]. Thus, Cotl1-/- mice represent the first ADF-H KO mouse 
model with unaltered platelet number and size and cytoskeletal dynamics. 
The differential function of Cotl1 compared to other ADF-H family members might in part be 
explained by the low sequence identity between Cotl1 on the one hand and Twf/Cof on the 
other hand. Although the actin-binding site is structurally highly conserved, which results in a 
high structural homology of these proteins and determines their ability to bind to actin, the low 
sequence identity could result in completely different functions of these proteins. Another 
hypothesis why Cotl1-deficiency did not affect cytoskeletal dynamics was that other actin-
binding proteins compensated for the lack of Cotl1. Strikingly, indeed, a strong increase in 
Phospho-Cof levels was detected in Cotl1-deficient platelets (Fig. 13 D). The increased 
phosphorylation of Cof in the absence of Cotl1 may ultimately cause reduced F-actin severing 
and might thereby act as a compensatory mechanism. This would be in line with findings of 
Kim et al. who showed that Cotl1 and Cof compete with each other for F-actin binding thereby 
protecting F-actin from Cof-mediated severing [104].  
Besides its interaction with F-actin, Cotl1 is known to upregulate 5-lipoxygenase (5-LO) 
activity. 5-LO catalyzes the first steps of the conversion of arachidonic acid (AA) into 
leukotrienes (LT) [110]. Likewise, cyclooxygenases catalyze the initial step of the conversion 
of AA into thromboxanes (TxA/B2), prostacyclin (PGI2) and prostaglandines (PGE/F2). 
Therefore, it was conceivable that Cotl1-deficiency affects AA metabolism. However, TxB2 
levels were not significantly altered in Cotl1-deficient platelets (Fig. 15). Investigation of LT 
levels did not yield meaningful results, probably due to low amounts of these lipid mediators in 
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platelets, which were below the detection range of the ELISA kit used here. Further studies 
are ongoing to determine the exact role of Cotl1 for AA metabolism. Platelet-stored LTs are 
known to contribute to inflammatory responses, e.g. during acute inflammation [170]. Lack of 
Cotl1 may lead to downregulation of 5-LO activity and hence reduced LT levels, which might 
influence in vivo platelet function and explain some of the observed in vivo defects of Cotl1-
deficient platelets.  
Cotl1-deficiency resulted in significantly reduced aggregate formation of platelets on collagen 
in vitro under flow (Fig. 16), which translated into defective thrombus formation (Fig. 17 A, B) 
and prolonged bleeding times in vivo (Fig. 17 C). Notably, the reduced aggregate formation on 
collagen in vitro under flow was most striking at high shear rates, thus pointing towards a GPIb-
dependent mechanism [8, 172]. Recent studies showed that blockade of the vWF binding site 
on GPIbα by p0p/B-Fab treatment significantly reduced platelet tethering to the injured carotid 
artery and thus resulted in abolished aggregate formation at sites of vascular injury [153]. The 
protection from in vivo arterial thrombus formation in Cotl1-deficient mice is in line with these 
observations. Moreover, adhesion of Cotl1-/- platelets to vWF was significantly reduced (Fig. 
18). Of note, this defect was not caused by altered GPIb expression levels (Table 1). 
Altogether, these results suggest defective GPIb-vWF binding in Cotl1-deficient platelets, 
however, the mechanism how Cotl1 influences this interaction remains elusive. Different 
hypotheses will be discussed briefly in the following. First, GPIbα is a known target of ADAM 
family metalloproteases which shed GPIb from the platelet surface [189]. Therefore, enhanced 
GPIbα shedding could be the reason for the impaired GPIb-vWF interactions in Cotl1-deficient 
platelets. Shedding of GPIbα from the platelet surface as assessed in a time course experiment 
by flow cytometry was, however, unaltered in Cotl1-deficient platelets (data not shown). 
Notably, although vWF is the main ligand of GPIb, other interaction partners are present in the 
circulating blood, Among these are 14‐3-3ζ, Fln A, src family kinases and phosphatidylinositol‐
3 kinase for GPIbα and calmodulin and 14‐3‐3ζ for GPIbβ [190]. Further experiments will 
address whether Cotl1-deficiency also affects the interaction of GPIb with these interaction 
partners. Fln A expression as assessed by Western blotting was indeed slightly altered in 
Cotl1-deficient platelets (data not shown), however, this minor decrease cannot account for 
the observed defects of Cotl1-deficient platelets. Cotl1 might also affect the mechanosensing 
capability of GPIb. Receptor-mediated cell mechanosensing is a multistep process that is 
initiated by binding of cell surface receptors to their ligands on the ECM or the surface of 
adjacent cells. Mechanosensing is per definition the ability of a cell to sense mechanical signals 
of its microenvironment, including force, stress, and strain but also substrate rigidity, topology, 
and adhesiveness. This ability is crucial for the cell to respond to the surrounding mechanical 
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cues and adapt to the changing environment e.g. by (de)activation, proliferation/apoptosis, and 
(de)differentiation [191].  
The release of second wave mediators potentiate thrombus formation at sites of vascular 
injury. Therefore, impaired release of second wave mediators could be another reason for the 
reduced aggregate formation of Cotl1-deficient platelets in vitro and in vivo. Indeed, α-granule 
release was reduced in Cotl1-deficient platelets (Fig. 19 B). However, contradictory, ATP 
release from dense granules was significantly enhanced in Cotl1-deficient platelets (Fig. 19 
A). Notably, the increased secretion of dense granules of Cotl1-/- platelets was not restricted to 
a specific agonist, but occurred in response to GPCR-, as well as ITAM-coupled agonists. 
Although the exact role of the actin cytoskeleton in exocytotic events in platelets is 
controversial, several studies using actin-disrupting agents supported a model, in which the 
cytoskeleton of resting platelets may act as a barrier for granule release and that platelet 
activation leads to (partial) rupture of actin filaments, thereby enabling degranulation [192]. 
Further studies on the secretion of other granule-stored proteins will answer this question. Co-
infusion of ADP and the thromboxane analogue U46619 using the in vitro flow chamber model 
largely reverted the defective thrombus formation of Cotl1-deficient platelets; however, it could 
not be normalized to wild-type levels (Fig. 20). These results suggest that both defective GPIb-
vWF interactions and decreased second wave mediator secretion contribute to the reduced 
aggregate formation in Cotl1-deficient mice. Of note, these results show that the amount of 
released second wave mediators does not seem to be the major determinant of thrombus 
growth under the experimental conditions used in this study but that the defective GPIb-vWF 
interaction predominates the observed protection from arterial thrombus formation in Cotl1-
deficient mice.  
Taken together, the results presented here revealed multiple and novel roles for Cotl1 during 
hemostasis and arterial thrombus formation as well as for granule exocytosis, whereas its 
proposed impact on platelet formation and cytoskeletal remodeling could not be confirmed.  
5.2 Profilin 1 regulates integrin function in mouse platelets by mediating cyto-
skeletal rearrangements 
The MK- and platelet-specific Pfn1fl/fl-Pf4Cre mouse line has previously been investigated by our 
group [178]. In summary, Pfn1-deficient mice displayed a microthrombocytopenia which was 
caused by (1) cytoskeletal alterations, (2) an accelerated platelet clearance and 3) premature 
platelet release into the BM. Pfn1-deficient platelets showed a thicker marginal band and a 
highly disrupted actin cytoskeleton. However, in this study the impact of Pfn1-deficiency on 
platelet function has not been addressed. 
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Due to the highly disrupted actin cytoskeleton in Pfn1-deficient platelets it was conceivable to 
find impaired αIIbβ3 integrin function as recent studies by Stritt et al. showed that the 
organization of the circumferential actin cytoskeleton modulates calpain-mediated αIIbβ3 
integrin closure [99]. Indeed, Pfn1fl/fl-Pf4Cre platelets showed impaired αIIbβ3- and β1-integrin 
inside-out activation (Fig. 23 A, B). Fibrinogen binding to agonist-stimulated platelets occurs 
via αIIbβ3 and results in platelet aggregation, presumably by crosslinking adjacent activated 
platelets, thus contributing to hemostasis and thrombosis [193]. Spontaneous platelet 
aggregation is, however, prevented by tightly regulating the fibrinogen binding activity of 
αIIbβ3. Preliminary evidence suggests that the submembranous actin keeps αIIbβ3 in a low 
affinity state and that relief of this constraint by initiating actin filament turnover enables αIIbβ3 
to bind fibrinogen [194]. In line with this, fibrinogen binding to αIIbβ3 integrins was markedly 
reduced in Pfn1-deficient platelets (Fig. 23 D). As fibrinogen binding to αIIbβ3 integrins is a 
reversible process, time course experiments were performed, however, reduced fibrinogen 
binding to αIIbβ3 integrins was observed for all additional time points tested (5 min and 20 min, 
data not shown) in Pfn1fl/fl-Pf4Cre platelets. Likewise, integrin outside-in signaling in Pfn1-
deficient platelets was markedly impaired (Fig. 24 A-C, E). Since integrin outside-in signaling 
is a process highly dependent on functional cytoskeletal remodeling upon platelet activation 
[12], it is currently difficult to dissect the contribution of the grossly disrupted actin cytoskeleton 
and impaired integrin signaling to the defects observed in Pfn1-deficient platelets. Altogether, 
the observations might point to an impaired linkage of integrins to the submembranous actin 
cytoskeleton in Pfn1-deficient platelets. 
Aggregation responses of Pfn1fl/fl-Pf4Cre platelets were only slightly affected by the impaired 
integrin activation (Fig. 23 E). In contrast, adhesion and aggregate formation of Pfn1fl/fl-Pf4Cre 
platelets on collagen under flow were markedly reduced, translating into a profound protection 
from arterial thrombus formation and prolonged bleeding times in vivo (Fig. 25). Thus, the 
integrin activation defect together with the defective actin cytoskeletal organization in Pfn1-
deficient platelets translated into a pronounced in vivo phenotype thereby highlighting Pfn1 as 
a critical factor for platelet function in hemostasis and thrombosis. The discrepancy between 
aggregation responses in vitro versus in vivo can be explained by the potentially impaired 
connection of integrins with the actin cytoskeleton of Pfn1fl/fl-Pf4Cre platelets, which seem to be 
still sufficient to mediate platelet aggregation in the turbidometric aggregometry assay, but 
insufficient to resist shear forces generated under flow.  
Tln1 recruitment to β-integrin tails represents a key step in integrin activation as lack of Tln1 
results in abolished integrin activation [195]. Since we observed defective integrin activation, 
we speculated that Tln1 recruitment to β-integrin tails is altered in Pfn1-deficient platelets and 
indeed, an abnormal cytoplasmic localization pattern of Tln1 and β3-integrin could be detected 
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in Pfn1fl/fl-Pf4Cre platelets (Fig. 26). Moreover, we speculated that the so-called integrin closure, 
the switch of β3-integrins from high- to low-affinity state, could be affected by lack of Pfn1. 
Strikingly, a significantly increased percentage of PS-positive Pfn1fl/fl-Pf4Cre platelets with 
inactivated integrins could be identified upon agonist stimulation (Fig. 27). As described by 
Stritt et al. accelerated integrin closure could be caused by increased calpain-mediated 
cleavage of αIIbβ3 integrins in Pfn1-deficient platelets [99]. Strikingly, cleavage of β3-integrin 
tails and hence dissociation of the integrin-cytoskeleton linkage was increased in stimulated 
Pfn1fl/fl-Pf4Cre platelets, which was reverted by chemical inhibition of calpain (Fig. 28). Similarly, 
calpain inhibition improved spreading of Pfn1fl/fl-Pf4Cre platelets on fibrinogen and restored Tln1 
and β3-integrin localization (Fig. 29). These results support the previously described 
mechanism of calpain-mediated integrin closure and show that accelerated integrin closure 
caused by enhanced calpain activity, is the underlying reason for the impaired integrin 
activation in Pfn1-deficient platelets.  
The full reversion of the accelerated loss of β3-integrin in stimulated Pfn1fl/fl-Pf4Cre platelets to 
wild-type levels by inhibition of actin assembly using the F-actin polymerization inhibitor 
Latrunculin A (Fig. 30), supports the hypothesis that both enhanced calpain-mediated integrin 
closure as well as the defective organization of the cortical actin cytoskeleton contribute to the 
defects observed in of Pfn1fl/fl-Pf4Cre platelets. Therefore, Pfn1 might act as an organizer of the 
circumferential actin network, thereby linking integrins to the underlying cytoskeleton and 
limiting calpain-mediated integrin closure. In support of this, an increased Pfn1 activity could 
be detected in Twf2a−/− platelets, which resulted in a thickened cortical cytoskeleton and 
sustained integrin activation due to limited calpain-mediated inactivation [99]. In summary, 
these findings highlight a central role of Pfn1-mediated actin rearrangements for platelet 
integrin function with implications for hemostasis and thrombosis. 
5.3 Thymosin β4 regulates reactivity and procoagulant activity of platelets 
Tβ4 is a moonlighting protein and hence it exerts intra- and extracellular functions. The multiple 
biological functions of extracellular Tβ4 are intensively studied: for example, Tβ4 
administration promotes EC migration, tubule formation and angiogenesis in vitro [143] and 
promotes angiogenesis and wound repair in vivo [144, 145]. Direct administration of Tβ4 
following a myocardial infarction in mice protected heart tissue from cell death and enabled 
heart myocytes to survive after hypoxia [144]. All these observations make Tβ4 a potential 
therapeutic treatment, although the underlying mechanisms remain largely unknown [129]. 
Moreover, its function for cytoskeletal dynamics is still poorly studied. Therefore, the aim of 
this thesis was to investigate the effect of a constitutive Tβ4 KO on platelet formation and 
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function and to shed light on the underlying signaling network by analyzing the effect of 
recombinant Tβ4. 
The deletion of Tβ4 resulted in a moderate thrombocytopenia, but largely normally sized 
platelets. The reduced platelet counts were not accompanied by elevated MK numbers in BM 
and spleen. Further studies will be required to address the reason for the thrombocytopenia in 
Tβ4-/- platelets. Possible mechanisms are defective proplatelet formation as seen for Pfn1-
deficient animals or an accelerated clearance from the circulation, e.g. by macrophages as 
shown for Twf2-deficient platelets [99] [129]. Since Tβ4 is one of the major actin-sequestering 
molecules in cells, it was likely that lack of Tβ4 affects the platelet cytoskeleton. Indeed, Tβ4-/- 
platelets displayed an increased F-actin content in the resting state and significantly reduced 
agonist-induced F-actin assembly, which could be rescued by pre-incubation with the F-actin 
polymerization inhibitor Latrunculin A (Fig. 32 A, B). This suggested that either a diminished 
G-actin pool or a defective actin polymerization was the reason for the reduced agonist-
induced F-actin assembly of Tβ4-deficient platelets. Sedimentation of the actin cytoskeleton of 
Tβ4-deficient platelets revealed a marked reduction in the content of G-actin (Fig. 32 C, D), 
which is in line with studies suggesting that Tβ4 complexes about half of the monomeric actin 
in resting cells [184]. The robust reduction of their G-actin pool might be a reason for the 
reduced F-actin assembly in Tβ4-/- platelets. Investigation of the tubulin cytoskeleton of Tβ4-
deficient platelets revealed increased levels of microtubules. Interestingly, a significant 
increase in the number of microtubules per platelet has been described for Pfn1-deficient 
platelets suggesting that both actin-sequestering proteins exert additional (indirect) effects on 
the microtubule cytoskeleton [129]. In Pfn1-deficient platelets, an increased microtubule 
stability could be observed. However, Tβ4-deficient platelets showed no alteration in 
microtubule stability. This suggested a minor influence of Tβ4 on microtubule functionality. The 
increased number of microtubules might rather act as a compensatory mechanism to 
guarantee a grossly normal platelet structure and shape. 
As altered cytoskeletal dynamics were shown to influence platelet reactivity [99], we 
speculated that lack of Tβ4 may affect integrin activation. Tβ4-/- platelets showed significantly 
impaired αIIbβ3 integrin activation, whereas β1-integrin activation and degranulation were only 
moderately altered (Fig. 35 A, B). Tβ4-deficient platelets displayed a profound aggregation 
defect upon stimulation with thrombin, CRP and CVX; however, aggregation was increased 
upon collagen stimulation (Fig. 35 D). The hyperresponsiveness towards collagen stimulation 
was caused neither by altered α2β1 activity nor by increased second wave mediator release 
(data not shown). In summary, ITAM-coupled agonists induced a variable platelet activation 
response, which might be the reason of a differential GPVI signaling. Integrin outside-in 
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signaling was, on the contrary, significantly enhanced in Tβ4-/- platelets (Fig. 36 A, C), which 
could not be reverted by second wave mediator blockade (data not shown). This discrepancy 
between decreased integrin inside-out and accelerated outside-in signaling may in part be 
explained by increased F-actin levels in Tβ4-deficient platelets as integrin outside-in signaling 
is highly dependent on actin dynamics [12]. 
The altered platelet reactivity under static conditions translated into defective aggregate 
formation under flow (Fig. 37) and into a profound protection from arterial thrombus formation 
in vivo (Fig. 38). So far, it remains unclear whether the altered cytoskeletal dynamics or the 
lack of exogenous Tβ4 in Tβ4-/- mice caused the observed thrombus formation defect. Studies 
on KO mouse models of other actin-binding proteins with impaired actin dynamics such as 
Pfn1 or Cof revealed a similar protection from thrombus formation under flow ([129] and 
unpublished observations). However, the use of a constitutive KO mouse model in this study 
makes it difficult to distinguish between effects of Tβ4-deficiency in platelets or other cell types. 
In assays were not only washed platelet are investigated, effects of other cell types may be 
important as Tβ4 is highly abundant in many different cell types. For example, high 
concentrations of Tβ4 are stored in PMNs, which are among the first cells to enter a wound 
site and release factors, which then recruit additional cells to the injured site [143]. Taken 
together, the observed in vivo defects are influenced by many factors and further studies will 
address whether the defective thrombus formation in Tβ4-deficient mice is caused by altered 
actin dynamics or the lack of exogenous Tβ4. To differentiate between the role of endo- and 
exogenous protein function in in vivo assays, it might be helpful to generate bone marrow 
chimeras or to transfer Tβ4-deficient platelets into wild-type animals.  
As thrombus formation is potentiated by the release of second wave mediators, we assessed 
agonist-induced dense granule ATP release, which was overall increased in Tβ4-deficient 
platelets, except a profound decrease upon CRP stimulation (Fig. 39 A). In line with this, α-
granule release was significantly decreased upon CRP stimulation (Fig. 35 C). The number of 
granules seems, however, unaffected in Tβ4-deficient platelets as assessed by TEM of 
washed platelets (data not shown) and thus cannot account for the observed altered granule 
release. To assess this further, it will be interesting to determine the total content of P-selectin 
and ATP as well as the agonist-induced release of other granule-stored proteins, such as 
Serotonin in Tβ4-deficient platelets.  
Procoagulant activity under flow and thrombin generation was increased in Tβ4-/- platelets (Fig. 
40, 41 A-C). In line with this, an enhanced intrinsic coagulation (Fig. 41 D-E) could be observed 
in Tβ4-/- mice. Notably, these assays are carried out in plasma or whole blood, hence platelet-
unspecific factors must be considered in interpretation of this results. To shed light on the 
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question, which of the observed effects are caused by endogenous (the actin-sequestering 
function) or exogenous Tβ4 protein functions (Tβ4 release by platelets and other blood cells), 
a set of experiments was repeated where platelets were pre-incubated with recombinant 
protein. As the described Tβ4 concentration in human plasma was estimated to 0.03-0.4  
µg mL-1 [139], a concentration range of 0.1 to 10 µg mL-1  was chosen for the in vitro pre-
incubation of platelets. Notably, the concentration of recombinant Tβ4 used for in vivo assays 
is much higher- 6 mg kg-1 [196]. Whereas aggregate formation under flow was reverted to wild-
type levels by addition of recombinant Tβ4 (pre-incubation or co-infusion; Fig. 42 and 
preliminary observations), the defective αIIbβ3 integrin inside-out activation of Tβ4-/- platelets 
was even more pronounced. Interestingly, pre-incubation with recombinant Tβ4 further 
enhanced aggregation of both wild-type and Tβ4-/- platelets in comparison to the untreated 
controls upon collagen stimulation (Fig. 43 B). In line with this, recombinant Tβ4 increased the 
spreading rate and elevated ATP secretion (except for CRP stimulation) of both wild-type and 
Tβ4-/- platelets (Fig. 44, 45). These diverse results need further investigation to better 
understand the mode of action of Tβ4. Therefore, another aim of the thesis was to establish 
an expression and purification protocol for recombinant Tβ4, which was adopted from Li et al. 
[188]. Successful expression and purification of recombinant DsbA-tagged Tβ4 could be 
achieved using E. coli expression strain BL21 (DE3) (Fig. 46, 47). The production of untagged 
protein, however, requires further optimization. Experiments with the recombinant protein will 
focus especially on its in vivo effects, release and uptake in platelets, its half-life and its effects 
on major platelet signaling pathways. Due to the current lack of knowledge about all these 
aspects, these experiments are of high clinical relevance. 
5.4 Concluding remarks and future perspectives 
The findings presented in this thesis provide new insights into the regulation of cytoskeletal 
dynamics and the role of several actin-binding proteins for platelet production and function. 
Although the ADF-H protein family member Cotl1 is dispensable for platelet production and 
actin dynamics, this thesis shows for the first time that Cotl1 is a major regulator of hemostasis 
and thrombosis in mice. This might be a result of defective GPIb-vWF signaling or a reduced 
release or dampened sensitivity towards second wave mediators. Moreover, altered 5-LO 
activity might account for the observed defects in Cotl1-deficient mice, which is under current 
investigation. To this end, it is planned to assess levels of AA metabolites by mass 
spectrometry with the help of our collaboration partners. Furthermore, biomechanical 
properties of the KO platelets will be assessed to check whether altered stability and thus a 
stronger deformation of the platelets might be a reason for the observed defects of Cotl1-
deficient platelets in vitro under flow and in vivo. The findings presented here underline the 
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diversity of actin-binding proteins, which share some common features but their differential 
sequence and structure often results in complete distinct biological functions. The protection 
from in vivo thrombus formation in Cotl1-deficient mice highlight Cotl1 as potential novel target 
for anti-thrombotic drug development. However, although bleeding times were not strikingly 
higher, an increased bleeding risk must be considered.  
The importance of Pfn1 for thrombopoiesis has been elucidated in earlier studies. The work 
presented here focused on its role for platelet function and established Pfn1 as a central 
regulator of platelet integrin activation. The suggested underlying mechanisms of the observed 
defects of Pfn1fl/fl-Pf4Cre platelets are an enhanced calpain-mediated integrin closure together 
with a defective organization of the cortical actin cytoskeleton. The results described in this 
thesis further stress the importance of a functional actin cytoskeleton for proper platelet 
function in vitro and in vivo highlighting the outstanding role of Pfn1 as a master regulator of 
platelet integrin function and of the organization of the actin cytoskeleton. 
Tβ4 has previously been described as a miracle cure, exerting various beneficial functions in 
a large variety of disease models. Moreover, it fulfils an important intracellular function, since 
it is one of the major G-actin-sequestering proteins. In this thesis, the expected role of Tβ4 in 
cytoskeletal dynamics could be confirmed. Accordingly, the G-actin pool of Tβ4-deficient 
platelets was largely diminished concomitant with an increase in F-actin levels. This had 
divergent effects on platelet reactivity, since spreading, clot retraction as well as granule 
release were markedly enhanced in KO platelets, whereas signaling events upon CRP 
stimulation were significantly diminished in vitro. Additionally, aggregation defects on collagen 
in vitro under flow and a protection from arterial thrombus formation in vivo could be detected. 
In contrast, Tβ4-deficiency caused enhanced thrombin generation, procoagulant activity and 
coagulation, which was a result of increased levels of FVIII, IX and XI. Together, these results 
establish Tβ4 as a critical regulator of thrombosis, platelet reactivity and coagulation. In 
addition to its intracellular role, pre-incubation of platelets and blood with recombinant Tβ4 
revealed an overall stimulatory role of exogenous Tβ4. However, the underlying mechanisms 
or signaling pathways remain elusive and are under current investigation. To this end, further 
experiments with the recombinant protein (commercial and self-made) are planned. These will 
address its effect in in vivo models of arterial thrombosis or thrombo-inflammatory brain 
infarction. In additional experiments, the underlying signaling pathways by which Tβ4 exerts 
its effects will be investigated. Here, the Akt-ILK-PINCH pathway will be of major interest, since 
Tβ4 was already shown to upregulate Akt phosphorylation. The protection from in vivo 
thrombus formation in Tβ4-deficient mice highlight Tβ4 as potential novel target for anti-
thrombotic drug development. However, Tβ4 is expressed in many different cell types and 
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hence interfering with Tβ4 expression or release might have severe side effects. Nevertheless, 
elucidation of the role of exogenous Tβ4 is of high clinical relevance as its status as miracle 
cure highlights it as novel drug for anti-inflammatory and pro-angiogenic treatment. 
In summary, the work presented in this thesis will ultimately help to understand the diverse 
regulatory machinery guaranteeing actin polymerization and sequestering in platelets.  
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7. APPENDIX 
7.1 Abbreviations 
AA   Arachidonic acid 
AC   adenylyl cyclase 
ACD      Acid citrate dextrose   
Abp1   Actin-binding protein 1 
ADF      Actin depolymerizing factor   
ADF-H     ADF-homology domain   
ADP      Adenosine diphosphate  
α-TAT1   α-tubulin N-acetyltransferase 1  
Akt      Protein kinase B   
Anxa5     Annexin V  
APC      Adenomatous polyposis coli  
APS      Ammonium persulfate   
Arp2/3     Actin-related proteins 2/3  
ATP      Adenosine triphosphate  
BM      Bone marrow  
bp   Base pairs 
βT   β-thymosin 
BSA       Bovine serum albumin  
C. elegans  Caenorhabditis elegans 
Ca2+      Calcium cation  
CA      Central/acidic domain  
CalDAG-GEFI  Ca2+-dependent DAG-regulated guanine nucleotide exchange factor 
cAMP     Cyclic adenosine diphosphate  
CAP      Cyclase-associated protein  
Cdc42     Cell division control protein 42   
CLEC-2    C-type lectin-like type II transmembrane receptor   
Cof      Cofilin  
Coll       Collagen  
COTL1  Coactosin-like protein 1 
CRP      Collagen-related peptide  
CP      Capping protein  
CVX      Convulxin  
D. melanogaster Drosophila melanogaster 
D. discoideum  Dictyostelium discoideum 
DAG      Diacylglycerol  
DAPI      4'-6-Diamidino-2-phenylindole  
°C      Degree Celsius  
Da       Dalton  
DIAPH     Mammalian Diaphanous  
DIC      Differential interference contrast  
DNA      Deoxyribonucleic acid  
dNTP     Deoxynucleotide triphosphates  
DMSO     Dimethylsulfoxide  
DTT   1,4-Dithiothreitol 
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E. coli   Escherichia coli 
EC      Endothelial cell  
ECL      Enhanced chemiluminescence  
ECM      Extracellular matrix   
EDTA      Ethylenediaminetetraacetic acid  
e.g.      Exempli gratia  
EGTA     Ethylene glycol tetraacetic acid  
ELISA      Enzyme-linked immunosorbent assay  
et al.      Et alii  
ETP      Endogenous thrombin potential  
F-actin    Filamentous actin  
FACS   Fluorescence-activated cell sorting 
f.c.   Final concentration 
FCS       Fetal calf serum  
FcR      Fc receptor   
Fig.       Figure  
FITC     Fluorescein-isothiocyanate   
FLAP   5-lipoxygenase-activating protein 
FlnA      FilaminA  
FSC      Forward scatter  
g      Gravitation force  
G-actin     Globular actin  
γ-TuRC    γ-tubulin-ring complex  
GAPDH    Glycerinaldehyd-3-phosphat-Dehydrogenase  
GEF      Guanine nucleotide-exchange factor   
GP       Glycoprotein  
GPCR   G-protein coupled receptors  
Grb2    Growth factor receptor-bound protein2  
GTP    Guanosine triphosphate  
h   Hours 
HDAC    Histone deacetylase  
HE    Hematoxylin and eosin  
Hem    Hematopoietic protein  
HEPES    N-2-Hydroxyethylpiperazine-N'-2-ethanesulfonic acid  
5-HETE  5-Hydroxyeicosatetraenoic acid 
5-HPETE  Arachidonic acid 5-hydroperoxide 
HRP    Horseradish peroxidase  
Ig     Immunoglobulin  
IHC      Immunohistochemistry  
ILK   Integrin-linked kinase 
IMAC   Immobilized metal-ion affinity chromatography 
IP     Immunoprecipitation  
IP3      Inositol-1,4,5-triphosphate  
IPTG   Isopropyl β-D-1-thiogalactopyranoside 
ITAM      Immunoreceptor tyrosine-based activation motif  
i.v.       Intravenously  
k      Kilo 
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KD    Dissociation constant 
KO   Knockout 
LAT      Linker of activated T-cells  
LatA      Latrunculin A  
LB   Luria-Bertani 
LIMK   LIM domain kinase 
5-LO   5-lipoxygenase 
LT   Leukotriene 
M   Molar  
mDia     Mammalian Diaphanous  
Mena     Mammalian Ena orthologue   
MFI      Mean fluorescence intensity  
min      Minute  
MK       Megakaryocyte  
MLC      Myosin light chain  
MMP     Matrix metalloproteases  
MPV   Mean platelet volume 
MT      Microtubule  
MTOC     Microtubule-organizing center  
NAD      Nicotinamide adenine dinucleotide  
NMMIIA    Non-muscle myosin IIA  
NP-40      Nonidet P-40  
NS   Non-significant 
O.D.   Optical density 
o/N   Over night 
Orai1     Ca2+ release-activated calcium channel protein 1  
5-oxo-ETE  5-oxo-eicosatetraenoic acid 
P      Phosphorylation/ Pellet  
P. pastoris  Pichia pastoris 
PAA     Polyacrylamide  
PAGE      Polyacrylamide gel electrophoresis  
PAK      p21/Cdc42/Rac1-activated kinase  
PAR      Protease activated receptors   
PBMC     Peripheral blood mononuclear cells  
PBS       Phosphate buffered saline  
PC   Phosphatidylcholine 
PCR      Polymerase chain reaction  
PE      R-phycoerythrin   
PF4       Platelet factor 4  
PFA       Paraformaldehyde  
Pfn       Profilin   
PGE   Prostaglandin 
PGI2      Prostacyclin  
PH      Pleckstrin homology domain  
Pi     Inorganic phosphate 
PI   Propidium iodide/ protease inhibitors  
PI3K      Phosphoinositide 3-kinase    
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PIP2      Phosphatidylinositol 4,5-bisphosphate  
PIP3      Phosphatidylinositol-3,4,5-trisphosphate  
PIPES     Piperazine-N,N′-bis(2-ethanesulfonic acid)  
PK       Proteinkinase  
PL       Phospholipase  
PLP      Poly-L-proline  
PMN   Polymorphonuclear cell 
PMSF     Phenylmethylsulphonylfluorid   
PRP      Platelet rich plasma  
PVDF     Polyvinylidene difluoride  
PS      Phosphatidylserine  
PTT   Partial thromboplastin time 
Rac1     Ras-related C3 botulinum toxin substrate 1  
RBC      Red blood cell  
Rest      Resting  
Rhd      Rhodocytin  
RhoA     Ras homolog gene family, member A   
Rho-GEF    Rho-specific guanine nucleotide exchange factor  
Rho-GTPase   Ras-homologue-guanine triphosphatase  
RNA      Ribonucleic acid  
ROCE     Receptor-operated Ca2+ entry   
ROCK     Rho associated coiled-coil containing protein kinase  
rpm      Rotation per minute  
RT       Room temperature  
RT-PCR    Reverse transcription polymerase chain reaction  
s   Second(s) 
S      Soluble  
S. cerevisiae  Saccharomyces cerevisiae  
SD   standard deviation 
SDS-PAGE    Sodium dodecyl sulfate polyacrylamide gel electrophoresis  
SH2      Src-homology 2  
SIRT2    NAD-dependent deacetylase sirtuin-2  
SLP-76    SH2 domain-containing leukocyte protein of 76 kDa  
SN      Supernatant  
SOCE     Store-operated Ca2+ entry 
SSC   Side scatter 
STED    Stimulated emission depletion   
STIM     Stromal interaction molecule  
Syk     Spleen tyrosine kinase  
t   Time 
T      Total  
TAE   TRIS acetate EDTA 
TBS       TRIS buffered saline  
TEM      Transmission electron microscopy  
TEMED    Tetramethylethylenediamine  
TESK   TES kinase 
TF      Tissue factor  
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TGF-β1    Transforming growth factor-β1  
Thr      Thrombin  
Tln-1      Talin-1  
TMB      3,3,5,5-tetramethylbenzidine   
tMCAO  Transient middle cerebral artery occlusion 
Tβ4    β4-thymosin  
TP   TxA2 receptor 
TRIS      Tris(hydroxymethyl)aminomethane  
TTC   2,3,5-triphenyltetrazolium chloride 
TTL      Tubulin-tyrosine kinase  
TLLL      TTL-like family member  
TRPM7    Transient receptor potential melastatin-like 7  
Twf      Twinfilin   
TxA2      Thromboxane A2  
U   Units 
U46      U46619  
UV   Ultraviolet 
V      Verproline homology motif  
VASP     Vasodilator-stimulated phosphoprotein  
vWF      Von Willebrand factor  
WAS      Wiskott-Aldrich syndrome  
WASp     Wiskott-Aldrich syndrome protein   
WAVE     WASp family verprolin-homologous protein  
WIP      WASp-interacting protein  
WT       Wild-type 
X. laevis  Xenopus laevis   
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7.2 Vectors 
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